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Abstract 
 
This thesis aims to adapt and develop a mouse model for stable dyssynchronous pacing and 
systematic investigation of mechanisms of structural gap-junctional remodelling (GJR) and 
correlation to functional changes. GJR, an altered abundance or localisation of connexin 
proteins strongly correlates with arrhythmogenic substrates.  
 Wild type Cx43+/+ and heterozygous Cx43 knockout Cx43+/− (66% mean reduction in Cx43) 
mice were paced in vivo subxiphisternally at 10-15% above anaesthetised sinus rates for one 
to six hours avoiding intubation, vascular access, thoracic or mediastinal disruption. 
In Cx43+/+ mice, pacing resulted in electrical and mechanical dyssynchrony. 
Echocardiographic (ECHO) and electrocardiogram (ECG) indices, ventricular effective 
refractory period (VERP) and arrhythmia inducibility were not significantly altered. Pacing 
attenuated transmural gradients of Cx43 immunosignal in the LV free wall. Significant 
reductions in Cx43 mRNA abundance at the LV free wall occurred. Cx43, its isoforms and 
interacting protein expression were unchanged. Fractionation studies of 6hr-paced hearts 
demonstrated reduced Cx43 in membrane fractions while cytosolic fractions increased 
significantly. Cx43 degradation studies demonstrated substantially increased ubiquitinated 
forms with pacing. 
Cx43 protein expression in paced and unpaced Cx43+/− mice hearts was unchanged. In 
contrast to Cx43+/+ cells, Cx43+/− mice demonstrated significantly shorter action potential 
durations (APD), increased steady-state (Iss) and inward rectifier (IK1) potassium currents. 
Pacing prolonged action potential duration (APD) at 50ms and 90ms increased VERP at 
80ms/100ms and significantly reduced Iss in Cx43+/− vs. unpaced Cx43+/− hearts.  
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Pacing induces electro-mechanical dyssynchrony in wildtype Cx43 (Cx43+/+) hearts, results 
in remodelling of the cardiac gap junctions without sustained measurable effects or increased 
arrhythmia inducibility. Transgenic hearts (Cx43+/−) respond quite differently to pacing, 
which may be relevant in cardiac disease, where Cx43 is focally reduced. Pacing could lead 
to the remodelling of repolarisation currents in regions of reduced Cx43, enhancing 
dispersion of refractoriness and potentially creating a substrate for arrhythmia re-entry.  
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Overview 
 
The focus of the work in this thesis is the establishment of a novel murine model of sub 
diaphragmatic pacing and the study of electroanatomical effects i.e. aberrant electrical 
activation (dyssynchrony) on architectural and more specifically gap junction remodelling 
(GJR). The effects of pacing induced dyssynchrony are tested in mice with naturally 
occurring levels of connexin 43 (Cx43+/+) and genetically reduced Cx43 (Cx43+/−). To further 
explore the functional electrophysiology effects of gap junction remodelling, I quantify 
connexins and their cardiac isoforms in wildtype Cx40 (Cx40+/+), Cx40+/- and Cx40 knockout 
(Cx40-/-) mice and correlate findings to functional atrial electrophysiology data from optical 
mapping experiments. 
In this chapter, I outline the key observations in the gap junction biology field on which the 
aims and hypotheses of this thesis are based. I present the current knowledge base for the 
molecular process driving gap junction remodelling with dyssynchrony. I include key, 
relevant concepts in the gap junction biology field as relates to their structure, function, bio 
assembly, modulation, phosphorylation, altered gap junction intercellular communication, 
their role in action potential propagation and how their remodelling alters electrophysiology 
and results in atrial and ventricular arrhythmias.  
The clinical relevance of dyssynchrony and gap junction remodelling, is that they strongly 
correlate with arrhythmic sudden death, the commonest cause of mortality in western 
societies e.g. in the USA and the UK. 
In Chapter 2, I present the establishment of the subdiaphragmatic pacing model. In Chapter 3, 
I outline the electrocardiographic measurements at baseline and after pacing or sham-pacing 
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in Cx43+/+ wildtype mice as well as Cx43+/- mice. Chapter 4 presents the echocardiography 
findings at baseline, during pacing and after pacing in Cx43+/+ and Cx43+/- mice. 
Subsequently, Chapter 5 explores the arrhythmia inducibility with programmed electrical 
stimulation and ventricular effective refractory period at baseline and after pacing in Cx43+/+ 
mice and Cx43+/- mice. Chapter 6 correlates the anatomical data with electrophysiology at 
baseline and after pacing in Cx43+/+ as well as Cx43+/− mice. Chapter 6 also includes data 
quantifying connexins and their cardiac isoforms in wildtype Cx40 (Cx40+/+) and Cx40 
knockout (Cx40-/-) mice and correlates these to atrial optical mapping data. Chapter 7 
integrates the findings throughout the thesis to draw some conclusions. 
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Aims and Hypothesis  
Scope of Thesis and Rationale of studying dyssynchrony induced 
pacing. 
 
The	  Hypotheses	  and	  Aims	  of	  the	  set	  of	  studies	  in	  this	  thesis	  are	  based	  on	  
the	  following	  key	  observations:	  	  	  
	  
1. Prolonged aberrant ventricular electrical activation has been associated with focal 
structural gap junction remodelling. Animal models of dyssynchrony demonstrate this 
observation; gap junction remodelling in canine models induced by pacing, localised to the 
pacing probe; whilst radiofrequency ablation of the canine left bundle branch resulted in no 
change to total Cx43 expression, however subcellular location was redistributed in late-
activated myocardium from intercalated discs to lateral myocyte membranes(1-4). 
2. Gap Junction Remodelling (GJR) due to altered Cx43 (as well as Cx40, Cx45 isoform) 
patterns of distribution and expression is associated with altered patterns of electrical 
conduction, activation and arrhythmia propensity; as in the cardiac specific Cx43 knockout 
mouse (CKO), the central common pathway of figure of eight re-entrant arrhythmia circuits 
in myocardial infarction (MI) models and altered contractility patterns (as in the chimeric 
Cx43 CKO mouse)(5-8). Cx43 normally localises to the intercalated disc, primarily situated 
at the terminal ends of healthy cardiac myocytes whereas in cells from the infarct border zone 
Cx43 is distributed throughout the lateral surface of the cardiac myocyte; much emphasis has 
been placed correlating gap junction lateralisation and arrhythmia substrates(8;9). 
3. Cx43 demonstrates rapid trafficking and turnover with a short biological half-life of 1.5 
hours and responds dynamically to changing external factors e.g. areas of gap junction 
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remodelling were observed in dog hearts after 21 days of pacing(1); strikingly, less than an 
hour of ischaemia-reperfusion in an isolated rat heart demonstrated redistribution of 
Cx43(10). It therefore seemed possible that pacing-induced gap junction remodelling might 
also occur over a short time between 1.5- 6 hours. 
4.Prior studies have indicated that in the diseased heart Cx43 abundance can be variable, with 
focal areas of reduced expression corresponding to hibernating and ischaemic zones; such 
structural alterations affect other cellular membrane components such as connexin isoforms, 
other proteins which form part of the gap junction nexus and related ion channels(9;11-13). 
5. Gap junction remodelling is also accompanied by altered ion channel expression, which 
occurs in a chamber, species-specific manner and strongly correlates with atrial and 
ventricular arrhythmias e.g. the central common pathway of figure of eight re-entrant 
arrhythmia circuits in MI models(12). It represents a common endpoint for several disease 
states such as ischaemia, infarction, hibernation, heart failure and atrial fibrillation (8;14-16). 
6.A simple small-mammal in vivo model that avoids the risks of blood loss, ischemia, 
thoracotomy and ventilation for prolonged ventricular pacing has not been available (3). 
7.Short-term pacing reduces connexin expression; this has previously been described by 
Sambelashvili et al, however, this has been in the setting of strong electric currents, up to 100 
times greater representing a model of cardiac tissue damage rather than altered activation 
suggesting a voltage-dose response(17). 
8. GJR due to altered connexin isoform expression e.g. Cx40 has been correlated in atrial and 
ventricular arrhythmia. 
9. The developing heart demonstrates spatiotemporal gap junction remodelling while further 
age related cardiac membrane changes also occur (5;18;19). These models have furthered our 
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understanding of adaptive mechanisms driving gap junction remodelling and raised important 
questions regarding variations in age related myocardial electrical conduction.  
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This	  thesis	  has	  the	  following	  specific	  and	  novel	  goals:	  
 
1.To develop and refine an in vivo subdiaphragmatic murine pacing induced dyssynchrony 
model that allows prolonged pacing, with 100% stable capture, is well tolerated and 
reproducible without thoracic, abdominal, vascular or cardiac injury, without need for 
intubation and in the absence of ischaemia or hypothermia. 
2. To demonstrate feasibility of the pacing protocol, undertake a set of experiments designed 
to test the duration of pacing tolerated in wildtype mice: 
Over the short term i.e. 15, 30, 45 and 60 mins. 
Over the longer term i.e. 4hr and 6hr. 
3. To demonstrate survival of animals after 1hr pacing experiments in wildtype mice 
   immediate survival experiment- 4.5hr survival study (3 half-lives) 
   Long-term survival experiment-2 week survival study. 
4. To establish whether there is any effect of subdiaphragmatic pacing on cardiac function, 
assess the following measurable parameters in wildtype Cx43+/+ mice  
4.1 Characterise ECG parameters, at baseline, and after pacing at 15, 30, 45 
mins, 1hr, 4hr and 6hr. 
4.2 Characterise ECHO parameters, at baseline, during pacing and after 1hr 
and 6hr pacing.  
4.3 Characterise arrhythmia inducibility testing using PES and determine the 
VERP, at baseline and after 1hr and 6hr pacing. 
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4.4 Characterise the pacing threshold at baseline and after 1hr, 4hr and 6hr 
pacing. 
5. Repeat all of the above measured parameters and determine functional effects in transgenic 
Cx43+/− mice: 
5.1 Characterise ECG, parameters at baseline and after 6hr pacing. 
5.2 Characterise ECHO parameters at baseline and after 6hr pacing 
5.3 Characterise arrhythmia inducibility and VERP at baseline and after 6hr 
pacing. 
5.4 Characterise the pacing threshold at baseline and after 6hr pacing 
5.5 Characterise functional effects, if any, and whether sustained after a period 
of recovery (2hr). 
6. To determine the epicardial breakthrough activation pattern and conduction velocity post 
pacing using optical mapping in Cx43+/+ and Cx43+/- mice (and Cx40+/+ mice). 
7. Characterise cellular electrophysiology (using patch clamp) in Cx43+/+ wildtype as well as 
Cx43+/− mice at baseline and after 6hr pacing and look at the following measurable 
parameters: 
 7.1 Resting membrane potential,  
7.2 Action potential duration at 50ms and 90ms. 
 7.3 Activation and repolarisation kinetics  
7.4 At baseline and post 6hr pacing in the Cx43+/+ and Cx43+/− mice. 
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8. To determine the effects of subdiaphragmatic pacing on cardiac architecture/structure. 
8.1 Macroscopic study of whole heart and cellular architecture:  
After 1 hour of pacing (using HPS staining to determine macroscopically whether 
there are features of cellular injury due to the electrode or pacing). 
8.2 Establish a semiquantitative method (using immunohistochemistry) for assessing 
Cx43 cellular and tissue immunofluorescence in wildtype Cx43+/+ and Cx43+/- mice  
8.2.1 Assess measurables at baseline and after 1hr, 4hr and 6hr pacing.  
8.2.2 Mean Cx43 Immunofluorescence Index 
8.2.3 Assess Cx43 Distribution using Cx43 immunosignal/tissue area as well 
as Cx43 lateralisation study  
8.2.4 Cx43 plaque numbers 
8.2.5 Size of Cx43 plaques. 
9. Assess these parameters outlined in 8.2 in whole heart and on a regional basis to determine 
if there is local or spatial Cx43 heterogeneity post sham-pacing and pacing in Cx43+/+ and 
Cx43+/− mice. 
9.1 LV vs. RV 
9.2 LV Base vs. Mid vs. Apex 
9.3 LV septum vs. LV free wall 
9.4 Epicardium vs. Mid-myocardium vs. Endocardium. 
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10. Utilise the semi quantitative method for assessing Cx43 and Cx40 colocalisation in a 
Cx40 transgenic model i.e. Cx40+/+, Cx40+/- and Cx40-/- mice. 
11. Characterise changes in Cx43 protein expression levels (using immunoblotting) after 
sham-pacing and after pacing in wildtype Cx43+/+and Cx43+/− mice: 
11.1 At baseline and after 6hr pacing and sham-pacing 
11.2. Determine Cx43 expression using immunoblotting  
11.2.1. at baseline and after 6hr pacing. 
11.2.2 on a regional basis  
LV epicardium and endocardium. 
LV free wall and LV septum 
LV Base and Apex 
12. Assess rates of Translation at baseline and after 6hr pacing in whole heart lysates from 
Cx43+/+ and Cx43+/− mice and assess Cx43 mRNA on a regional basis (using qRT-PCR) in 
12.1.  LV free wall epicardium 
12.2.  LV free wall endocardium 
13. Assess Cx43 distribution at baseline and after 6hr pacing using Cell fractionation 
techniques to assess Cx43 trafficking between membrane associated and cytosolic pools. 
14. Assess degradation of Cx43 in Cx43+/+ mice after 6hour sham-pacing and 6hr pacing  
using immunoblotting for ubiquitin (with Cx43 coimmunoprecipitation). 
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15. Examine the relationship of Cx43 with other connexin isoforms (Cx40, Cx45) and its 
binding partners e.g. cadherin (using immunofluorescence colocalisation methods) after 6hr 
sham-pacing and 6hr pacing  
  15.1 In wildtype mice 
  15.2 In Cx43+/- mice 
16. To correlate structural remodelling (aims 8-15) in wildtype Cx43+/+ and Cx43+/− mice 
post 6hr pacing and sham-pacing with functional effects (aims 4-7). 
17. To characterise the Cx43 and Cx40 immunosignal in a Cx40 transgenic model 
17.1 in RA, RAA, LA and LAA 
17.2 in young and old hearts 
17.3 correlate structural data with optical mapping measured regional 
conduction velocity of Cx40+/+, Cx40+/- and Cx40-/- mice.  
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These	  specific	  and	  novel	  goals	  enable	  addressing	  the	  following	  specific	  
and	  novel	  Hypotheses:	  
	  
PRINCIPAL HYPOTHESES 
 
Hypothesis 1. 
In a model of reproducible short-term (less than six hours) in vivo right ventricle (RV) pacing 
without the need for intubation, or thoracic disruption using the sub diaphragmatic route 
without effects of ischaemia, or heart failure, I hypothesise that RV pacing with resultant 
aberrant electrical activation would generate gap junction remodelling (GJR) due to 
disruption in connexin trafficking and correlate with increase arrhythmia propensity and/or 
impaired cardiac contractility.  
Hypothesis 2. 
In the setting of additional stress to the cellular anatomical architecture of the model e.g. 
genetically reduced basal levels of Cx43, (or the action potential prolonging effect of drug 
e.g. 4-AP) dyssynchronous pacing would correlate with more profound effects on cardiac 
function and cellular electrophysiology.  
Hypothesis 3. 
I hypothesise that gap junctional remodelling in Cx40+/+, Cx40+/- and Cx40-/- mice results in 
altered Cx43 expression, conduction velocity and pattern of propagation in an age and 
chamber specific manner. 
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Subhypotheses	  
1. Pacing induced Gap junction remodelling in wildtype mice demonstrates Cx43 
immunosignal lateralisation. 
2. Remodelling of Cx43 at a structural level correlates with changes in regional transcription 
in wildtype and Cx43+/− mice after 6hr dyssynchronous pacing. 
3.Gap junction remodelling occurs at a structural level and demonstrates differences on a 
regional and chamber specific basis thus creating connexin heterogeneity as a consequence of 
pacing induced dyssynchrony in wildtype Cx43+/+ and Cx43+/- mice. 
4. Gap junction remodelling correlates with altered trafficking and degradation of Cx43 
protein 
5. Pacing induced dyssynchrony alters phosphorylation state of Cx43 and alters Cx40, Cx45 
and cadherin protein abundance at the intercalated disc. 
6. Short-term dyssynchronous pacing of the murine heart demonstrates features of cardiac 
memory. 
7. Altered activation of the ventricle would alter the relationship of gap junctions in 
subcellular and membrane pools and result in changes in the distribution of Cx43 utilising 
cell fractionation and immunostaining (colocalisation studies) to determine whether this 
occurs by disassociation from its scaffolding proteins e.g. cadherin at the adherens junction. 
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Rationale of study and clinical relevance  
Human	  Models	  of	  Dyssynchrony	  
Heart	  Failure	  
Heart failure remains the leading cause of morbidity and mortality in westernised societies, 
with majority of patients having impaired cardiac systolic pump function, and a significant 
proportion, cardiac dyssynchrony with associated conduction delay (20;21). Estimates place 
this proportion of patients at 30% for having electrical dyssynchrony i.e. a widened QRS on 
ECG (LBBB), however as high as 60% for mechanical dyssynchrony i.e. with ECHO or MRI 
metrics of dyssynchrony.  
Dyssynchrony is an independent risk factor for morbidity and mortality in heart failure 
beyond the traditional risks that predict poor outcomes. Dyssynchrony creates a 
heterogeneous workload with late and early activated myocardial regions demonstrating 
differences in work efficiency, perfusion, glucose requirements and metabolism with adaptive 
changes to cellular architecture (22;23). Therapies aimed at restoring synchrony have shown 
clear clinical benefits both in improving symptoms and survival in patients with 
dyssynchrony(3).  
Ischaemia	  
	  
Regional myocardial ischaemia, caused by atherosclerotic narrowing in coronary arteries is 
affected by reductions in blood flow which may either be dynamic e.g. ischaemia caused on 
exertion or after a heavy meal; or it may be chronic or fixed in nature as in the case of an old 
myocardial infarction. However, the resultant oxygen-demand mismatch results in altered 
cellular function e.g. due to altered Ca2+ state in the local tissue with altered mechanical 
function resulting in regional wall motion abnormalities, a form of dyssynchrony. 
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Ectopy	  and	  Tachyarrhythmia:	  
	  
Spontaneous ectopy in the ventricle can occur often as a result of multifocal sources in 
diseased hearts or a unifocal source as is the case in a structurally normal heart e.g. with 
unifocal outflow tract generated Ectopy. These aberrant sources of depolarising cells can 
result in mechanical dyssynchronous activation, which in time may alter the cardiac 
architecture. The rate at which they depolarise can result in sustained tachyarrhythmia. 
Sustained tachyarrhythmia as a model is a well described entity resulting in structural 
impairment (in the case of tachycardia induced cardiomyopathy), mechanical dyssynchrony, 
and associated structural and gap junction remodelling.   
 
In humans, data from studying cohorts of patients subjected to cardiac pacing (a form of 
artificially induced ectopy and dyssynchrony) either with a single chamber or dual chamber 
device highlight the importance of dyssynchrony induced by pacing the RV alone. Such 
clinical studies have emphasised the deleterious effects of dyssynchrony and have stirred 
interest in alternate site pacing and programming that minimises right ventricular 
pacing(24;25). Contrastingly, specialised pacing that restores synchrony improves mortality 
and functional parameters in those with heart failure induced dyssynchrony(4).  
Animal	  Models	  of	  cardiac	  Dyssynchrony	  
Left	  bundle	  branch	  block	  (LBBB)	  induced	  Dyssynchrony.	  
 
Animal models have been designed to study dyssynchrony- Eppinger and Tothberger 100 
years ago achieved a prolonged QRS by incising the interventricular septum in canine hearts 
and their canine work represents the very first model of a proximal bundle branch lesion. 
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Such a model of dyssynchrony has been observed in humans with LBBB as well as monkeys 
and pigs (23).  
 
Important differences exist between species at the anatomical level of the left bundle branch 
with ox and sheep demonstrating thicker bundles extending to the epicardial surface while 
rabbits have fine subendocardial sheets as a left bundle. Canines appear to model the human 
LBBB model closest with doubling of their QRS duration when surgically disrupting the left 
bundle. A more recent study using catheter ablation of the LBBB in a canine has opened the 
possibilities for a less invasive approach. Other animal models e.g. pigs, using LBBB 
disruption combined with RV pacing only achieve a 50% prolonged QRS duration and have 
therefore been less favoured for modelling studies of human dyssynchrony(23). 
 
 An important difference in these animal models is that they are all usually free of any 
underlying disease processes thus differing substantially from human models of cardiac 
dyssynchrony (where cardiac disease is present). Incision of the proximal bundle in animal 
models, however, disrupts the ventricle, which must be opened to allow access to the left 
bundle; making this model unsuitable for the study of haemodynamic effects of 
dyssynchrony. This paved the way for alternative strategies e.g. catheter ablation of the Left 
bundle and the use of pacing as a model of dyssynchrony (26). 
Pacing	  Induced	  Dyssynchrony	  
	  
Wiggers et al in 1925 used an artificial stimulus and in the canine left ventricle demonstrated: 
1.slowing in rise of interventricular pressure, 2.lengthening of the isometric contraction 
phase, 3.lowering of maximum systolic pressure and 4.an increase in the duration of systole. 
A set of elegant experiments performed by Prinzen et al in 1999 and 2002 demonstrated the 
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effects of multisite pacing on haemodynamics and showed that RV pacing delays transeptal 
and intraventricular conduction with haemodynamic change comparable to LBBB 
models(20).  
An important difference with RV apical pacing is that it 1.Induces slow intramyocardial 
conduction instead of fast conduction through the purkinje fibres and 2.the site of 
stimulation-induced breakthrough differs from the intrinsic breakthrough site. This latter 
effect alters LV depolarisation through the interventricular septum compared to LBBB. 
A more recent canine model of LBBB has utilised proximal ablation of the LBBB to generate 
a model of LBBB dyssynchrony combined with CRT pacing(20). 
	  
Structural	  remodelling	  with	  Dyssynchrony	  and	  electromechanical	  
delay.	  
 
In the human and animal models outlined above, there is an interrelationship between altered 
work and mechanical load and adaptive structural changes that take place i.e. the ventricle 
must adapt to the change in workload that dyssynchrony imposes and this usually results in 
changes in extracellular matrix, myocyte hypertrophy and alterations in structural proteins 
such as gap junctions. In the context of pacing induced dyssynchrony, hypertrophy is 
observed in the wall furthest from the pacing site i.e. the late activated region. Contrastingly, 
thinning appears nearest to the site of pacing i.e. the early activated segment (20).  
 
The mechanism behind these adaptive changes is unclear though cardiac load and 
neurohumoral factors are thought strong contributors. Ventricular asynchrony results in 
redistribution of mechanical work and alters perfusion and oxygen demand. During pacing 
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there is a reduction in regional myocardial perfusion and O2 consumption nearest to the 
pacing site.  
 
Models of electrical stimulation, altered perfusion and ischaemia/hypoxia have been shown to 
result in gap junction remodelling in cell cultures, tissue and at the whole heart level. The 
duration of exposure to such noxious stimuli is an additional factor predicting severity of 
GJR. Thus, if dyssynchrony is sustained over a sufficient length of time it results in structural 
change. 
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Gap Junctions-specific key observations on which hypothesis and aims of thesis are 
based 
In this next section, I will lay out key concepts from the gap junction biology field that are 
relevant to the hypothesis and aims of this thesis. These key observations form the basis of 
my work in the study of dyssynchrony induced gap junction remodelling, with possible 
alterations in gap junction intercellular communication and cellular coupling. Observations in 
the field may assist understanding the mechanisms driving dyssynchrony induced GJR. I will: 
(i) Define gap junction remodelling and present the structure of a connexon. 
(ii) Present how gap junctions as well as individual connexins are organised and 
distributed in the normal heart. 
(iii)  Share with readers how assembly of gap junctions occurs and how this relates to 
their function vis. gap junction intercellular communication (GJIC).  
(iv)  Contrastingly, I will also describe the process that remodels gap junctions in the 
heart’s adaptive response to external stimuli 
(v) Present the process of oligomerization, intracellular trafficking and targeting to 
the cell membrane. 
(vi)  Describe the regulatory process affecting internalisation and degradation. 
(vii) Include the regulatory effect of phosphorylation in these sub-cellular 
compartments will also be considered since they all affect the expression of gap 
junctions. 
(viii) Introduce the connexin gene family, in addition to translational and post-
translational modifications that also alter gap junction expression. 
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(ix)  Describe how gap junctions modulate the propagation of the action potential 
(x) Present evidence from animal and human models of cardiac disease examining the 
role of gap junction remodelling in the genesis of arrhythmias within atrial and 
ventricular tissue. 
(xi)  Describe the role of connexin binding partners and protein-protein interactions, 
which integrate into a gap junction nexus and their role in disease. 
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Connexins forming Gap Junctions: 
 
Gap Junctions are dodecamers formed from protein subunits called connexins: six connexins 
form one connexon and two connexon hemi-channels make up a gap junction (27;28). 
Connexons are targeted to the membrane to form gap junction channels when they dock with 
connexons of neighbouring cells (see Figure 1 and Figure 7). Multiple channels cluster to 
form plaques of varying size. 
 It is generally accepted that connexins alone generate gap junction channels (29-31). 
Experimental work demonstrated sequences consistent with integral membrane proteins with 
a transmembrane domain as well as the reconstitution of connexins into artificial membranes 
and in heterologous (e.g. yeast) systems.  Furthermore, electron microscopy and 
immunocytochemical studies localised connexins to gap junction plaques (32;33). The term 
“gap junction” has prevailed from the electron microscopy work of Revel and Karnovsky 
appearing as a small gap of 2-3nm where the plasma cell membranes of adjacent cells are 
closely apposed (33;34). 
Initially, it was thought that all gap junctions contained the same protein, however, 
differences in electrophoretic mobilities of bands detected by SDS-PAGE (21-70kDa) 
resulted in the current nomenclature system using the word connexin (abbreviated Cx) and 
followed by a suffix indicating the molecular mass of the polypeptide connexin in kilodaltons 
(kDa)(35;36).  
The existence of such gap junctions as a low resistance pathway was first postulated by 
Weidmann well before the discovery of the gap junction structure when he observed that the 
space constant for the spread of current between strips of myocardium exceeded the expected 
value for a single Purkinje fibre(37). Robertson’s studies provided evidence for a neuronal 
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junction structure responsible for intercellular electrical transmission(33) while others 
working in excitable tissues observed the presence of a junctional structure (38).  
Connexin Isoforms and genes coding for connexins 
 
The connexin family consists of 21 gene members in humans and 20 genes in mice (see Table 
1), though not all are expressed in the heart. Connexins are tissue-specific e.g. hepatocytes 
express Cx26 and Cx32 (39-41) while cardiomyocytes express Cx40, Cx43 and Cx45 
(42;43). They are co-expressed in distinct combinations, which influence structure and 
function (30;44;45). The presence of two or more connexins in each tissue type is a consistent 
principle, which seems to allow for compensatory mechanisms in order to overcome loss or 
mutation (see Table 1)(46-49).. They also exhibit the principle that there are certain functions 
that cannot be compensated for despite the co-expression of two or more connexins, so called 
“non-redundant” functions (50).  
Of all connexin family members, Cx43 is the most ubiquitously expressed and can be found 
endogenously expressed in 35 distinct tissue and cell types, some of which include 
cardiomyocytes, astrocytes, keratinocytes, endothelial cells and smooth-muscle cells(51). The 
connexin genes are located on a variety of chromosomes with a clustering of connexin genes 
on murine chromosome 4, which is similar to a region on human chromosome 1.  Genes 
encoding connexins appear to have a first exon containing the 5’-untranslated sequences and 
a large second exon with the complete coding region as well as remaining untranslated 
sequences. There are exceptions to this gene structure e.g. Cx32, Cx36 and Cx45.  
Furthermore, variations in the number of introns and exons have been described. 
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Figure 1 -A schematic diagram of a group of gap junction channels 
Each cell contributes a hemichannel (connexon), which spans the lipid bilayer (representing 
the cell membrane; in yellow) to dock with the opposing connexon to form the complete gap 
junction channel. Each hemichannel is formed by six protein subunits, called connexins 
(Courtesy of Dr Rasheda Choudhury).  
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Mouse Connexins Human Connexins Mouse tissue/organ Mouse cell type 
Cx23 Cx23 - - 
 Cx25   
Cx26 Cx26 Liver, skin Hepatocytes, 
keratinocyte 
Cx29 Cx30.2 Brain Oligodendrocytes 
Cx30 Cx30 Skin Keratinocytes 
Cx30.2 Cx31.9 Testis Smooth-muscle cells 
Cx30.3 Cx30.3 Skin Keratinocytes 
Cx31 Cx31 Skin Keratinocytes 
Cx31.1 Cx31.1 Skin Keratinocytes 
Cx32 Cx32 Liver, Nervous Hepatocytes, Schwann 
cells 
Cx33  Testes Sertoli cells 
Cx36 Cx36 Retina, Nervous Neurons 
Cx37 Cx37 Blood vessels Endothelial cells 
Cx39 Cx40.1 Developing muscle Myocytes 
Cx40 Cx40 Heart, Skin Cardiomyocytes, 
Keratinocytes 
Cx43 Cx43 Heart, Skin Cardiomyocytes, 
Keratinocytes 
Cx45 Cx45 Heart, Skin Cardiomyocytes, 
Keratinocytes 
Cx46 Cx46 Lens Lens fibre cells 
Cx47 Cx47 Nervous Oligodendrocytes 
Cx50 Cx50 Lens Lens fibre cells 
 Cx59   
Cx57 Cx62 Retina Horizontal cells 
Table 1  Mouse and homologous human connexin family members;  
 
Representative tissues and cell types where mouse connexin family members are found. 
Reproduced with permission from D.W.Laird (2006) Life cycle of connexins in health and 
disease Biochemical Journal, 394(3) 527-543. © the Biochemical Society (51). 
[47]	  
	  
Molecular Topology of Connexins 
 
Amino acid sequencing experiments have aided in predicting the structure of connexins, 
which include four hydrophobic transmembrane domains and a hydrophilic carboxy terminus 
(CT) tail (see Figure 2;see inset 2 in Figure 7). Three hydrophilic domains separate the 
hydrophobic regions such that there are two extracellular loops (EL) and another on the 
intracellular aspect (IL or cytoplasmic loop CL). Sensitivity to proteases of isolated liver and 
heart gap junctions and oligonucleotide antiserum to segments of Cx26, Cx32 and Cx43 have 
been used to map connexin topology (31;35;41;52-57). The CT tail has been identified as a 
key component to the remodelling process of gap junctions. 
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Figure 2 -Molecular Topology of Connexins 
Panel A-Illustration of the four transmembrane domains (M1-M4), two extracellular loops 
(E1-2), N and Carboxy (C) tail terminus of a connexin protein. Panel B- a superimposed 
connexin molecule forming the pore unit within each of two adjoining connexons in yellow. 
With permission from Kumar et al (28). 
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Gap Junction organisation in the normal heart: 
Gap Junction Distribution and Expression: 
 
Connexins in the heart are expressed in distinct combinations and relative quantities in a 
chamber and site-specific manner. Connexin 43 is the predominant connexin expressed by 
ventricular and atrial cardiomyocytes. Cx40 and Cx45 are co-expressed though in lower total 
quantities than Cx43 see figure 3,4 and 5 (5). The orientation of the connexon at the polar 
ends of the cell, particularly in the heart facilitates electrical transmission in the orientation of 
the fibre axis (see Figure 5) (58;59).  
Diversity in gap junction function occurs as a consequence of different constituent connexins- 
Cx40, Cx43, and Cx45 in the heart (see Figure 3 and Figure 6) (5;43). This diversity is 
further enhanced due to differences in regional expression. This leads to functional 
heterogeneity and adaptively alters gap junctional conductance. Gap junctions may also be 
modulated by chemical or voltage gating, thus altering channel gating properties and the 
molecular transjunctional selectivity (see Figure 3 and Figure 4) (5;43).  
Although, at first glance this may seem counterintuitive, this broad range of mechanisms for 
modulating connexon function influences the physiological role of the underlying tissue e.g. 
in the heart, the specialised conduction tissue (such as the common and right bundle branch 
as highlighted in figure 4) acts as a small electrotonic source of cells transmitting to 
downstream cells (the working myocardium). This reduced coupling property of Cx40 and 
Cx45 actually favour their role in coordinating downstream myocardial activation(58).  
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Figure 3 -Connexin expression in mammalian heart 
Overview of typical connexin expression pattern of normal adult mammalian heart. With 
permission from Severs et al (5).	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Figure 4 Connexin expression patterns in rat myocardium. 
A triple labelled confocal merged image of Cx43 (blue), Cx40 (red) and Cx45 (green) 
showing the common bundle and right bundle branch which only express Cx40 and Cx45 
whereas Cx43 is present in the adjacent working myocardium alone. With permission from 
Severs et al (60). 
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Figure 5 -Cx43 distribution pattern in ventricular myocardium. 
In panel A (rat left ventricle; longitudinal section) gap junctions appear in rows and this 
corresponds to viewing an intercalated disc from an edge-on view. Contrastingly, a face-on 
view of human myocardial gap junction demonstrates larger peripheral gap junctions. In 
Panel B the white line denotes multiple discs of varying size from isolated rat myocytes. With 
permission from Severs et al (5). 
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Gap Junction Channel Configurations and their biophysical properties. 
 
Connexons and hemichannels may be composed of six identical subunits (homomeric) or 
have two or more different subunits (heteromeric);(see Figure 6). Full gap junction channels 
may also exhibit various configurations with two identical connexons forming homotypic 
channels while two different connexons form heterotypic channels thus altering the 
permeability and conductance properties of the channels formed; (see Figure 6) (43;61;62).  
These variations in expressed connexins modulate gap junction intercellular communication 
(GJIC) (63).Since each connexin subunit has its own unique gating and perm-selective 
properties it follows that different combinations of connexins yield gap junctions with new 
biophysical properties. In doing so this changes the interconnecting communication and 
electrical properties or coupling between cells(58).  
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Figure 6 -Potential for gap junction channel diversity when combining constituent 
connexins 
Varying combinations of connexins form connexons, hemichannels and gap junction 
channels. Cx45 is coded in white and Cx43 in grey. With permission from  
Moreno et al (43). 
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Electrophysiological properties of Gap Junctions: 
Gap Junction Intercellular Communication: 
 
Gap junctions are involved in communication, coupling cells electrically and metabolically, 
allowing non-specific communication, and passive diffusion of metabolites along electro-
chemical gradients; peptides conjugated to fluorescent dyes in transfer studies have 
demonstrated the relative non-selective nature of the channel for molecules <1kDa in size 
(28;64). The passage of inorganic ions (Na+, K+, Ca2+) and small molecules/ secondary 
messengers such as adenosine, ADP, ATP, cAMP and IP3 are well described(27). 
Factors that modulate communication include (i) the distribution and levels of expression of 
connexins, (ii) trafficking and degradation, (iii) the constituent connexins partaking in the 
formation of the channel and (iv)modulation of gating itself via voltage and chemical gating; 
ultimately affecting the numbers of channels and their open or closed configuration. In turn, 
this affects the propagation of action potentials between cells(58). 
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Electrophysiological role of Gap Junctions in Cellular Coupling. 
Gap Junction and Action Potential Propagation. 
 
Impulse propagation at the whole organ level of the heart is meticulously orchestrated. 
Initiation of the electrical impulse occurs at the SA node, spreads over the atria, and 
penetrates through the fibrous AV ring via the AV node and conduction system along the 
bundle branches and specialised purkinje-ventricular interface thus invading both ventricles. 
This results in the synchronous contraction of the working myocardium. When any disruption 
to this orchestrated process occurs, it results in dyssynchrony between the chambers of the 
heart with significant and deleterious electrical and mechanical effects; illustrated in more 
detail in the next section cardiac pathology induced gap junction alterations.  
Impulse propagation in the heart interests clinicians and basic scientists because alterations in 
conduction velocity (θ) may contribute to cardiac arrhythmias(58). 
 At a cellular level, 4 discrete elements affect local circuit currents and the propagation of an 
action potential: 
1. Excitatory inward current channels i.e. Na+, K+ and Ca2+ (INa, IK and ICa(L) and ICa(T)); this is 
considered the source factor. It exerts its effect by the maximal upstroke velocity of action 
potentials, dV/dtmax . 
2. Intracellular longitudinal resistance ri = the sum of the cytoplasmic resistance (rc) and gap 
junction (GJ) resistance (rj); This is a sink factor and consumes charge. 
3. Capacitance of the non-junctional membrane, cm. This is also a sink factor and consumes 
charge. 
4. Extracellular longitudinal resistance ro. This is also a sink factor consuming charge. 
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These 4 elements determine the conduction velocity (θ) of an action potential and an 
approximation is that θ2 is proportional to dV/dtmax and inversely proportional to (ro + ri). The 
space constant, λ, describes the tendency for current to spread between adjacent cells.  
Though this is a reductionist approach it is useful and has been applied in mathematical and 
computer models to integrate experimental findings and predict likely outcomes (58;65). 
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Gap Junction Trafficking, Targeting, Turnover and Degradation: 
 
An important factor modulating communication, as mentioned earlier, is the trafficking and 
degradation of connexins and the gap junctions they form. The biosynthetic study of 
connexins has been furthered with the advent of anti-connexin antibodies utilised in 
metabolic labelling and immunoprecipitation (66).   
Pulse-chase experiments demonstrate that Cx43 is initially synthesised as a 40-42kDa 
polypeptide that is subsequently posttranslationally modified to forms with slower SDS-
PAGE mobility due to phosphorylation of serine residues (67-70). Phosphates are added to 
Cx43 particularly at a serine-rich sequence near the carboxy terminus (CT) to yield 
phosphoform with degrees of phosphorylation (P0, P1 and P2) soon after translation. Various 
drugs that inhibit protein trafficking have been used to demonstrate that partial 
phosphorylation of Cx43 occurs before exiting the Golgi apparatus (71;72).  
 The location at which connexins oligomerize into connexons appears connexin specific with 
Cx32 assembling at the endoplasmic reticulum (ER) while Cx43 assembles in the trans-Golgi 
network (73-77). Contrastingly, Cx26 hemichannels appear to be directly incorporated into 
the plasma membrane post translation(78) and in liver tissue, Cx26 appears in an ER/Golgi 
intermediate compartment while Cx26/Cx32 constructs are preferentially located in a Golgi 
membrane fraction (74).  
This has raised an important concept in gap junction biology that connexins (including 
cardiac connexins) localise in subcellular pools and in doing so avail themselves to rapid 
trafficking when needed(79). There appear to be specific pathways for transporting newly 
synthesised connexins to the plasma membrane; a discovery achieved with chemical 
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inhibition experiments disrupting the Golgi compartment and that disassemble microtubules 
(75;80;80-82).  
The role of the microtubules has emerged as an integral option to transporting packaged 
vesicles in association with motor proteins directly to the cell membrane (83). They are 
regulated by the microtubule plus-end binding proteins such as EB1 and p 150GLUED which 
target Cx43 vesicles to specific membrane sub domains through interactions with the 
adherens junctions (AJ) complex (Figure 7) (83). Interestingly, EB1 is displaced from 
microtubules of stressed human and mouse myocardium limiting the delivery of connexons to 
the cell membrane (84;85).  
So far, two important paradigms exist for the transfer of Cx43 vesicles: i) the direct targeting 
of gap junctions towards the intercalated disc/adherens junction complex and ii) the passive 
diffusion paradigm vis. Cx43 hemichannels are incorporated into the lateral plasma 
membrane and diffuse along towards the intercalated disc/gap junction complex(86).  
The localization of Cx43 to the plasma membrane appears influenced by the cadherin/catenin 
complex(87;88) (especially Ca2+ dependent cadherin) and cell adhesion itself appears to play 
a role in phosphorylating Cx43 to its P2 isoform and restoring GJIC in S180 cells transfected 
with LCAM (E-cadherin)(70;89). Cell contact sites mediated by the cadherin/catenin 
complex act as foci for gap junction formation as shown by colocalisation of connexins with 
E-cadherin or β-catenin(87). Antibody studies directed to cadherin disrupt gap junction 
formation in Novikoff hepatoma cells.(90). 
Recent data also supports the targeting of gap junctions to the periphery of GJ plaques while 
internalisation of centrally located GJ aggregates removes older gap junctions(91). The 
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mobility of connexins (Cx43 in particular) into discrete plasma-membrane domains appears 
to be part of the process of GJ formation (see Figure 7)(92). 
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Figure 7-Connexin Trafficking and Targeting to Gap Junction Plaques 
Connexin moieties (inset 2 showing molecular topology of connexin) are assembled into 
connexons (“hemichannels”) in the endoplasmic reticulum (ER).  Connexons are either 
inserted into the plasma membrane directly from the ER or, as is the case most often with 
Cx43, are packaged into vesicles in the Golgi apparatus (GA) and transported via 
microtubules to the membrane.  The mechanism by which connexin hemichannels are 
subsequently targeted to the gap junction plaque (inset 3) is as yet undefined (inset 1 
illustrating open and closed hemichannels on the lateral membrane) With permission from 
Saez et al (27). 
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Gap Junction Degradation: 
	  
In contrast to mechanisms for production and trafficking of connexins, degradation also 
modulates the gap junctions. The half-life of connexins is very short, 1-1.5 hours for Cx43 
(93;94). Modulating the degradation of gap junctions alters the available channels at the GJ 
plaque in the cell membrane and directly affects intercellular communication (GJIC)(95;96). 
This is a key area of interest in the study of GJR.  
Morphological and biochemical studies in models of ischaemia and remodelling have 
demonstrated that gap junctions are internalised into endosomes as “annular gap junctions” 
and followed by degradation in lysosomal or autophagosomal compartments (see Figure 7) 
(89;97-100). The ubiquitin pathway targets gap junctions for degradation (101-108).  
  
[63]	  
	  
 
Regulation of coupling and Biosynthesis of Gap Junctions;The role of 
Phosphorylation of Gap Junctions: 
 
Connexins are phosphoproteins amenable to phosphorylation; with the exception of Cx26 due 
to its limited length and few C-terminal tail amino acids (highlighting the importance of the 
CT tail in phosphorylation state). Phosphorylation occurs either in vivo or in vitro at protein 
kinase consensus sites or can be directly incorporated (as in 32P studies) and alters mobility 
on SDS page; of all connexins, Cx43 is most extensively investigated and modified by 
protein kinases and phosphatases (89;109;110).  
Phosphorylation of Cx43 allows for sub states with altered dynamic properties and varying 
GJIC (30;111;112). Cx43 phosphorylation is mediated by protein kinases including v- and c-
src kinase, protein kinase C, mitogen activated protein kinase, cyclin dependent kinase 2, 
casein kinase 1, and protein kinase A.   Balancing the dynamic interplay of phosphorylation 
and dephosphorylation are protein phosphatases such as PP1 and PP2A (112-114). This is 
illustrated in detail (see Figure 8). 
Phosphorylation has been implicated in a broad range of mechanisms causing gap junction 
remodelling including connexin biosynthesis, trafficking, assembly, membrane insertion, 
channel gating, internalisation and degradation (27;109;110;115;116).  
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Figure 8  Cx43-binding proteins and proteins phosphorylating Cx43 
Protein kinases that are known to phosphorylate Cx43- shown along the top of a 
diagrammatic gap-junction plaque. Scaffolding proteins and proteins of unknown function 
shown to bind directly or indirectly to Cx43 are illustrated along the bottom of the gap-
junction plaque. It is not necessarily expected that all proteins shown here bind to Cx43 while 
it is a resident of the gap-junction plaque. MAP kinase, mitogen-activated protein kinase; 
CIP85, Cx43-interacting protein of 85 kDa. Reproduced with permission from D.W. Laird 
(2006) Life cycle of connexins in health and disease Biochemical Journal, 394(3) 527–543. 
© the Biochemical Society(51). 
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Connexin Proteome, binding partners and Protein-Protein Interactions 
 
The gap junctions appear to be closely related to neighbouring protein partners. Detergent 
extraction techniques in earlier studies stripped the associated signalling and scaffolding 
proteins and had erroneously suggested that there is autonomous connexon function. This 
paradigm has shifted in the field as increasing numbers of binding partners are identified and 
collectively called the “gap junction proteome” or “nexus”. Combinational techniques such as 
coimmunoprecipitation, colocalisation, cofractionation, yeast-two hybrid and cell-free 
affinity binding studies have been employed in discovering partner proteins (51;117). 
Given that Cx43 is the most ubiquitous of the connexin isoforms it has been the primary 
focus for most of this work. Therefore an important limitation to this data in understanding 
mechanisms of GJR is whether these interactions apply to all the other connexin isoforms; 
this has yet to be studied. 
Broadly there are 5 major groups of interaction: 
1. Inter-connexin interactions; structural and temporal coexpression of different connexins.  
2. Post-translational modifiers; includes protein kinases (8 have been identified), protein 
phosphatases (3 have been studied), Nedd 4 ubiquitin ligase, organ of Corti protein 1 (OCP1) 
and ubiquitin (in response to phorbol esters and epidermal growth factors) 
3.Scaffolding and cytoskeletal proteins form bridges to microfilaments and microtubules and 
cross-talk with occludin, claudins and N-cadherin to form a junctional nexus; they include 
zonula-occludens 1, 2, 3 (ZO-1, ZO-2, ZO-3) and ZO-1 associated nucleic acid binding 
protein (ZONAB), plakophilin-2 (PKP2), actin, spectrin, drebrin, cortactin, β catenin, tubulin 
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and EB1. This interaction plays a role in regulating gap junction distribution, gap junction 
plaque size and internalization. 
4. Trafficking regulators. 
5. Other molecules and growth regulators; an area, as yet, not easily classified protein 
partners which influence cell growth (NOV, CCN3, Disc large homolog 1), channel closure 
via Ca2+ (as in interaction with calmodulin) and other channel modifying agents Aquaporin-O 
(AQP-O), Acetylcholine receptor (AChR) and purinoceptor (PzX7). A putative and 
controversial role linking connexins to mitochondrial function has been suggested by 
interactions with translocase of the outer membrane 20 (Tom20), heat shock protein 90 
(Hsp90) and the adenine nucleotide transporter (ANT). 
The arrangement of all these molecules and interrelationships is depicted in Figure 9.  
  
[67]	  
	  
 
 
Figure 9 The arrangement of junctional complexes into a nexus 
Gap junctions, adherens junctions consisting of cadherins and tight junctions made up of 
occludins and claudins often closely arrange in epithelial cells and share common binding 
proteins that scaffold to actin and microfilaments. Binding-protein-mediated cross-talk 
occurs. This allows these three junctional complexes to act as a nexus. They are governed by 
some common regulatory events. Reproduced with permission from D.W. Laird (2006) Life 
cycle of connexins in health and disease Biochemical Journal, 394(3) 527–543. © the 
Biochemical Society(51). 
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Cardiac Gap Junction Remodelling in Human Cardiac Disease and in 
Animal Models. 
Gap Junction Remodelling strongly associates with arrhythmogenic and disease substrates. 
GJR has been seen in mutated genes of congenital hearts and in the acquired forms of 
ischaemic heart disease, hypertrophy secondary to pressure and volume overload as well as 
dilated cardiomyopathy(9;14-16).  
Gap junction remodelling due to mutations in connexin-encoding genes.  
Developmental malformations in connexin knock-out mice suggest that the cardiac myocyte 
gap junctions have the potential to act as pathways for direct passage of signalling molecules 
and ions from cell to cell especially during cardiac morphogenesis(5). In humans much 
interest was generated by the observation of complex cardiac malformations and visceroatrial 
heterotaxia or hypoplastic left heart syndrome with mutations of the Cx43 gene affecting 
phosphorylation sites in the Cx43 carboxy tail (118;119). A range of Cx43 mutations are 
clearly associated with oculodentodigital dysplasia affecting the eyes, limbs, teeth, face and 
in some the heart (120-122). Anomalies of the aortic arch in a small proportion of cases are 
due to chromosomal and Cx40 gene deletion while somatic missense mutations and 
polymorphisms in the gene’s regulatory region have been linked to atrial fibrillation (5;123-
125).  
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Gap Junction remodelling in acquired adult heart disease. 
1. Effects of acute cardiac ischaemia on gap junction remodelling 
 
Occlusion of a coronary artery results in ischaemia with the affected territory of myocardium 
experiencing major alterations in impulse formation and propagation. Action potential 
upstroke velocity decreases, conduction velocity transiently increase then slows; changes in 
refractory period ensue with localized conduction block and re-entry arrhythmia. These are 
not uniform changes and ectopic foci also arise in ventricular myocardium.  
Experimental animal studies demonstrate rapid dephosphorylation of Cx43, electrical 
uncoupling and altered distribution of gap junction immunolabelling to the sides of 
myocytes- referred to as “lateralization” (126;127). Immunolabelling using antibodies 
directed to different phosphorylation sites on Cx43 suggest that dephosphorylated Cx43 is 
associated with laterally distributed gap junctions while gap junctions that are at the polar 
intercalated disc orientation contain phosphorylated Cx43. 
An important concept in the field which has yet to be fully clarified is whether the striking 
lateralized immunofluorescent signal is attributable to potentially functional gap junctions 
connecting side-by-side myocytes and what proportion represents vesicles of gap-junctional 
membrane internalised due to cellular stress (5;65). 
Ischaemic preconditioning reduces the adverse effects of ischaemia on gap junctions raising a 
possible role by connexins extending beyond their electrical coupling. Possible mechanisms 
include the opening of hemichannels altering cellular swelling, releasing ATP and reducing 
membrane potential during ischaemia (128-130).Gap junction mediated passage of 
ionic/molecular signals appears responsible for the spread of ischaemia-reperfusion injury 
from myocyte to myocyte thus leading to cell rigour contracture and cell death (131;132). 
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This idea has been supported by the use of uncoupling agents such as heptanol during or prior 
to an ischaemic insult and the resulting reduced infarct size. Trafficking of Cx43 to 
mitochondria has been proposed as central to the role of Cx43 in preconditioning with 
numerous proposed candidate mechanisms (5;133). Conversely, agents such as AAP 10 and 
rotigaptide that maintain the open state of gap junctions have also been studied to challenge 
the paradigm in the translational sciences vis. that closed channels are beneficial (134-136). 
2)Altered distribution and expression in heart failure  
 
Cx43 gap junction immunosignal lateralization is a feature of the infarct border zone of 
surviving myocytes around the bordering scar tissue in the human ventricle and also in 
animal models of acute infarction (see Figure 10) (8).	  
Ultrastructure techniques such as electron microscopy have aided our understanding of the 
structural changes that this lateralized signal represents and reveal that both laterally disposed 
gap junctions connecting adjacent cells and internalized non-functional gap junction 
membrane contribute to this abnormal pattern.  
A similar change has been found in models of rat ventricular hypertrophy and correlates with 
reduced longitudinal conduction velocity, a potential proarrhythmic feature. In a dog model 
of infarction the lateral gap junction label correlates spatially with electrophysiologically 
identified figure-of-eight re-entrant circuits(8). Gap junction changes distant from the infarct 
scar tissue, in particular reduction in the size and number of gap junctions per unit length of 
intercalated disc, and fewer side-to-side connections between cardiac cells characterize 
longer term remodelling events in dog myocardium. 
 In idiopathic dilated cardiomyopathy, myocarditis, compensated hypertrophy due to valvular 
aortic stenosis and end stage human heart failure smaller areas of gap junction disarray have 
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been reported. Patches of few or absent gap junctions are seen amongst normally arrayed gap 
junctions in decompensated hypertrophy due to aortic stenosis and emphasise that even in the 
absence of infarcts, Cx43 gap junction distribution becomes heterogeneous. In hypertrophic 
cardiomyopathy, the commonest cause of sudden cardiac death due to arrhythmia in young 
adults there is a particularly disordered arrangement of gap junctions dictated by the 
haphazard myocyte orientation, which characterizes this disease(9).  
In “hibernating myocardium” there is a unique form of gap junction remodelling where the 
large Cx43 gap junction typically found at the edges of the intercalated disc are smaller in 
size and the overall amount of immunodetectable Cx43 per intercalated disc is reduced, 
compared with normally perfused segments of myocardium within the same heart. This 
finding was the first indication that not only does gap junction remodelling contribute to 
arrhythmia in ischaemic heart disease but also impaired ventricular contraction(14). 
In transplant patients (a treatment option for end stage heart failure), there is marked 
reduction in ventricular Cx43 transcript and protein levels and occurs irrespective of 
aetiology (ischaemic, non-ischaemic or valvular). The reduction is spatially heterogeneous 
and progressive over the course of the disease. This has been indicated by the pattern of 
change in pressure-overloaded hearts with aortic stenosis and its presence in non-failing 
hearts with ischaemic heart disease(5).   
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Does Gap junction remodelling and reduced Cx43 contribute to atrial and ventricular 
arrhythmia? 
 
This is a critical question as it is commonly assumed that such reductions in Cx43 in the 
disease human ventricle lead to slowed conduction, and render the ventricle more susceptible 
to re-entry arrhythmia. Therapeutic interventions that increase coupling have been proposed, 
however experimental cell and theoretical models show that action potential propagation can 
fail in well coupled cells if these form a large mass or “sink” receiving a relatively small 
depolarizing “source” current i.e. a so called “source-sink mismatch”. In these instances 
reducing the coupling in the sink can overcome conduction block. Thus the reduced Cx43 of 
sufficient magnitude to reduce coupling may represent a protective mechanism or response 
that increases the safety of conduction(5). 
However, there is a surplus of gap junctions in the mammalian heart and computer models 
predict that even substantial reductions in content make relatively little difference to 
propagation velocity. In keeping with this theory, the magnitude of reduction associated with 
sudden cardiac death in the cardiac restricted Cx43 knockout mouse is in the order of 90%, 
much greater than the average reduction of ~50% observed in the failing human ventricle. Of 
course, there is considerable spatial heterogeneity in the extent of reduction with some 
regions of diseased hearts approaching >90% reduction of control values. Such heterogeneity 
is critical to both altered impulse propagation and contractile dysfunction. This was elegantly 
demonstrated experimentally in a chimeric mouse model generated to give patches of 
myocardium lacking Cx43. When combining areas with heterogeneous gap junction 
distribution with areas expressing reduced Cx43 levels they appear to act co-operatively to 
create an arrhythmogenic substrate at less severe levels of overall gap junction reduction than 
theoretical models predict. In selectively bred cardiac-restricted knock-out mice, 59% 
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reduction in Cx43 does not alter propagation velocity or susceptibility to arrhythmia, but 
when Cx43 reduction reaches 18% of control levels and appears heterogeneous there is a 
50% slowing of conduction velocity and 80% of animals are inducible into lethal ventricular 
arrhythmias. Furthermore, the threshold for arrhythmia may be facilitated by other factors 
such as ischaemia e.g. halving the Cx43 content in transgenic mice and subjecting them to 
ischaemia is sufficient to increase the incidence, frequency and duration of ventricular 
tachycardia(65).  
Extrapolating findings from mouse to man could be argued as being flawed due to the small 
size of the murine heart and its theoretical inability to accommodate large re-entrant circuits; 
however, in a dog model of heart failure it has been shown that a heterogeneous 50% 
reduction in Cx43 results in slowed transmural conduction and dispersion of action potential 
duration of magnitude sufficient for conduction block and re-entry(5).   
 
Connexin 45, connexin 40 and the Purkinje/working ventricular myocyte interface. 
 
Since Cx43 is the main focus of most arrhythmic models it raises the question as to the role 
of the other connexins and in particular Cx40 and Cx45 in the human heart. A report of 
elevated expression of Cx45 in the failing human ventricle alongside the reduced Cx43 
significantly alters the Cx43:Cx45 ratio. Since co-expression and mixed assembly of gap 
junctions with Cx43 and Cx45 is possible this would predict channels with substantially 
different functional properties. Experimentally overexpressing Cx45 such that the Cx45:Cx43 
ratio is substantially increased in transgenic mice has demonstrated increased susceptibility to 
ventricular tachycardia and reduced gap-junctional intercellular communication(65). 
Increased Cx40 expression has been found in the failing human ventricle in a regionally 
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restricted manner and confined to end-stage ischaemic heart disease. The endocardial surface 
and adjacent to purkinje fibres appears to be the site of Cx40 upregulation and highlights the 
purkinje/working ventricular myocardium as a potential site of altered electrical coupling that 
may trigger arrhythmogenesis. Amongst older surviving cardiac restricted Cx43 knockout 
mice there is increasing propagation across purkinje/myocyte junctions, which alters 
activation and favours wave-front collisions paralleling patterned cell culture experimental 
findings as classically described by Rohr. Nonetheless cautious interpretation is necessary 
since there are important differences between in vivo models, in vitro patterned cell cultures 
and species differences, as is the case between porcine, human and murine models. It appears 
that the architecture of the purkinje/myocardial interface is a complex structure with a zone of 
mediating cells, the transitional cells that connect the purkinje fibres to the myocardium(5).  
Since, this process occurs from the endocardium the model utilised in this thesis is unique in 
that it not only induces dyssynchrony between the ventricles but it also reverses the activation 
pattern across the transmural surface of the myocardium. This is very relevant as it stands in 
contrast to the ex vivo LV wedge preparations utilised to study tissue dispersion and 
heterogeneity in understanding the mechanisms of arrhythmia(5). 
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Gap junction remodelling in atrial fibrillation 
 
Intense interest abounds in understanding the commonest atrial chamber related arrhythmia, 
atrial fibrillation (AF) and the role of gap junctions. There are many contradictory findings in 
this area (in humans high, low and even unchanged levels of Cx43 and Cx40 expression in 
AF have all been described) and there is a challenge to find more refined and rigorous 
approaches to tease out the effects of gap junctions and connexins.  
It is possible that differences between humans and animal models relate to differences in 
species, age differences, disparity of experimental protocols for AF induction and in humans 
dissimilar clinical sub-sets of patients with divergent associated pathological factors. Many 
aspects contribute to the pathophysiology of AF, including focal triggers and altered 
conduction, and there are important differences in the principal drivers between chronic AF 
(here gap junction remodelling may occur as part of AF-related remodelling) and paroxysmal 
or triggered AF (pre-existing features of connexin or gap junction expression act as a 
predisposing factor in AF occurrence)(137;138).  
The issue is further complicated by the multi-factorial nature of AF and the relative 
importance of gap junctions as causal contributors may vary between patients.  Technical 
deficiencies include the common lack of antibody specificity. Confusion persists due to 
considerable variation in the appearance of normal atrial myocardium and the gap junction 
arrangement observed both at the end of cells or lateralized to the plasma membrane in 
healthy samples.  
Also heterogeneity as observed in the goat model of AF where patches of absent Cx40 have 
been described as AF-induced change resemble the natural appearance of human atria. This 
has complicated the development of reliable quantitative methods for comparing AF and 
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normal samples. The work by Allessie suggested changes in gap junctional gating, 
distribution and expression. Increased vulnerability to inducible AF has been demonstrated in 
animal models of heptanol induced gap junction uncoupling(139). Furthermore, altering cell 
coupling in a model of sterile pericarditis demonstrated a transmural gradient in the volume 
fraction of Cx40 and Cx43 which favoured atrial conduction abnormalities (140). Cx40 
knock-out mice and Cx40 genetic polymorphism association studies in humans have 
identified higher AF susceptibility and emphasised the role of Cx40 in AF 
(124;125;137;138;141;142).  
The contribution of Cx43 in AF is less clear with contradictory results reported with 
increased levels in the canine model but unchanged levels in the goat model. The 
inflammatory molecule tumour necrosis factor (TNF) overexpressed in a mouse model is also 
implicated in AF susceptibility through its role in fibrosis and remodelling with reduction in 
Cx40 levels (138;143). 
An important distinction to make is that the sub diaphragmatic pacing induced dyssynchrony 
model does not utilise the rapid rates of firing utilised to pace the goat. Tachycardia is a well-
recognised entity that alone induces heart failure with the passage of time likely due to 
cellular oxidative stress and an inability to cope with the contractile and therefore energy 
demands imposed on the cell. There are also changes in calcium handling which result in 
overload (4;23). However, clinical studies of physiological atrial pacing have also highlighted 
an increased propensity to atrial fibrillation though cautious interpretation is needed as the 
original pacing indication may suggest other underlying heart disease that affects the 
conduction system or the atrium (144-146). The sub diaphragmatic pacing model bypasses 
these issues in generating the hypothesis and tests it without tachycardia or any apparent 
underlying disease process. 
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Gap Junction Remodelling and Ventricular arrhythmia 
Gap junctions have been implicated in uncoupling cells during the acute and subacute phase 
of myocardial ischaemia resulting in conduction slowing. The predominant mechanism of 
ventricular tachycardia (VT) in acute, subacute, and chronic phases of myocardial ischaemia 
is re-entry; focal triggers contribute less so (8;12;147-149). Re-entry is due to dispersion of 
action potential duration in the acute phase or anisotropy in the chronic phase of myocardial 
ischaemia. The epicardial border zone of healing canine infarcts has disturbed Cx43 
distribution and correlates with re-entrant ventricular tachycardia circuits (see Figure 10). 
The inverse relationship between Cx43 levels and arrhythmia is highlighted in the cardiac 
restricted Cx43 transgenic mice, which despite structurally normal hearts appear to succumb 
to sudden cardiac death at around 2 months from lethal ventricular arrhythmias(6).  
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Figure 10 Gap Junction remodelling in epicardial border zone of healing canine infarct. 
Gap Junction remodelling in epicardial border zone of healing canine infarct correlates with 
the location of figure-of-eight re-entrant tachycardia circuit. Reproduced with permission 
from Peters et al (8). 
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Co-­‐expression	  of	  multiple	  connexins:	  non-­‐canonical	  properties	  
 
The predominant nature of Cx43 in the ventricle has facilitated observation that gap junction 
remodelling predisposes to arrhythmia. Co-expression of Cx40 has unexpected functional 
effects (as seen in atrial tissue and the purkinje/myocardial interface). In vitro expression has 
consistently found that expressing Cx40 alone makes high conductance gap junctions and it’s 
been assumed that co-expression with Cx43 in vivo would elevate cell-to-cell coupling. 
 However, this has not been borne out. Cultured neonatal atrial myocytes from heterozygous 
Cx43 and Cx40 knockout mice, with 50% reduction of Cx40 levels, demonstrate an increased 
propagation velocity. With near zero levels expressed, Cx40 propagation increases even 
further. This inverse relationship between Cx40 levels and propagation velocity against a 
background of Cx43 expression helps explain previous contradictory findings in the human 
atrium(5). 
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Cellular mechanisms of gap junction remodelling as derived from disease 
models  
	  
As with all proteins, connexin expression may be regulated at the transcriptional and post-
transcriptional levels. The interaction of transcription factors with their target elements to 
control transcript expression has advanced as our knowledge of the structure of the genes 
encoding Cx43, Cx40 and Cx45 has progressed. In a recent study the role of microRNA-1 in 
silencing GJA1 (the gene encoding Cx43) and KCNJ2 (K+ channel subunit Kir 2.1) in 
ischaemic heart disease has been identified as a post-transcription regulator. These 
microRNAs are endogenous non-coding RNAs that interact with target mRNAs to prevent 
translation; levels appear elevated in diseased human ventricle and antisense blocking of this 
elevation prevents arrhythmia in a corresponding animal model (51;117;117;150).  
Apart from connexin synthesis, regulatory mechanisms may affect assembly into connexons, 
channels and gap-junction plaques as well as degradation. Extracellular signalling pathways 
leading to altered connexin expression in disease may be triggered in part by mechanical 
forces and involve cAMP, angiotensin II, and growth factors such as VEGF, activated via 
protein kinases such as focal adhesion kinase and c-Jun N-terminal kinase  (JNK). JNK 
activation in a transgenic mouse model leads to down-regulation of Cx43, slowing of 
ventricular conduction, contractile dysfunction and congestive heart failure. 
Research has focused on connexin partner proteins, which possess regulatory properties that 
interact with the carboxy-terminal domain of Cx43. This domain houses important residues 
involved in channel gating and phosphorylation (which itself can affect a variety of processes 
from trafficking to assembly and degradation).  
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Several protein-protein interactions and binding partners have been discussed earlier and it is 
worth noting again the role of zonula occludens-1 (ZO-1) and tubulin. Binding sites at the 
carboxy-terminus exist for such motor proteins driving the trafficking and targeting 
connexins to their destination. ZO-1 appears intimately involved in regulating gap junction 
size such that removal or blocking of this protein results in larger and more extensive gap 
junction plaques. An important finding given that consistent up-regulation of ZO-1 is 
observed in disease models with an increased proportion of interacting Cx43.  Furthermore it 
is apparent this is not an isolated effect with likely “cross-talk” with adhesion junction partner 
proteins such as N-cadherin, β-catenin, γ-catenin, plakophilin-2 (PKP2) and desmoplakin. 
These proteins affect the stability and formation of gap junctions(51;117).  
Not only can this “cross-talk” occur at the membrane level but also within the cytoplasm and 
interactions occur with other signalling pathways such as Wnt mediated by β-catenin. The 
carboxy-terminus domain again appears to be a critical link in these interactions and when 
truncated forms have been expressed in mice this has resulted in larger yet fewer gap junction 
plaques with altered spatial organization at the intercalated disc(51;117). 
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Limitations	  to	  understanding	  GJR	  
 
An important limitation in the gap junction field is that although interest in exploring 
interactions between connexins and adhesion junction molecules has exploded, the technique 
of immunofluorescence and co-localization of proteins lacks resolution to infer an interaction 
at a molecular level and it may merely reflect distant juxtaposition. There remain unanswered 
questions as to the exact site of interaction between adhesion junction proteins with gap 
junctions and clarifying the hierarchy of binding partner interactions(5). 
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Chapter 2 
Development of the sub diaphragmatic model of pacing induced 
dyssynchrony  
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Overview 
Dr Gutstein originally described sub diaphragmatic programmed electrical stimulation; this 
gave rise to the idea that adapting the same technique could facilitate dyssynchronous right 
ventricular pacing (151). Advantages of this approach include the ability to study the whole 
animal and whole heart in vivo under conditions of general anaesthesia and analgesia, with 
thermoregulation, without disruption of the thoracic structures or need for cardiac surgery, 
intubation or mechanical ventilation and without damage to abdominal or mediastinal 
structures. Furthermore, the safety and tolerability of programmed electrical stimulation using 
this approach allowed administration of intraperitoneal drugs e.g. amiodarone and to perform 
temporal studies (151).   
By refining this approach, I aimed to achieve pacing of varying duration and elicit aberrant 
activation across the myocardial surface. I aimed to study the structural effects and determine 
whether gap junction remodelling (GJR) occurs. I also aimed to determine whether this 
resulted in functional changes.  
The Fishman/Gutstein lab’s transgenic mouse lines made the study of genetically modified 
mice such as the Cx43+/− cohort, with pacing, possible. It also allowed collaboration with 
other investigators interested in testing in vivo arrhythmia inducibility in their models (see 
other work arising from this period of study and publications).  
In Chapter 2, I will present the project overview, the establishment of the model including 
adequate monitoring, analgesia and recording of electrocardiogram; safe positioning of the 
stimulating probe, adequate electrical capture, reproducibility of the protocol, absence of 
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visceral damage, demonstration of survival and measurement of the pacing threshold at 
baseline and after pacing in Cx43+/+ mice. This addresses objectives 1-3 of the thesis.	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Project overview 
A series of experiments to assess functional parameters at the specified time points are 
presented in table 2; a summary of the study design. The 15-minute time point represents 
pilot experiments to establish technical feasibility of pacing, ECG and ECHO measurements. 
 
[87]	  
	  
Table 2. Overview of study design and time points selected for duration of 
dyssynchrony (Y=Yes). 
 Duration of Pacing 15 min 30min 45 min 1hour 4hour 6hours 
ECG data Y Y Y Y Y Y 
ECG axis sub study Y - - Y - - 
ECHO data Y - - Y - Y 
PES - - - Y - Y 
Immunohistochemistry(IHC) 
 and Quantification 
- - - Y Y Y 
Thresholds Y Y Y Y Y Y 
Drugs (4-AP)  - - Y - - 
Survival Study:       
4.5hours survival    Y - - 
2 weeks survival    Y - - 
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IACUC approval, wild type murine strain and age 
 
The studies were performed in accordance with the regulations of the Institutional Animal 
Care and Use Committee (IACUC) of the New York University (NYU) School of Medicine. 
Dr Gutstein and Ms F Liu coordinated access to animal resources and arranged surgical 
space, (kindly accommodated in the adjoining microbiology lab of Prof Martin Blaser and Dr 
Guillermo Perez-Perez at the Veteran Affairs Medical Centre (VAMC) and commercial 
vendors supplied oxygen and isoflurane.  
For Wildtype experiments the C57BL/6J strain (Jackson Lab, Maine, USA) was used. Adults 
were 3-4 months in age and sex matched. C.C. Little originally developed these mice in 1921, 
from a mating of Miss Abby Lathrop’s stock that also gave rise to strains C57BR and C57L. 
These became available through Charles River in 1974 when they were acquired from NIH. 
Animals were housed in the animal facility of the Veteran Affairs Medical Centre (VAMC) 
where the development of the model took place.  
Cx43+/− mice. 
Mice with reduced basal levels of Cx43 were kept at the VAMC having been previously 
produced. They were housed with their WT littermates and maintained in mixed background 
consisting of C57BL/6J, SV129 and FVB strains. 
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Design of Monitoring and analgesia 
 
Initial experiments were performed to anaesthetise mice directly under a nose cone both for 
induction and maintenance of anaesthesia. Handling involved a manoeuvre of pinching the 
nape of the neck and distal tail simultaneously and then orientated to maintain a supine 
position. The nose of the mouse once placed in the nose cone resulted in rapid anaesthesia 
though was associated with some degree of animal resistance. Furthermore, this arrangement 
resulted in leakage of anaesthetic gases in the local area. Refinements included use of carbon 
scavengers in the anaesthetic circuit. Animals were immobilised once under general 
anaesthesia with adhesive tape applied to all 4 limbs. This also stabilised the limbs for ECG 
recordings and avoided movement artefact. Surgical tape was applied to each of the paws 
against a firm glass plate surface (see figure 14) 
Initial pilot experiments only allowed study of single animals at any time. Earliest 
experiments were performed in series for 1 hour-using 12 mice (6 paced and 6 sham paced 
for 1 hour) thus resulting in a 14 hour day. Further refinement included duplication of the set 
up to expedite throughput; initially 2 sets of nose cones were set up joined to the vaporiser 
via a T tube (with 2 separate anaesthetic gas scavengers) with a 3-way tap system. This 
allowed diversion of anaesthetic gases with the higher doses for induction being piped to one 
animal and then switching the supply of gas to both mice. Where one mouse was already 
asleep, there would be a period of some seconds where the circuit was switched off to allow 
induction of the second mouse. In the event of higher dosing of anaesthetic gas, this posed a 
risk of apnoea in either of the two mice and required extreme vigilance in managing these 
experiments since airway access and therefore manual ventilation was not available. 
Maintenance continued on lower concentration of isoflurane necessitated positioning animals 
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180 degrees apart due to concerns over the short tube length and dead space constraints. 
These refinements meant that longer duration experiments including the 4 hour pacing 
protocol and 6 hour pacing protocol were possible.  
In 2006 a final refinement to the scalability model was made when we transferred to the 
Smilow Institute at Tisch hospital. A bench top Biopac system was set up using 
AcqKnowledge software for Mac from Dr Fishman’s lab and MP 100 boxes. I refined 
anaesthetic management with veterinary staff at Vetequip (Vetequip, Inc. Pleasanton, CA.)  
with introduction of an induction chamber, vaporiser with multi-procedural tubing, taps and 
activated charcoal filters to ensure consistent levels of anaesthesia, animal safety, comfort 
and higher throughput (up to 4 experiments could be performed in a 6-8 hour time window). 
Inhaled isoflurane (4% volume induction) achieved general anaesthesia of mice inside an 
induction chamber and the mice were then transferred to a nose cone for maintenance (1.5 vol 
% maintenance; Baxter, Deerfield, IL) inhalation of a mixture of oxygen and isoflurane. 
Adhesive tape applied to each of the limbs immobilised animals on a glass plate lying on top 
of a Gaymar® (Gaymar Inc. NY, USA) heating pad set at a constant 37oC and expanded 
circuit of the Gaymar® Pump to maintain 2 heating pads for a total of 4 mice at any one time. 
A ground electrode was attached to either the ear or subdermally across the manubrium 
sterni. Removal of hair was achieved using Nair® to expose the smooth ventral epidermis. 
The epidermis was then cleaned with alcohol prior to any surgical procedure.  
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Figure 11- Bench top small mammal anaesthesia set up as provided by Vetequip. 
Vaporiser, tubing and induction chamber (reproduced with permission courtesy of Vetequip);	  
http://www.vetequip.com/images/big-­‐901806.jpg).  
[92]	  
	  
A cohort of CD-1 mice (Charles River Lab, Wilmington, MA, USA) were used for the 
immunoblotting of ventricular lysates and quantification of mRNA expression experiments.  
Recording of electrocardiograms for monitoring.  
 
Pilot experimental ECG recording involved using surgically tunnelled leads. A refinement 
included an ECG setup that could be moved between the animals using commercially 
available ECG electrodes that had a sharp needle insertion (see figure 12) and proximal 
connector that could be clipped off thus avoiding repeated surgical removal and insertion of 
the ECG leads at different stages of the pacing experiments.  
Electrode leads were applied to each of the four limbs, signals amplified and digitally 
monitored and stored on PC or Mac. Using Ponemah physiology software and/or Biopac MP 
100 we were able to record data points at baseline, during pacing to document 1:1 capture 
and following cessation of pacing. This data could then be analysed offline at a later time. 
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Application of the stimulating electrode for pacing or sham pacing 
 
After the baseline electrocardiogram recording, the ventral epidermis was cleaned with 
alcohol and sterile instruments used to make a 1cm incision in the epigastric region and 
expose the xiphisternum and diaphragmatic aspect of the abdomen. Once the liver was safely 
retracted, a custom made UE-GM1 cardiac stimulating electrode with a 200µm monopolar 
platinum tip (Frederick Haer & Co, Bowdoinham, ME) mounted on a micromanipulator and 
connected externally to the Medtronic stimulator was positioned on the right ventricular (RV) 
surface.  
A limitation to the project was a limited number of pacing probes. These were fragile and 
prone to bending at the tip. Any structural damage to the probe if sufficiently severe resulted 
in ineffective pacing with damage to the diaphragm. Extreme caution was necessary at this 
point to avoid damaging the abdominal, and critically thoracic structures as the thoracic 
integrity maintained negative pressure for spontaneous respiration. Subtle 
micromanipulations adjusted the angle, depth and height of the stimulating probe.  
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Figure 12 Example of pin electrodes supplied by Biopac; 
The distal pin electrodes illustrated were accompanied with a detachable extension clip on the 
proximal end of the leads for ease of application and removal. (Reproduced with permission 
from Biopac website;http://www.biopac.com/research.asp?SubCatID=59&Main=Electrodes). 
 
Confirmation of capture 
 
Capture with pacing during experiments was confirmed with electrocardiographic monitoring 
in real-time throughout the duration of the experiment. Pacing was performed using a Model 
2352 Medtronic Programmable Stimulator (Medtronic, Minneapolis, MN) and this device 
was also used for programmed electrical stimulation after a pacing experiment. The 
stimulating output was set at a fixed pulse width of 1.0ms and twice the diastolic threshold. 
The paced cycle length was set, maintained and adjusted throughout experiments to ensure a 
10-15% faster heart rate than the anesthetised sinus rate.  
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Managing fluid balance 
 
Gauze soaked in PBS was applied across the open wound to minimise evaporative fluid and 
conductive heat loss. However, no additional fluid was administered during pacing. 
 
Infection control and bleeding. 
 
The experiments required a sterile field and appropriate surgical clothing was worn with 
sterile gowns and gloves, as well as clean surgical hats, masks and shoe covers. In the event 
of bleeding, as occurred when animal euthanasia was performed under anaesthesia with 
transection of the aorta, I managed this using gauze and absorbent disposable surgical pads 
(separate pads for each experiment).The pads also provided some cushioning for instruments 
and required a square to be cut in them to accommodate the glass plate on which the mouse 
was immobilised. Topical antibiotic ointment was used for experiments where survival was 
being assessed after closure and to avoid surgical site infection. 
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Regulator inspection  
At least 2 pacing experiments (6 hour protocol) were performed from start to finish under 
close supervision of animal inspectors who reviewed surgical and animal handling. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
Figure 13 Stimulating electrode inserted through small subxiphoid incision into contact 
with the diaphragmatic surface of the RV. 
This open area would be covered with PBS soaked gauze to avoid dehydration. Reproduced 
with permission from Gutstein et al (151). 
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Figure 14-Pacing setup demonstrating positioning of the animal with pacing probe in 
situ. 
The probe is connected to a micromanipulator and stand. The mouse is asleep via nose cone 
and limbs fixed with adhesive pad to glass plate. A warm pad lies beneath the disposable 
surgical pad and glass plate to keep body temperature constant at 37C. ECG electrodes are 
surgically implanted in each of the limbs; these are the older style electrodes illustrated (151). 
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Sham pacing 
Age, sex and strain-matched control mice were prepared in the same way described above i.e. 
with the pacing electrode in contact with the heart but the programmable stimulator was not 
switched on. 
 
Reproducibility of positioning the Stimulating Electrode: 
 
In four animals, a midline sternotomy was performed at the end of the pacing protocol 
confirming that though the electrode traversed the diaphragm, it did not puncture the heart 
and was consistently positioned on the RV. 
 
Mediastinal viscera are not disrupted or damaged by the pacing electrode. 
 
The main advantage of the model was its consistent ability to avoid trauma to mediastinal 
structures; The heart, local structures (including the abdominal viscera i.e. liver, diaphragm 
and lungs) were not disrupted by the electrode. 
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Myocardial Tissue Appearance after short-term pacing and programmed 
electrical stimulation: 
 
To determine whether microscopic damage resulted from subdiaphragmatic pacing and 
Programmed Electrical Stimulation, Hearts from a subset of six subdiaphragmatically paced 
and PES tested animals were removed on death, fixed in 10% formalin, and embedded in 
paraffin for histological evaluation. No evidence of fibrosis or intramyocardial haemorrhage 
was seen on haematoxylin-phloxine-saffron (HPS) - stained histological sections from these 
hearts. 
 
	  
Figure 15 -Myocardial tissue appearance after electrophysiological study from a 
subdiaphragmatic approach.  
A: apical surface of the heart of a study animal after electrophysiological study. No gross 
evidence of tissue damage is seen. B: haematoxylin-phloxine-saffron (HPS)-stained apical 
section from a study animal showing normal tissue architecture without evidence of 
disruption or injury. Scale bar = 1 mm (A); 100µm (B). Reproduced with permission from 
Gutstein et al (151) 
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Procedural Deaths: 
 
A total of 400 mice were used for all experiments. Two procedural deaths occurred due to 
hypothermia; perforation of the heating pads by surgical instruments (with ensuing gradual 
loss of water and thermoregulation) resulting in hypothermia and asystole. Four episodes of 
pneumothorax occurred (n=4). Factors contributing to pneumothorax included: (i) loss of 
capture necessitating repositioning of the electrode within a few 100µm- 1mm and 
(ii) prolonged procedures with repeated placement of the stimulating electrode e.g. longer 
protocols were needed with 6hr pacing and (iii) repeated PES and (iv) repositioning of ECG 
limb leads . Where pneumothoraces compromised cardiorespiratory function and therefore 
the integrity of the preparation, experiments were terminated and the animal euthanized while 
under general anaesthetic. Other losses occurred due to liver injury n=1, apnoea due to 
excessive anaesthesia n=1. A total of 10 mice died .This gave a procedural all-cause mortality 
of 2.5 % though losses were greatest during the early stages of developing the model (see 
Table 3). 
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Cause of death 
 
number % of total 
Early stages of 
training and ECG 
repositioning 
 
2 2/400 (0.5%) 
Hypothermia 
 
2 2/400 (0.5%) 
 
Pneumothorax 
2 2/400 (0.5%) 
 
Multiple Probe 
repositioning 
1 1/400 (0.25%) 
 
Long protocol 
1 1/400 (0.25%) 
 
Apnea/Excess 
anaesthesia 
1 1/400 (0.25%) 
 
Liver injury 
1 1/400 (0.25%) 
Total deaths 
 
10 10/400 (2.5%) 
 
Table 3 Procedural deaths from pacing sub diaphragmatically.  
Total all cause mortality 2.5%.  
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Evaluation of mechanical and electrical capture: 
 
Surface electrocardiograms demonstrated substantial widening of the QRS complex during 
pacing, suggesting aberrant interventricular electrical conduction. (Fractional shortening was 
marginally decreased from 44.2 ± 2.0% at baseline to 37.2 ± 2.8% during pacing (p< 0.05). 
Rather than measure aortic doppler velocities as had been done by the Kass group, I 
demonstrated mechanical capture on echo whilst the pacing stimulator was turned on. 
 
 
	  
 
Figure 16 –Echo before and during pacing. 
Echo  demonstrating mechanical capture and mechanical dyssynchrony with septal to 
posterior wall motion delay. Reproduced with permission from Kontogeorgis et al (152).  
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Figure 17- Electrical capture and electrical dyssynchrony during pacing. 
Electrical capture and electrical dyssynchrony during pacing as evidenced by broadening of 
the QRS. (recorded from Biopac MP100 system). Reproduced with permission from 
Kontogeorgis et al(152).  
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4.5hr, and 2 week Survival Study after 1 hr pacing. 
 
The aim of this study was to determine the impact of the surgical procedure as well as the 
1hour pacing protocol on the animals. Six mice were paced for 1hour and six sham-paced 
(the electrode was placed in contact with the RV surface sub diaphragmatically but the 
stimulator was turned off). At the end of the procedure the epigastric incision was sutured and 
the animals recovered. Within a few minutes, once the inhaled anaesthesia wore off, the 
animals began mobilising and became progressively more active in their cages. There were 
no signs of distress over the next few hours and days with good patterns of feeding and 
drinking as well as interaction with their fellow mice and when handled. After 4.5hrs 3 paced 
mice were sacrificed and their hearts examined macroscopically and immunostained for 
Cx43. Once again, no obvious qualitative macroscopic injury was observed and no difference 
on immunostaining for Cx43. 
After 2 weeks the remaining 3 paced mice that were recovered were sacrificed. Their hearts 
were examined in a similar fashion. There were no signs of injury to other viscera (examined 
at the time of sacrifice). The Cx43 immunosignal was then qualitatively examined by me and 
Dr Gutstein in a blinded fashion. We were unable to distinguish the paced from the unpaced 
tissue samples. The sham-paced animals had an uneventful recovery and no losses were 
incurred as a result of the surgical procedure. These findings are consistent with the 
longitudinal studies previously undertaken by Dr Gutstein(151). 
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Measuring Threshold parameters at baseline, 1hour and after 6 hours pacing 
protocol 
 
The objective was to model altered activation rather than induce tissue damage; hence the 
stimulator output was limited to approximately twice the stimulating threshold. The mean 
stimulator output was 0.366 ± 0.011mA.These levels were sufficient for stable electrical 
capture throughout all pacing experiments. The average threshold determined after 1hour 
sham-pacing was 0.21 ± 0.04mA (n=6) and after 1 hour pacing 0.191 ± 0.049mA (n=6) and 
this was not significantly altered (p=0.52). The average threshold prior to 6 hours pacing was 
0.165 ± 0.007mA (n=65). In a subset of eight mice, the threshold was determined after 6 
hours of pacing with an average post-pacing threshold of 0.162 ± 0.026mA (p=NS). The 
unchanged threshold values underscore the stability of the experimental preparation.  
 
Figure 18 Pacing thresholds after 1 hour (n=6; p=ns). 
No difference in pacing thresholds after 1hr pacing.  
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Figure 19-Pacing threshold at baseline (n=65) and after 6 hours pacing (n=8;p=ns). 
No difference in pacing threshold after 6hr pacing. 
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Conclusion 
 
In this chapter I have shown that the sub diaphragmatic model of pacing is a feasible 
approach to pacing the murine heart and inducing dyssynchrony. Cautious placement of the 
pacing probe avoids injury to the diaphragm and thoracic structures making pacing of the RV 
epicardial surface possible and safe. There is no need for intubation, vascular access and 
thoracotomy. Mice survive the surgery, are free of any obvious distress for up to 4.5 hours as 
well as 2 weeks after the 1hour pacing procedure. When pacing is switched off the mice also 
recovered well. There was no evidence of macroscopic injury to the heart and the HPS 
staining did not show any pacing related changes. Pacing capture thresholds remained stable 
throughout the experiments at 1 hour and 6 hours thus highlighting the stability of the 
preparation. Pacing achieved electrical and mechanical capture as demonstrated on ECG and 
ECHO with features of electrical and mechanical dyssynchrony. 
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Chapter 3 
Electrocardiographic assessment in the subdiaphragmatic model 
of dyssynchrony 
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Introduction 
 
In Chapter 3, I outline data from an experimental series performed at baseline, after sham-
pacing and after pacing at 1hr, 4hr and 6hr intervals in C43+/+ and Cx43+/− mice. This 
addresses objectives 4 and 5 of the thesis mentioned in Chapter 1. 
The origins of the ECG can be traced as far back as the 19th century when in 1887 Augustus 
Waller demonstrated the amplification of the source voltage of the heart on the surface of the 
skin in humans(153). It wasn’t until the 20th century before this became more widely applied 
in clinical medicine. Correlating the timing of ECG with mechanical events (such as heart 
sounds) in the heart followed in 1911 by T Lewis and other investigators such as H C Bazett 
in 1920 and Wiggers who had been working with dogs to correlate the onset of the R wave on 
ECG with systole (154-156). 
ECG analysis in mice has been used extensively in the literature to study models of 
arrhythmia. Interest in the field of cardiovascular research has put the ECG as a central tool 
in analysing electrophysiology to characterise various models. The mouse poses some 
challenges to performing ECG (as well as programmed electrical stimulation) given its small 
size. The first in vivo attempt at programmed electrical stimulation required intubation and an 
open chest model by Berul et al(157). These investigators followed the convention of using 
needle electrodes implanted subcutaneously strapped the rodent limbs to minimise movement 
induced artefact. It has also been shown by Danik et al, using this same approach that there is 
a significant challenge in models of long QT syndrome to find consistency in the 
measurement of the QT interval such that the authors arbitrarily assigned 3 separate 
deflection points that may correlate with return to baseline denoting the end of repolarisation 
(13;148;151;158;159).  
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In the field of cardiac memory, mouse models have therefore not been favoured given that 
they differ substantially from large mammals in their shorter repolarisation profile. Yet, mice 
remain unique in that average sinus heart rates are in the order of 500-600 beats per minute 
and their need to sustain such rapid rates justifies this difference of rapid repolarisation in the 
action potential. When compared with that of humans its clear that the ion channels expressed 
by mice are different. Yet, within the human heart significant differences exist between 
ventricular and atrial ion channels expressed and therefore action potential morphology(fig 
20). Understanding the electrophysiology in mice can be particularly helpful in understanding 
the high rates sustained by human atrial tissue during atrial fibrillation, for example. These 
regional heterogeneities are highly significant and considered contributory in the study of 
mechanisms of arrhythmia in disease models as well as in human disease (2-4;160).  
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Figure 20 Schematic illustrating region specific differences in action potential 
morphology and duration.  
Note altered rate of depolarisation or upstroke of SA node cells compared to rapid upstroke 
of atrial and ventricular myocardial cells. This is due to regional differences in the ion 
channels expressed at the cell surface. Reproduced with permission from Kass et al (160). 
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Figure 21 Figure illustrating differences in regional ion channel expression. 
Differences in human ventricle (on left) and atrium (on right); Reproduced with permission 
from Kass et al (160). 
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Figure 22 - Difficulty in identifying the QT interval on murine ECG. 
One heartbeat on murine ECG with intervals demonstrated. After the p wave there are 3 
deflection points that have been designated arbitrarily by Danik et al as Qa, Qb and Qc 
.Reproduced with permission from Danik et al(159). 
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Method: 
Recording of electrocardiograms and application of the stimulating electrode 
for pacing 
Electrode leads were applied to each of the four limbs, and signals were amplified and 
digitally monitored on PC or Mac. Using Ponemah physiology software and Biopac MP 100 I 
recorded data points at baseline, during pacing to document 1:1 capture and following 
cessation of pacing. This data could then be analysed offline. 
In the preceding chapter describing the development of the model I have described the 
technique of positioning the pacing probe but here I present in more detail the method of 
ECG recording.  
ECG recordings 
 
Signals were amplified using a Honeywell ECG amplifier (Honeywell, Morristown, NJ), 
converted from analogue to digital with an ACQ-16 Acquisition Interface and recorded with 
Ponemah Physiology software (Gould; Valley View, OH). ECG Intervals, including p wave 
amplitude and duration, PR interval, QRS amplitude and duration, axis and QTc interval were 
calculated from limb leads I, II and III. These were recorded at baseline, during pacing and 
after completion of pacing and then analysed by myself offline to look for any changes in the 
ECG in the pacing model. In the next section I will present the data from these experiments. 
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Figure 23 -Biopac MP100 and AcqKnowledge ECG system. 
Reproduced with permission from Biopac website; 
http://www.biopac.com/Research.asp?CatID=43&Main=Systems. 
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Figure 24 - Ponemah Physiology Platform. 
Upper and lower left panel (ACQ 16 unit) with permission from Data Science International  
(http://www.datasci.com/products/software/ponemah/ponemah-5-10).; 
http://www.datasci.com/products/signal-conditioners-and-amplifiers/acq-16-
acquisition-interface-unit). 
Right panel (Honeywell ECG amplifier) used in the first year of experiments. 
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Results: 
Electrocardiographic assessment after short-term pacing at 1hr and 4hrs: 
 
Pre and post-study six lead electrocardiograms in mice paced for 1, 4, 6 hours as well as 
sham-paced controls were analysed. No significant change from baseline values of PR 
interval, QRS duration, RR interval or rate corrected QT interval (QTc) in any of the paced 
groups was observed when compared with sham-paced controls. QRS amplitude was 
modestly but significantly diminished after 1 hour pacing when compared at baseline but not 
4hour and 6 hour time points. See Table 4. 
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Figure 25 ECG at baseline and after sham pacing at 1hour, 4hour and 6 hours. 
ECG morphology demonstrating “cardiac memory” at 1 hour and 6hour time point in lead I 
and III. 
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ECG Axis substudy at 1hour pacing time point 
 
An additional 7 mice were paced and sham-paced for 1 hour and QRS amplitude analysed 
separately in each of six leads (I, II, III, avR, avL and avF). These experiments demonstrated 
no difference in QRS amplitude. This suggested that the effect observed may have been 
related to only studying lead II in the earlier analysis and that once combined with the other 
leads a correction of the error occurred given it was likely due to an ECG axis shift. 
    
Electrocardiographic indices at 6hour time point: 
 
No significant differences were observed in ECG parameters in paced and sham-paced mice 
after six hours. See Table 5.  Electrocardiographic Indices in C57BL/6J Wildtype Sham-
Paced and Paced Mice. 
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Table 4.  Comparison of Electrocardiographic Data at 1hour, 4hour and 6 hour in 
Sham and Paced Mice 
 Sham-paced, n=17 Paced 1 hr, n=11 Paced 4 hr, n=16 Paced 6 hr, n=14 
PR Interval, ms 
40.9 ± 1.1 
(-1.2 ± 0.9) 
44.5 ± 1.3 
(+3.0 ± 1.7) 
44.7 ± 2.4 
(+1.8 ± 3.0) 
49.4 ± 3.7 
(+6.1 ± 3.6) 
QRS Duration, ms 
11.7 ± 0.4 
(-0.4 ± 0.5) 
12.0 ± 0.5 
(+0.5 ± 0.6) 
12.8 ± 0.5 
(+0.4 ± 0.6) 
14.1 ± 1.1 
(+0.9 ± 1.1) 
RR Interval, ms 
140 ± 4.5 
(+7.1 ± 4.6) 
121 ± 3.2 
(-11.1 ± 5.7) 
137 ± 6.3 
(+7.1 ± 5.6) 
145 ± 4.7 
(+0.9 ± 7.0) 
QTc, ms 
106 ± 3.2 
(-2.8 ± 3.6) 
122 ± 4.9 
(+7.3 ± 5.7) 
123 ± 2.9 
(-3.7 ± 4.3) 
106 ± 2.3 
(+0.6 ± 4.1) 
QRS Amplitude, µV 
(Lead II only) 
114 ± 7.5 
(+5.1 ± 5.9) 
98.4 ± 6.9 
(-30.8 ± 12.1)* 
(p<0.01) 
118 ± 13 
(+6.3 ± 7.8) 
103 ± 7.9 
(-7.8 ± 5.4) 
 
Post-pacing data and changes from baseline (in parentheses) are presented as group means ± 
SEM.  Comparisons between groups of changes from baseline were performed with ANOVA 
followed by Fisher’s protected least significant difference test.  *, p < 0.01 compared to 
Sham-paced and Paced 4 hr (p = 0.05 compared to Paced 6 hr). 
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Table 5.  Electrocardiographic Indices in C57BL/6J Wildtype Sham-Paced and Paced 
Mice 
 Sham-Paced, 6 hr (n=8) Paced, 6 hr (n=14) 
QRS Duration, ms 
11.1 ± 0.7 
(-1.3 ± 0.7) 
14.1 ± 1.0 
(0.9 ± 1.1) 
RR Interval, ms 
144.6 ± 8.0 
(12.6 ± 8.3) 
144.6 ± 4.7 
(0.9 ± 7.0) 
QTc, ms 
97.7 ± 4.2 
(-6.7 ± 5.7) 
106.2 ± 2.3 
(0.6 ± 4.1) 
 
Post-pacing data (and changes from pre-pacing baseline) are presented as group means ± 
SEM.  Comparisons between groups were performed with unpaired T-tests.  For 
electrocardiographic indices, n = 8 sham and 14 paced. With permission from Kontogeorgis 
et al (179)	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Table 6 Electrocardiographic Measurements at Baseline (Pre-sham and pre-pacing) in 
WT and Cx43+/− Mice 
 
WT pre-sham 
pacing (n=6) 
WT pre-pacing 
(n=6) 
Cx43+/− pre-sham 
pacing (n=7) 
Cx43+/− pre-pacing 
(n=9) 
QRS Duration, ms 11.7 ± 0.5 12.7 ± 0.8 10.4 ± 0.8 9.8 ± 1.1 
RR interval, ms 131 ± 4.4 134 ± 2.4 137 ± 5.3 139 ± 6.0 
QTc, ms 114 ± 7.4 126 ± 9.3 119 ± 7.3 119 ± 17.9 
 
Data is presented as group means ± SEM.  Comparisons between groups were performed 
with ANOVA.  
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Table 7 Electrocardiographic Indices after Pacing or Sham-Pacing Protocol in WT and 
Cx43+/− Mice 
 
WT sham 
paced(n=6) 
WT paced (n=6) 
Cx43+/− sham 
paced (n=7) 
Cx43+/− paced 
(n=9) 
QRS Duration, ms 
12.0 ± 0.3 
(0.3 ± 0.6) 
13.2 ± 1.3 
(0.5 ± 1.4) 
9.8 ± 0.8*( p<0.05) 
(-0.6 ± 0.7) 
10.1 ± 0.7*(p<0.05) 
(0.2 ± 1.4) 
RR interval, ms 
136 ± 4.3 
(5.7 ± 6.3) 
138 ± 6.9 
(4.2 ± 7.3) 
134 ± 9.8 
(-2.9 ± 5.9) 
142 ± 13.2 
(2.9 ± 14.7) 
QTc, ms 
116 ± 3.7 
(1.2 ± 6.0) 
127 ± 5.3 
(1.8 ± 9.2) 
130 ± 11.1 
(11.4 ± 13.0) 
167 ± 23.3 
(48.3 ± 34.6) 
 
Post-pacing data (and changes from pre-pacing baseline) are presented as group means ± 
SEM.  Comparisons between groups were performed with ANOVA.  *, p < 0.05 compared 
with WT paced;  compared with all other groups.  For electrocardiographic indices, n = 6 WT 
sham paced, 6 WT paced, 7 Cx43+/− sham paced and 9 Cx43+/− paced. With permission from 
Kontogeorgis et al (179). 
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Table 8.  Differences in Electrocardiograph Measurements, Delta, in Wildtype and Cx43 
Heterozygous KO Mice 
 
WT  sham- pacing 
delta (n=6) 
WT post-pacing 
delta (n=6) 
Cx43+/− post-sham 
pacing delta (n=7) 
Cx43+/− post-
pacing delta (n=9) 
QRS Duration, ms 0.03 ± 0.001 1 ± 0.001 -1 ± 0.001 0.02 ± 0.001 
RR interval, ms 6 ± 0.006 4 ± 0.007 2 ± 0.006 0.3 ± 0.015 
QTc, ms 1 ± 0.006 2 ± 0.009 5 ± 0.013 4.8 ± 0.04 
 
Data is presented as group means ± SEM.  Comparisons between groups were performed 
with ANOVA.  *, p < 0.05; **, p < 0.01 compared to matched wildtype littermates.  No 
significant differences between groups. 
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Electrocardiographic parameters at baseline and after short-term pacing in Cx43+/− mice and 
deltas. 
Surface electrocardiograms in Cx43+/− mice were compared to matched wildtype littermates 
at baseline (See Table 6). ECG in Cx43+/− mice and Cx43 sham-paced mice after 6hr pacing 
demonstrated a slightly but significantly reduced QRS duration in both paced and sham-
paced mice (See Table 7).  No significant differences in RR interval or QTc were noted 
(although paced Cx43+/− mice did appear to have longer QTc intervals). A comparison of 
ECG differences, deltas between wildtype Cx43 and Cx43+/− mice after 6hr sham-pacing or 
6hr pacing demonstrated no significant change (See Table 8). 
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Figure 26  Surface electrocardiograms in Cx43+/− mice at baseline and after pacing were 
compared to matched wildtype littermates at baseline and after 6hr pacing. 
The surface ECG demonstrates significant shortening of the QRS duration in unpaced and 
paced Cx43+/− mice relative to unpaced and paced WT mice. Reproduced with permission 
from Kontogeorgis et al (161). 
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Discussion: 
 
The ECG data characterising the wild type Cx43+/+ mice and Cx43+/− mice with pacing 
looked for differences that might suggest pacing induced dyssynchrony results in significant 
change to integrated action potential morphology at the body surface. The evidence for 
electrical capture confirms that the pacing probe exerted an electrical stimulus with altered 
activation across the myocardium.  
The ECG figures at the 1hour, 4hour and 6hour time point suggest that changes consistent 
with cardiac memory could be observed as early as after 1 hour of pacing in lead I and III but 
without measurable differences in ECG parameters. This initially suggested that 1 hour of 
pacing alone may be a sufficient time point for the pacing model in order to study 
remodelling. Changes evident within lead II QRS amplitude appeared consistent with 
findings from previous work on the Cx43 transgenic line(6;7). However, a separate ECG axis 
sub-study was undertaken to explore whether this observed change in QRS amplitude might 
be due to a change of axis. All 6 limb leads were incorporated into the analysis. This further 
study aided in correcting for what was likely an axis shift in lead II rather than a true 
reduction in QRS amplitude.  
Despite the difficulties in measuring the QT interval in mice, I consistently and manually 
measured this from all time points using the equivalent of deflection point Qc as described in 
the Danik et al paper. The calculation of the corrected QTc also followed the standard 
approach in the literature, which involves use of the Bazett formula(159). 
The data for the p wave amplitude, duration and PR interval as well as QRS were also 
analysed. However, in the subdiaphragmatic pacing model, both wildtype and Cx43+/− mice 
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did not demonstrate conduction slowing or delay at the AV node as would be inferred by PR 
interval prolongation.  
The most striking difference was noted in the surface ECG in Cx43+/− mice with shorter QRS 
duration at baseline and after pacing as compared to matched Cx43+/+ mice as well as features 
suggestive of QTc prolongation which were not statistically significant.  
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Chapter 4 
Echocardiographic assessment in the pacing induced 
dyssynchrony model 
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Introduction: 
 
In Chapter 4, I determine the echo parameters at baseline, during pacing and after cessation 
of sham- pacing and pacing in Cx43+/+ mice. I assess mechanical synchrony and evaluate 
mechanical capture and mechanical ventricular function. Furthermore, I evaluate echo 
parameters after sham-pacing and after pacing in Cx43+/− mice. Additional echocardiography 
experiments are performed after completion of a 2hour rest period following cessation of 
pacing to re-evaluate echo findings. This series of experiments addresses objectives 4 and 5 
of this thesis as mentioned in Chapter 1.  
 
History of  Echocardiography 
The use of ultrasound to assess myocardial contractility and non invasively assess blood flow 
with Doppler has gained widespread appeal both in clinical medicine as well as in 
cardiovascular research the full potential of which is yet to be realized. In some respects it 
gives humans the ability to copy the ability of some mammals who use high frequency 
ultrasound to navigate their environments as in the case of bats and water mammals. It was 
the early discovery of piezoelectricity by Curie and Curie that laid the foundation for the 
development of echo technology. Early pioneers of the technique were credited with patents 
in the case of Sokolov and Firestone. Experimentation following WWII by Wild meant he 
was first to examine the heart with ultrasound. However, it is Hertz and Edler who first used 
echo as we know it today(162).  
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Qualitative and Quantitative echo indices. 
The commonly used measurements in echo include a qualitative assessment of cardiac 
movement on 2D echo as well as M mode. Quantitative measures include wall thickness, 
chamber volume and the calculated functional indices such as fractional shortening and 
ejection fraction. Regional wall motion abnormalities are considered highly significant in 
clinical practise and often are thought to reflect coronary perfusion abnormality. However, 
there are other causes including delayed activation of the myocardium. Wall motion 
abnormalities have been observed in studies of conduction system disease e.g. LBBB.  
Echo is a vital tool in assessing patients with heart failure in reaching a diagnosis, assessing 
severity and in more recent years determining the presence of dyssynchrony. In heart failure 
if evidence for dyssynchrony exists this has important therapeutic implications for patients 
and expands their options to device based therapy such as CRT-P or CRT-D. National 
guidelines incorporate ECHO parameters for suggesting implantation of devices but have 
struggled to meet the expanding role for these devices. The evidence in favour of improving 
clinical outcomes as well as echo indices is extensive(3;21;163-165). 
Echo in animal research 
There is a wide literature base for echocardiography in various animal models as well as 
small mammals such as rodents. Apart from models of infarction where echo can assess the 
degree of infarct size it has also played a role in characterising models of dilatation, non 
ischaemic heart failure and pressure overload(6;7;15;22;162;166).  
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Role of echo in this thesis 
 In this model I was interested in demonstrating that pacing achieved mechanical 
dyssynchrony and therefore mechanical capture during pacing and altered the activation of 
the myocardium. I used the method of Pitzalis et al rather than adopt that of Kass and 
investigators who looked at aortic Doppler velocities in their mouse model of chronic pacing 
(2). Since rodents are challenging to manage in the awake state, I elected to perform all these 
experiments under general anaesthesia which is a commonly adopted practise(4).  
Furthermore since heart failure is known to result in mechanical dyssynchrony I was 
interested in using the model to characterise the functional effects in wildtype Cx43+/+ mice 
as well as heterozygous Cx43+/− mice. I was keen to look for any altered echo indices that 
might suggest a correlation to adaptive functional effects at the 6 hour time point - ECG data 
suggested there may be some changes with shortening of QRS duration in Cx43+/− mice at 
baseline and prolongation after pacing.
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Methods: 
Echocardiography 
As described earlier, once mice were anaesthetised and positioned on the heating pad with 
limbs immobilised and hair removed I proceeded to baseline echocardiography (Dr Gutstein 
also assisted and supervised). Measurements were obtained both online and offline for a 
blinded analysis. Review of the images from pacing induced mechanical capture and 
dyssynchrony were clearly not blinded. Parameters calculated included fractional shortening 
(FS), left ventricular volumes and ejection fraction (EF). Mice were imaged using a Philips 
HDI 5000 equipped with a 15MHz linear probe. Images were also printed and digitally 
captured on a flatbed scanner to allow blinded offline analysis.  
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Results: 
Determining the effects of short-term pacing on mechanical synchrony, 
capture,myocardial dimensions and contractility. 
 
Assessment of mechanical Synchrony 
 
Mice were examined prior to and during pacing using echocardiography to determine 
whether short-term pacing influenced synchrony of cardiac contraction. The septal-to-
posterior wall motion delay (SPWMD), an echocardiographic index of dyssynchronous 
contraction, increased significantly from 7.8 ±2.5ms before pacing to 27.9 ± 2.4ms during 
pacing (p˂ 0.01;n=6 each). Furthermore pacing significantly increased the delay in onset of 
systolic wall thickening measured from the septal to posterior walls (12.8 ± 1.1ms at baseline 
vs 31.6 ± 1.4ms during pacing, p˂ 0.001). 
 
Evaluation of mechanical and electrical capture: 
 
Surface electrocardiograms demonstrated substantial widening of the QRS complex during 
pacing (as demonstrated in figure17, chapter 2), suggesting aberrant intraventricular electrical 
conduction. Fractional shortening was marginally decreased from 44.2 ± 2.0% at baseline to 
37.2 ± 2.8% during pacing (p< 0.05). In the previous chapter I have shown the effect of 
pacing on the echo parameter SPWMD (figure 16, chapter 2) 
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Table 9   Echocardiographic Measurements before Initiation of Pacing and During 
Pacing in Wildtype C57BL/6J Mice 
 Pre-Pacing (n=6) During Pacing (n=6) 1hour. 
IDD, mm 3.8 ± 0.14 3.6 ± 0.08 
IDS, mm 2.1 ± 0.10 2.2 ± 0.12 
Fractional Shortening, % 44.2 ± 2.0 37.2 ± 2.8* (p<0.05) 
AWTs, mm 1.1 ± 0.14 0.85 ± 0.08 
AWTd, mm 0.53 ± 0.09 0.47 ± 0.05 
PWTs, mm 1.4 ± 0.14 1.2 ± 0.10 
PWTd, mm 1.0 ± 0.11 0.85 ± 0.13 
 
Data is presented as group means ± SEM.  Comparisons between groups were performed 
with unpaired T-tests.  *, p < 0.05.  IDD, IDS, intraventricular dimensions at end-diastole, 
end-systole; AWTs, AWTd, anterior wall thicknesses at end-systole, end-diastole; PWTs, 
PWTd, posterior wall thicknesses at end-systole, end-diastole. With permission from 
Kontogeorgis et al (179). 
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Evaluation of Ventricular Function 
 
Pacing resulted in slight reduction of ventricular function though fractional shortening was 
not significantly altered after cessation of pacing. Left ventricular dimensions and thickness 
were not significantly changed in paced mice compared to matched sham-paced controls or 
compared to baseline values (Table 9). Short-term pacing was therefore associated with 
dyssynchrony during pacing and a slight decrement in ventricular function that normalized 
immediately after cessation of pacing in wild type mice (Table 10).   
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Table 10 Echocardiographic Measurements in C57BL/6J Wildtype Mice after Cessation 
of Short-Term (6hour) Pacing 
 Sham-Paced, 6 hr (n=6) Paced, 6 hr (n=6) 
IDD, mm 
3.1 ± 0.13 
(0.3 ± 0.1) 
3.2 ± 0.18 
(0.1 ± 0.2) 
IDS, mm 
1.8 ± 0.12 
(0.2 ± 0.1) 
1.9 ± 0.12 
(0.1 ± 0.2) 
Fractional Shortening, % 
43.8 ± 1.7 
(-2.3 ± 1.7) 
40.6 ± 2.4 
(-1.1 ± 1.2) 
AWTs, mm 
1.2 ± 0.09 
(-0.13 ± 0.13) 
1.2 ± 0.12 
(0.03 ± 0.08) 
AWTd, mm 
0.8 ± 0.07 
(-0.07 ± 0.1) 
0.8 ± 0.1 
(0.07 ± 0.1) 
PWTs, mm 
1.6 ± 0.03 
(-0.43 ± 0.08) 
1.4 ± 0.16 
(-0.43 ± 0.29) 
PWTd, mm 
1.0 ± 0.05 
(-0.75 ± 0.12) 
1.0 ± 0.13 
(-0.42 ± 0.18) 
 
Post-pacing data (and changes from pre-pacing baseline) are presented as group means ± 
SEM.  Comparisons between groups were performed with unpaired T-tests.  IDD, IDS, 
intraventricular dimensions at end-diastole, end-systole; AWTs, AWTd, anterior wall 
thicknesses at end-systole, end-diastole; PWTs, PWTd, posterior wall thicknesses at end-
systole, end-diastole. With permission from Kontogeorgis et al (179). 
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Table 11  Post-Pacing Echocardiographic Measurements in WT and Cx43+/− Mice 
 
WT sham paced 
(n=6) 
WT paced (n=6) 
Cx43+/− sham 
paced (n=7) 
Cx43+/− paced 
(n=9) 
IDD, mm 
3.4 ± 0.10 
(-0.05 ± 0.10) 
3.2 ± 0.19 
(-0.12 ± 0.21) 
3.3 ± 0.12 
(-0.16 ± 0.21) 
3.5 ± 0.15 
(0.28 ± 0.14) 
IDS, mm 
1.9 ± 0.09 
(0.08 ± 0.06) 
1.8 ± 0.14 
(0.05 ± 0.18) 
1.8 ± 0.11 
(-0.04 ± 0.18) 
2.2 ± 0.21 
(0.41 ± 0.13) 
Fractional 
Shortening, % 
43.9 ± 1.4 
(-3.2 ± 1.7) 
43.6 ± 1.2 
(-2.8 ± 3.3) 
45.8 ± 1.7 
(-1.5 ± 2.7) 
38.4 ± 3.5 
(-7.0 ± 2.9) 
AWTs, mm 
1.0 ± 0.02 
(-0.02 ± 0.07) 
0.98 ± 0.06 
(-0.20 ± 0.12) 
1.1 ± 0.08 
(-0.03 ± 0.08) 
1.1 ± 0.08 
(-0.02 ± 0.11) 
AWTd, mm 
0.81 ± 0.08 
(-0.07 ± 0.08) 
0.80 ± 0.08 
(0.0 ± 0.12) 
0.79 ± 0.06 
(-0.03 ± 0.05) 
0.88 ± 0.06 
(-0.01 ± 0.08) 
PWTs, mm 
1.3 ± 0.09 
(-0.23 ± 0.13) 
1.6 ± 0.10 
(0.03 ± 0.08) 
1.4 ± 0.10 
(-0.14 ± 0.15) 
1.4 ± 0.08 
(-0.17 ± 0.10) 
PWTd, mm 
0.83 ± 0.09 
(-0.25 ± 0.17) 
1.2 ± 0.14 
(0.23 ± 0.18) 
0.97 ± 0.08 
(-0.19 ± 0.12) 
1.1 ± 0.08 
(-0.14 ± 0.12) 
SPWMD, ms 
6.2 ± 0.74 
(1.7 ± 1.2) 
4.3 ± 0.70 
(-0.67 ± 1.1) 
7.2 ± 1.5 
(-3.0 ± 1.3) 
17.7 ± 2.3** 
(8.6 ± 1.9)** 
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Table 11 Post-pacing data (and changes from pre-pacing baseline) are presented as group 
means ± SEM.  Comparisons between groups were performed with ANOVA.  **, p < 0.01 
compared to all other groups.  IDD, IDS, intraventricular dimensions at end-diastole, end-
systole; AWTs, AWTd, anterior wall thicknesses at end-systole, end-diastole; PWTs, PWTd, 
posterior wall thicknesses at end-systole, end-diastole; SPWMD, septal-to-posterior wall 
motion delay. With permission from Kontogeorgis et al (161). 
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Echocardiographic assessment at baseline, post pacing in WT and Cx43+/− 
mice: 
Cx43+/− mice imaged after cessation of 6hr pacing or sham-pacing had no significant 
differences (Table 11). Baseline echo characteristics including ventricular dimensions, 
fractional shortening, or wall thickness were not significantly different in the WT group 
(Table 9) and after cessation of 6hr pacing (Table 10). However, there was evidence of 
significant mechanical dyssynchrony after 6hour pacing in Cx43+/- mice compared to sham-
paced Cx43+/−, WT  paced and WT sham-paced mice (SPWMD =17.7 ± 2.3 p<0.01) (Table 
11).     
2hour	  recovery	  period	  
	  
The mechanical dyssynchrony was significantly sustained despite a recovery period of 2 
hours (SPWMD =17.7 ± 2.3 p<0.01). 
[141]	  
	  
Discussion: 
The echo data in this chapter underscore the absence of any overt disease process in these 
animals such as would be seen if there was impaired left ventricular function or altered wall 
thickness or volume dimensions. However, there is evidence here that pacing alters the 
activation pattern of the myocardium consistent with altered stress-strain during pacing with 
altered temporal relation between the interventricular septum and the posterior wall 
(SPWMD). In the canine model of LBBB induced dyssynchrony this had been suggested by 
an alternative imaging modality as in the case of MRI (26;167-170).  
A limitation to consider here is that the echocardiography did not utilise colour flow doppler 
to assess any possible underlying functional mitral regurgitation which may have occurred as 
a consequence of the distorted activation sequence a well recognised (at least in clinical 
studies) possible complication. Furthermore no attempts were made to measure nor calculate 
any velocity time integrals using pulsed doppler as surrogates of cardiac output or index 
given the scale of the animal. Nonetheless, the data supports the conclusion that there is no 
significant impairment in cardiac function with pacing. 
However, what is novel is the evidence of mechanical dyssynchrony at the end of the pacing 
procedure immediately after the stimulator was switched off. The measured SPWMD 
remained prolonged at 17.7ms immediately after cessation of pacing in all Cx43+/- animals 
that had been subjected to 6 hours of pacing. It seems reasonable to surmise that these 
experiments reflect some change in myocardial contractility due to a spatial and temporal 
heterogeneity within the affected area as measured on echo. Furthermore, this mechanical 
dyssynchrony was a sustained measurable after a 2 hour rest period possibly suggesting a 
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more permanent effect had taken place rather than a transient metabolic or ion overload 
effect.  
Based on the ECG and ECHO findings, it is possible that some degree of electrical 
heterogeneity might account for these differences. The data support the likelihood of a 
change in repolarisation properties as observed by the ECG QRS duration which prolongs 
with pacing in the Cx43+/− group.  However, without a further reductionist experiment to 
explore regional heterogeneity in Ca2+ or K+ ions it would be difficult to understand the 
mechanism behind such sustained mechanical effect. Furthermore, a detailed look at 
anatomical/structural effects was warranted to understand the mechanism of this observation.  
In a subsequent chapter (chapter 6) I undertake a more in depth analysis of what was taking 
place at a structural level as well as a functional level. In the following chapter, chapter 5, I 
present the experiments that try to assess whether there are any associated changes in tissue 
refractoriness and increased arrhythmia inducibility utilising subdiaphragmatic programmed 
electrical stimulation.  
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Chapter 5 
Programmed Electrical Stimulation and arrhythmia testing in the 
subdiaphragmatic dyssynchrony model. 
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Introduction: 
	  
In Chapter 5, I present the set of experiments performed to assess arrhythmia inducibility 
using programmed electrical stimulation and VERP after 1hour sham-pacing and pacing as 
well as when combined with 4-AP in Cx43+/+ mice. Furthermore, I present the PES and 
VERP after 6hr sham-pacing, 6hr pacing in Cx43+/+ and Cx43+/- mice. Finally, I evaluate PES 
and VERP in Cx43+/− mice after a 2hr recovery period following 6hr sham-pacing and 6hr 
pacing in Cx43+/− mice.  
Principles of Programmed Electrical Stimulation(PES) 
This technique is widely adopted in the clinical setting. Historically it was first performed by 
Wellens and Coumel in the late 1960s. Initially protocols were designed to induce and 
terminate supraventricular tachyarrhythmia (SVT) and aid diagnosis of the mechanism of 
these arrhythmias in individual patients to target ablation strategies. Their role expanded in 
subsequent years, the 1970s to induce ventricular tachyarrhythmia ( VT)  which correlated 
with clinical VT that post infarction or heart failure patients were experiencing(171). These 
studies furthered our understanding of the re-entrant nature of a large proportion of VT in the 
post infarction setting. It soon became a risk stratification tool to identify patients at risk of 
VT as inducibility became a recognised prognostic indicator of increased risk of sudden 
cardiac death (SCD) in post infarction patients. This became standard practise in recruiting 
patients for trials, testing efficacy of defibrillators and as a requirement in patient selection in 
published UK NICE guidelines. 
The disadvantage of this approach in clinical practice is that the technique is a poor risk 
stratification tool given its sensitivity and specificity(171). This likely reflects differences in 
the mechanism of sudden cardiac death which may be due to non-reentrant mechanisms and 
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bradycardia and temporal changes in those at risk of sudden cardiac death which cannot be 
predicted due to underlying disease process such as progression of coronary disease or heart 
failure .  
Nonetheless it has widespread use still in the clinical setting and in studying arrhythmia 
models in animal research. It allows a measure of the absolute refractory period which 
correlates with the refractory period of the action potential in the ventricle, called ventricular 
effective refractory period (VERP). The protocol originally designed by Wellens involves a 
pacing protocol of a train of beats at fixed cycle length (S1 drive train) followed by a first 
extrastimulus (S2) the coupling interval of which is progressively reduced until it falls on the 
refractory period of the last S1 beat. A second (S3) and occasionally a third extrastimulus 
(S4) has also been used and define progressively more aggressive protocols (151;171). 
Arrhythmia inducibility is thought to be triggered on the premise that one is activating 
myocardial tissue that has recovered from the last extrastimulus and a critical window allows 
re-entry (which may be functional or anatomical) to occur as other regions of myocardium 
recover and this sets-up re-entry. 
 In animal models, and in particular murine studies such provocation testing has been found 
to result in the induction of NSVT in up to 30% of normal wild type mouse hearts signalling 
a cautious interpretation of findings(151).  
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Methods: 
Programmed Electrical Stimulation to assess  
Ventricular refractoriness and arrhythmia inducibility 
 
These experiments were performed by me once Dr Gutstein had taught me the protocol. 
Programmed electrical stimulation (PES) was performed in control and paced mice at 
baseline and at the end of the pacing protocol. Baseline ECG recordings preceded the incision 
and probe placement as described earlier (in contact with diaphragmatic RV surface). Contact 
was verified throughout the experiment by real-time ECG monitoring to ensure 1:1 capture. 
The Medtronic programmable stimulator was utilised with output set at 1.0ms pulse width 
and twice diastolic threshold for a burst of 8 beats (S1) at either 100ms or 80ms cycle length 
followed by a single extrastimulus (S2) with progressive shortening of the coupling interval 
S1S2 (i.e. pacing at shorter cycle lengths in 10 ms decrements until loss of capture occurred) 
for determination of ventricular effective refractory period (VERP). The longest cycle length 
at which S1S2 failed to capture defined the VERP. Arrhythmia inducibility was tested by 
adding two extrastimuli (S2S3), with progressively shorter (10ms, 5ms or 2ms decrements 
approaching VERP) coupling intervals after the burst of 8 beats at 100ms and 80ms 
respectively. Ventricular arrhythmias lasting between 3 beats and up to 30 seconds were 
considered non sustained (NSVT) while those lasting >30 seconds, sustained. Two separate 
sites, just 1mm apart were tested for VERP and the mean of the two sites determined for each 
cycle length. 
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Figure 27 Programmed electrical stimulation in vivo demonstrating stimulus (in dark 
blue) and Lead I, II and III.  
Pacing with a train of eight beats is followed by a single extrastimulus for the determination 
of ventricular effective refractory period (VERP). Double extrastimuli were added to test for 
inducible arrhythmias. Reproduced with permission from Gutstein et al (151). 
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Results	  
Programmed Electrical stimulation after 1hr pacing and combined with 4-AP in 
wildtype mice: 
 Following 1 hour of pacing and sham-pacing a set of 6 mice in each group were tested for 
arrhythmia inducibility and changes in ventricular refractory period at cycle lengths of 80ms 
and 100ms.No significant differences were found (see fig 28).  
PES After 6 hr Pacing in WT mice 
Similarly after six hour pacing there was no significant difference in refractory period and 
inducibility of ventricular arrhythmia (see fig 29). 
At the outset of the project, experimentation using the shorter time period of 1 hour pacing 
and 1 hour sham pacing was used. I hypothesised that this would be of sufficient duration to 
modulate the degree of coupling between gap junctions and alter the conduction rendering 
them more prone to arrhythmia. 
Given the propensity toward arrhythmia in models of disease, possible options for stressing 
the myocardial substrate during pacing included reducing the oxygen mixture to model 
hypoxia (I considered this too non-specific as it would affect other organs), perform 
myocardial infarction surgery (unfavoured as it would defeat the purpose of the 
subdiaphragmatic approach by breaching the integrity of the thorax) and use potentially 
proarrhythmic drugs e.g. 4-aminopyridine (4-AP), a K+ channel blocker (without a known 
Na+ or Ca2+ blocking effect) that is known to prolong the action potential. This could be 
administered via the intraperitoneal route. A set of 6 paced and 6 sham paced experiments 
were undertaken and followed by administration of the drug, a 15-minute waiting period and 
then followed by PES. 
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Despite the added combination of the 4-AP drug to 1 hour pacing this did not increase the 
propensity toward arrhythmia or alter whole heart refractoriness. 
  
 
Figure 28 Programmed electrical stimulation to determine VERP after 1 hour paced 
and sham paced experiments. 
Using an 80ms and 100ms drive train (p=ns) in WT mice.  
No significant difference in VERP 80ms and 100ms after 1hr pacing. 
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Figure 29 Programmed electrical stimulation after 6 hours of pacing to determine 
VERP. 
Using an 80ms and 100ms paced drive train with single and double extrastimuli in WT mice. 
No significant difference in VERP 80ms and 100ms after 6hr pacing. 
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In vivo electrophysiology after 6hour pacing  
Wildtype mice 
After pacing for a longer period of time i.e. 6 hours of dyssynchrony, wildtype mice did not 
show any significant prolongation of VERP 80 or VERP 100 and no arrhythmia propensity 
on inducibility testing (figure 29). 
 
Cx43+/− mice 
After pacing, the VERP at 100ms pacing cycle length prolonged significantly in Cx43+/−  
mice to 49.4 ± 5.1ms compared to unpaced Cx43+/−  mice (30.3 ± 1.8ms;p<0.01), unpaced 
WT (36.6 ± 3.2ms) and paced WT(34.3 ± 1.9ms). Similar significant changes were observed 
at VERP 80ms (Table 12). 
Programmed stimulation after 2hours rest in paced Cx43+/− mice. 
The VERP remained elevated in the Cx43+/− mice despite a 2hour rest period after cessation 
of 6hr pacing. VERP 100= 50 ± 9ms and VERP80= 51.3 ± 7.4ms n=3. 
Arrhythmia inducibility: 
There were no differences between groups and although sustained arrhythmias could be 
induced with either single or double extra-stimuli they were in equal measure between the 
groups.
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Table 12.  Programmed Electrical Stimulation Measurements (post) in Wildtype and 
Cx43 Heterozygous KO Mice 
 
WT post-sham 
pacing (n=6) 
WT post-pacing 
(n=6) 
Cx43+/− post-sham 
pacing (n=6) 
Cx43+/− post-
pacing (n=6) 
VERP100, mm 34.3 ± 3.6 34.7 ± 2.8 30.3 ± 1.8 49.4 ± 5.1* 
VERP 80, mm 37 ± 3.7 34.8 ± 2.9 29.7 ± 1 49.8 ± 5.4* 
 
Data is presented as group means ± SEM.  Comparisons between groups were performed 
with ANOVA.  *, p < 0.05 compared with WT post-sham pacing and p < 0.01 compared to 
WT post-pacing and Cx43+/− post-sham pacing. VERP (Ventricular effective refractory 
period). With permission from Kontogeorgis et al (161). 
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Discussion:	  
 
 
In this chapter I present the data from programmed electrical stimulation protocol performed 
via the subdiaphragmatic approach as originally described by Gutstein et al (151). The 
technique is a useful tool in testing for arrhythmia inducibility and testing for changes in 
action potential duration that might alter the refractoriness of the myocardium. 
 
I found that after 1 hour of pacing and sham pacing there was no difference in the VERP and 
arrhythmia inducibility. The administration of intraperitoneal 4-AP did not increase the 
arrhythmia inducibility in wild type mice. This suggested that perhaps even if gap junction 
changes were taking place I was not observing a propensity to arrhythmia or sudden death. 
This would be consistent with the observations in the literature that suggest approximately > 
90% loss of gap junctions is necessary to result in vulnerable arrhythmia in a mouse 
model(6). However, it has also been proposed that only smaller reductions in gap junctions, 
approx. 50% are required when accompanied by additional stressors eg structural changes. 
These affect the action potential, as is often the case in clinical disease models and together 
with the slightly reduced gap junctions may lower the threshold toward arrhythmia. 
Nonetheless, the addition of 4-AP did not unmask such a finding. I decided against an 
infarction in my model as it would defeat the purpose of a relatively non-invasive approach 
whilst global hypoxia with its systemic effects I considered too non-specific. 
 
A longer duration of pacing for 6 hours in wildtype mice was therefore attempted in an effort 
to explore whether longer pacing periods might have more progressive and pronounced 
functional effects as measured by refractoriness and PES. Once again, in wildtype mice, 
perhaps due to the abundance of connexin protein at the outset, pacing induced 
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dyssynchronous activation appeared to be well tolerated and absorbed by the myocardium 
such that no apparent difference in VERP 80 or VERP 100, or arrhythmia propensity was 
noted. 
  
The Cx43+/− mice were of particular interest as their baseline levels of Cx43 are reduced by 
66% and they seem to respond differently to the effects of 6hr pacing. 
It was soon apparent that there was clear prolongation in the VERP after six hours of pacing 
experiments. Yet, these mice were not prone to arrhythmias. These changes were sustained 
even after a rest period of 2 hours suggesting that adaptive structural or electrical remodelling 
of some kind had occurred.   
 
Likely ion channel targets that might account for these changes included the primary drivers 
of murine repolarisation, K+ channels as well as possible changes in Ca2+. Together with the 
mechanical dyssynchrony presented in the earlier chapter, I initiated a set of experiments with 
Dr Morley and Dr Xiadong Li, to investigate further with optical mapping and patch clamp. 
 
In Chapter 6, I present the structural correlates of tissue studies undertaken at 1hr pacing and 
6hr pacing in wildtype mice after pacing as well as regional studies and further explore 
mechanisms for the observed differences in mechanical dyssynchrony and sustained VERP 
prolongation in Cx43+/− mice.  
[155]	  
	  
 
 
 
 
 
 
 
Chapter 6 
Electroanatomical correlation in Wildtype Cx43+/+, 
Cx43+/− mice and Cx40-/- mice 
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Overview: 
Introduction 
 
In the preceding chapter I have demonstrated that at least in WT Cx43+/+ there is no overt 
inducibility into arrhythmia and no change in VERP. However, despite the lack of changes of 
ECG parameters, ECHO or inducibility testing I still needed to test whether at least some 
form of subtle remodelling may be occurring at a structural level. In chapter 6, I will show 
that this is indeed the case based on the immunostaining, immunoblotting and cell 
fractionation data in wildtype mice. In WT mice in particular it appears that there are changes 
at the endocardium of the LV free wall and to study this further regional immunoblotting, 
qRT-PCR and fractionation experiments were performed. 
Separate to these experiments, I present a deeper look at the changes taking place in the 
Cx43+/− mice; suggesting that some form of remodelling is occurring and correlate this with 
the aid of data from experiments performed with Dr Li. My main intention in this chapter is 
to test the effects of pacing induced dyssynchrony on gap junctions at a structural level and 
correlate these with electrophysiology functional data at a cellular level.  
The murine pacing model represents single lead ventricular pacing with the electrode placed 
in contact with the epicardial surface of the right ventricle. Furthermore, it is a model of fixed 
pulse-width (effectively rheobase) and twice the minimum threshold for the stimulus needed 
to capture the heart (chronaxie). It therefore represents a model of low current output with 
dyssynchronous activation rather than a current-injury model(17). The duration of pacing 
over the mentioned time course avoids temporal changes in threshold and I addressed any 
loss of capture immediately due to constant ECG monitoring in paced experiments. Pacing at 
cycle length only just above sinus rhythm also ensures that this is not a model of tachycardia-
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induced changes (172-175). Since this is an in vivo, whole animal model, an additional 
advantage is that this does not denervate the heart but allows physiological effects of other 
systems such as the endocrine, higher autonomic and renin angiotensin system. Thus non-
cardiac systems are integrated when making comparisons between controls, sham paced and 
paced experiments and the data for connexin interactions reflects these interactions.  
I hypothesised that dyssynchronous activation may alter coupling properties between cells 
with electrotonic flow occurring through an unconventional direction e.g. epicardial to 
endocardial (and RV to LV) activation as opposed to the usual endocardial to epicardial 
activation. The orientation of cells in the myocardium, the transmural heterogeneity of gap 
junctions and the spatial heterogeneity of ion channels alter the coupling properties of the 
myocardium during normal activation. I hypothesise that pacing induced dyssynchrony likely 
alters and increases the spatial heterogeneity and alters coupling. Further, that gap junctions 
would adapt to this by altering their pattern of distribution or the absolute levels of connexins 
expressed through a disruption in trafficking.  
My objective is to see whether any meaningful conclusions can be drawn from the 
relationship between structure i.e. hemichannels and fully formed gap junctions i.e. whether 
there are structural signs to suggest increased lateralisation of connexin immunosignal and 
attempt to correlate these with functional changes. 
I test these using molecular tools such as immunostaining and apply a model of 
immunohistochemistry quantification which I developed. Data analysis was performed by Mr 
Ponzio and me. Also, immunoblotting for transcriptional levels of Cx43 expressed, were a 
joint effort with assistance from Dr Gutstein, Mr Ponzio, Ms Gupta and Dr Kang. I also 
assisted Mr Feig to perform a set of experiments and gather data to quantify transcriptional 
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effects using qRT- PCR. I will also test the effects of phosphorylation state with pacing and 
assess the relationship of Cx43 with its binding partners. 
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Methods: 
Collection and Storage of murine myocardium: 
Exposure of the heart was undertaken at the end of all experiments by midline thoracotomy 
followed by mobilising mediastinal structures and euthanasia of animals by aortic root 
transection at the base of the heart. Surrounding tissue was trimmed and the heart washed in 
PBS. Those destined for immunolabelling were flash frozen whole in liquid nitrogen and 
stored on site in Revco freezers at -800C. 
Haematoxylin-phloxine-saffron (HPS) staining 
These were kindly stained and photographed by myself (a set of H&E slides also) with help 
from Ms F Liu. Hearts from a subset of six animals were removed and fixed in 10% formalin 
and embedded in paraffin for histological evaluation after staining with HPS. 
Tissue Handling and Immunolabelling  
The following were performed by me having received training from Ms Fanny Liu and Dr 
Gutstein. At the end of each pacing experiment, hearts were rapidly excised and placed in a 
container with dry ice and frozen in Tissue Tek OCT compound (Sakura Finetek USA, Inc. 
Torrance, CA). The OCT mounted hearts were stored and retrieved when needed. 5µm thick 
sections were cut in an HM 560 cryostat (Microm, Walldorf, Germany) at -20oC, placed onto 
microscopy slides (Superfrost/Plus, Fisher Scientific, Pittsburgh, PA) and fixed in acetone. 
Sections were blocked with bovine serum albumin (BSA) and then double-stained with a 
custom-made rabbit polyclonal anti-Cx43 antibody at 1:1000 and wheat germ agglutinin 
(WGA) to visualise myocytes borders. A FITC-conjugated anti-Cx43 antibody was used to 
visualise Cx43.  
For cadherin staining, frozen sections were incubated with rabbit anti-pan-cadherin antibody 
1:5000 (Sigma), followed by a Texas Red-conjugated goat anti-rabbit secondary antibody 
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(Jackson ImmunoResearch Laboratories) and a FITC-conjugated anti-Cx43 antibody for 
colocalisation studies of these 2 proteins. 
Fluorescence microscopy visualised immunostained sections on an Axioskop 2 Plus 
microscope and I collected images using uniform exposure settings for each staining run on 
an Axiocam camera with AxioVision 4.30 software (Carl Zeiss, Munchen-Hallbergmoos, 
Germany). 
	  
Quantification of Cx43 and Cadherin Immunosignal 
Images of immunostained sections were acquired by me using a set of blinded 
immunostained slides. The images were digitally archived for offline analysis. Blinded image 
files were uniformly threshold by eliminating signal free areas above and below the 
distribution of intensity values using the histogram function on Adobe Photoshop. Digital 
image processing was then performed according to previously established techniques again in 
a blinded fashion, with NIH Image J to determine Cx43 and cadherin signal area as a 
percentage of total tissue area, as well as Cx43 plaque size and the number of Cx43 plaques 
per 40 x fields. 
 
Statistical analysis of Cx43 and Cadherin Immunosignal 
Quantitative immunofluorescence data were compared between groups with ANOVA using 
StatView (SAS Institute, Inc, Cary, NC) and data were expressed as mean ± SEM. These 
experiments were performed by me except for the RV analysis which was done by Marc 
Ponzio.  
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Figure 30. 40x magnification field acquired from the base of the left ventricle. 
Images are focused on the epicardial layer of myocardial cells co-stained for Cx43 (in green) 
and Cadherin (in red) with merged image (in yellow). 
Using NIH Image J software, images were converted into 8bit format. Using the image menu 
in Image J, and then adjust option, images were threshold to reflect signal area. Raw data 
were then measured by selecting the analyze menu, measure and analyse particles tool and 
exported into Excel for comparison. 
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Figure 31-Desktop view of Image J generated raw data measuring Cx43 total signal 
area, number per field and size of gap junction plaques. 
Figure represents blinded slide 10 with auto-threshold applied to remove signal-free areas 
from the analysis. Data for cadherin were captured in a similar fashion.  
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Immunoblotting and Densitometry-WT Mice 
 
The following experiments were performed by me with assistance from Marc Ponzio and Dr 
Gutstein. 
Endocardial ventricular tissue from paced and sham-paced hearts was prepared by Dounce 
homogenisation in lysis buffer supplemented with Complete® protease inhibitor cocktail 
(Roche, Mannheim, Germany) to assess total protein levels. The endocardial samples were 
prepared by mounting the excised LV free wall in an OCT block, separating the endocardial, 
mid-myocardial and epicardial regions by sectioning on an HM 560 cryostat and 
homogenising. The inner third of the LV free wall was considered the endocardial region, 
middle third mid-myocardial and outer third, epicardial. Protein concentration (determined by 
Bradford assay) was performed in triplicate. Equal loading was confirmed with coomassie 
staining and proteins were electrophoresed on 10% SDS-PAGE gels and transferred onto 
nitrocellulose blots (Bio-Rad laboratories, Hercules, CA). Immunoblots were blocked with 
milk followed by incubation with appropriate primary antibodies directed against Cx43, 
cadherin, Cx45 (Johnson), Cx40 (Alpha Diagnostics, San Antonio, TX) and GAPDH 
(Chemicon/Millipore, Billerica, MA). Horse radish peroxidise (HRP)-conjugated secondary 
antibody Santa Cruz Biotechnology, Santa Cruz, CA) was then applied, followed by HyGlo 
chemiluminescent processing (Denville Scientific, Metuchen, NJ) and autoradiography. At 
least two separate experiments were quantified by scanning the autoradiograph on  a Bio-Rad 
Gel Doc GS 800 and calculating band intensity using Quantity One Software (Bio Rad, 
Hercules, CA). Connexin band intensities were normalised to the relative intensity of the 
corresponding GAPDH band for each sample. Results were expressed as a percentage of 
matched controls. 
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Immunoblot Analysis in Cx43+/− murine experiments 
 
A custom manufactured rabbit polyclonal antibody directed against an epitope on the 
carboxy-terminus of Cx43 was used on ventricular lysates and a monoclonal antibody 
directed against GAPDH (Chemicon/Millipore, Billerica, MA). HRP-conjugated secondary 
antibody was then applied to the immunoblots, followed by HyGlo chemiluminescent 
processing. Cx43 band intensities from 3 separate experiments were quantified by 
densitometry and normalised to the relative intensity of the corresponding GAPDH band for 
each sample. 
Fraction Preparation and Immunoprecipitation 
 
These experiments were performed by Dr Gutstein and Marc Ponzio with assistance from me. 
Heart samples were Dounce homogenised centrifuged at 500g for 10 minutes removing the 
insolubles. Lysates were then layered over a 45% sucrose cushion. After centrifuging at 
7000g for 20 minutes the supernatant (considered the non-sarcolemmal fraction) was 
separated from the cloudy layer immediately overlying the sucrose (sarcolemmal fraction). 
Protein concentrations in each fraction (determined by Bradford Assay) were performed in 
triplicate and equal loading was confirmed with coomassie staining. The resulting fractions 
were analyzed by SDS-PAGE and Western blotting. 
The immunoprecipitation experiments were kindly performed by Pritha Gupta. 50µg of total 
heart lysate was incubated with polyclonal anti-Cx43 antibody. After addition of protein A 
agarose-immobilised protein beads (Roche) to the samples, the protein A suspension was 
centrifuged at 5000xg and the supernatant removed. The protein A beads were washed in IP 
buffer and resuspended in loading buffer prior to incubation at 100oC and analysis by SDS-
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PAGE. Resulting blots were incubated with a monoclonal antibody directed against ubiquitin 
(FK2, Biomol).  
RNA isolation and Quantitative Real-Time PCR (qRT-PCR) 
 
These experiments required the isolation of RNA from the LV free walls of paced and sham-
paced hearts excised and mounted in OCT and snap frozen in liquid nitrogen. Endocardial 
and epicardial thirds were collected by sectioning (performed by me) through the LV free 
wall as described earlier and then isolating RNA in an RNA free space using Trizol 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol (the isolations were 
carried out by me). 
I assisted Jonathan Feig through the remaining experiment-he kindly created the primer 
sequences; I aided in the assessment of RNA quality, estimation of RNA concentration and 
assisted with quantitative PCR to generate the data for the graphs which were created by 
Jonathan and Dr Gutstein. 
RNA quality was verified with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA). Ribogreen RNA Quantitation Kit (Molecular Probes/ Invitrogen, Carlsbad, CA) 
allowed assessment of RNA concentration. ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA) performed real time quantitative PCR using primer 
sequences as outlined in Kontogeorgis et al. Data were normalised to Cyclophilin A (primer 
sequences as outlined in Trogan et al 2002) and expressed as fold change compared to the 
sham-paced controls. Negative controls were performed for each of the samples, in which 
reverse transcriptase was not added prior to RNA quantification. Results per animal represent 
the mean of six measurements of each endocardial and epicardial sample. 
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Cardiac Myocyte Isolation 
 
Once I had completed pacing mice for 6hours, harvested whole hearts were prepared for cell 
isolation protocols and this was primarily performed by Marc Ponzio and Dr Gutstein for 
further experimentation by Dr Xiaodong Li. I assisted Marc and learnt how to generate the 
solutions for myocyte isolation and aided with hanging the heart on the Langendorff as well 
as mechanically dissociating hearts after digestion as well as adding solutions to generate 
healthy cells under microscopy. 
Ventricular myocytes were isolated from Cx43+/- and WT littermate hearts immediately 
following pacing or “sham-pacing” using an enzymatic technique. Mice were first anti-
coagulated with 1000U/kg heparin administered intraperitoneally 20min prior to removal of 
the heart whilst still under general anaesthesia. Under isoflurane anaesthesia hearts were 
rapidly removed and perfused in a constant-pressure Langendorff system with Minimum 
Essential Medium Eagle (Joklik modification; Sigma), 0.44mM EGTA, 34.5mM NaHCO3, 
1mM MgSO4 and 10mM 2, 3 Butanedione Monoxime at 37 oC for 5 min. Hearts were then 
perfused with the same solution containing 0.05% (wt/vol) collagenase (Worthington Type 
2), 0.1% bovine serum albumin, 12.5µM CaCl2, but without EGTA, 37 oC for 15min. 
The heart was removed from the Langendorff system and dispersed mechanically. The 
dissociated heart tissue was then incubated in medium containing 10% foetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA, USA) and 12.5 µM CaCl2 for 10min at room 
temperature followed by additional 10min incubation in medium containing 5% foetal bovine 
serum and 12.5 µM CaCl2. 
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Isolated myocytes were then incubated for 30 min at room temperature in Kraftbrűhe (KB) 
solution, which contained (in mM): 20 taurine, 50 glutamine, 10 glucose, 10 HEPES, 0.5 
EGTA, 3 MgSO4, 30 KH2PO4, 30 KCL, 85 KOH, (pH 7.2 adjusted with KOH).KB solution 
was gradually replaced with modified Tyrode’s solution (in mM: 140 NaCl, 4 KCL, 10 
HEPES, 1.1 MgCl2, 1.8 CaCL2 and 10 glucose, pH 7.4 adjusted with NaOH). For action 
potential measurements, ventricular myocytes were isolated from both ventricles. For 
potassium currents, cells were isolated exclusively from the right ventricle. Cells were used 
for patch-clamp experiments within 6 hours of isolation by Dr X Li. 
Patch	  clamp	  	  
Cellular	  Electrophysiology	  
Isolated myocytes were placed in a bath (~500 µl volume) on the stage of an inverted 
microscope (Nikon Diaphot, Tokyo, Japan) and whole-cell patch clamp recordings (15) were 
obtained at RT. Experiments were performed using an EPC 9/2 amplifier and Pulse 8.79  
software (HEKA Elektrotonik, Lambrecht,Germany). For recording action potential (AP), 
modified Tyrode's solution was used as the bath solution (components as above). Recording 
pipettes were fabricated from borosilicate capillary glass (Warner Instruments, Novato, CA, 
USA) using a Sutter Model P-97 micropipette puller (Novato, CA, USA) and polished using 
a MF-830 Micro Forge (Narishige, Japan) to resistances of 2-5 M when filled with pipette 
solution. The pipette solution for recording APs consisted of (in mM): 135 KCl, 4 MgCl2, 5 
EGTA, 10 glucose, 10 Hepes, 5 Na2-ATP, 3 Na2-creatine phosphate, pH 7.2 with LiOH. For 
recording potassium currents, the bath solution contained (in mM): 135 choline chloride, 5.4 
KCl, 1.1 MgCl2, 1.8 CaCl2, 0.001 ryanodine, 0.01 atropine sulfate, 0.5 CdCl2, 10 glucose 
and 10 Hepes; pH 7.4 (with NaOH); pipette solution contained (in mM): 115 potassium 
aspartate, 5.0 KCl, 7 MgCl2, 5 EGTA, 10 HEPES, 4 Na2-ATP, pH 7.2 (with KOH). After 
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establishing the whole-cell configuration, membrane capacitances (Cm) were determined by 
integrating capacitance transients recorded during a brief 5 mV step from a holding potential 
(HP) of –70 mV. The cell capacitance was calculated as the ratio of the integral of the  
capacitance transient divided by the voltage step. Series resistance (Rs) was estimated from 
the decay of the capacitative transients. In each cell, Rs was compensated electronically by 
80- 90%. Tip potentials were zeroed before membrane-pipette seals were formed. The liquid 
junction potential was calculated to be -18 mV (Axoscope, Axon Instruments). Membrane 
potentials were not corrected for the liquid junction potential. Only data obtained from cells 
with seal resistances > 1 G were analyzed. Action potential and potassium current recordings 
were performed in the whole-cell configuration. Action potentials were recorded at RT in the 
current clamp mode by stimulating with a 3 ms pulse at a frequency of 1 Hz.  
Peak outward potassium current (IKpeak) was recorded using 1 sec depolarizing voltage 
steps at 10 mV increments between -50 and +50 mV from a HP of -60 mV at 0.01 Hz. The 
interval between voltage steps was set at 10 sec to allow complete recovery of outward 
potassium current. Steady state inactivation of the outward potassium current was examined 
with a standard 2-pulse protocol consisting of 1 sec prepulses from -80 to +5 mV in 5 mV 
increments from a HP of -60 mV followed by a 500 ms test pulse to +40 mV. Recovery of Ito 
from inactivation was measured by using two depolarizing pulses to +40 mV from a HP of -
60 mV separated by sequentially increasing intervals of 5 to 185 ms in 10 ms increments 
(26). Outward potassium current was recorded before and after application of 2mM 4-
Aminopyridine (AP) to separate the 4-AP insensitive current (Iss) from the 4-AP sensitive 
current (Ito)(176). Inward rectifier potassium current (IK1) was recorded in response to 
voltage steps to potentials between -20 and -140 mV from a HP of -60 mV. Currents were 
low-pass filtered at 2.9 kHz, digitized at 10 kHz, and stored for subsequent off-line analysis.  
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Electrophysiology	  Data	  Analysis	  
	  
Data were analyzed using PulseFit 8.79 (HEKA). Iss was measured 100 ms from the end of 
each voltage step after application of 4-AP. The peak Ito was calculated as the maximal 
current amplitude after subtraction of the 4-AP insensitive current from IKpeak at each 
depolarizing voltage step. IK1 was measured 100 ms from the end of each voltage step. 
Potassium current densities were obtained by dividing the measured currents by the whole-
cell membrane capacitance, Cm. Inactivation of Ito was fitted using the following equation to 
current traces after subtraction of the 4-AP insensitive current from IKpeak:  
y (t) = a0+a1 exp (-t/ f) + a2 exp (-t/ s), 
Where t is time; f and s are the time constants of inactivation of Ito; a1 and a2 are the 
amplitudes of the inactivating current components; and a0 is the residual amplitude of the 
steady-state, non-inactivating component of the total outward K+ current after subtraction of 
the 4-AP insensitive component. Steady-state inactivation curves were obtained by using a 
two-pulse protocol as described above. Curve fitting after normalization of the current was 
performed using the Boltzmann equation, 1/ [1+ exp (V-V1/2)/k], where V is the prepulse 
potential, V1/2 is half-maximal inactivation potential, and K is slope factor for steady-state 
inactivation curves. The time course of recovery of Ito was described by a first-order 
exponential function as follows (177):  
y = 1 - exp-x/, 
Where y is the normalized current, x is time and is the time constant of recovery from Ito 
inactivation (recovery). 
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Optical mapping 
 
I assisted with these experiments in Dr G Morley’s lab. Isolated hearts were given 15minutes 
to equilibrate and perfused with voltage sensitive dye, di-4-ANEPPS (Molecular Probes) by 
injecting a 0.3ml bolus containing 125nmol/L into a 10ml compliance chamber within the 
perfusion line. High resolution optical mapping of voltage dependent fluorescence was 
performed on an upright Olympus microscope (BX50WI) with a reflected light fluorescene 
attachment. Images were acquired at 947frames/sec with 12-bit resolution of 40 µm (2x 
objective,N.A 0.14).No pharmacological e.g. blebbistatin or mechanical manipulations were 
used to limit motion (178). I assisted his lab staff to generate solutions for perfusing the heart 
as well as recording raw data and reviewing the data offline as well as generating the graphs 
for epicardial breakthrough. 
Statistics WT Mice: 
Data are expressed as mean ± SEM.  Quantitative immunofluorescence data were compared 
between groups with ANOVA using StatView (SAS Institute, Inc., Cary, NC).  Data from 
electrocardiography, echocardiography, programmed electrical stimulation, immunoblot 
densitometry and qRT-PCR were compared between groups with unpaired two-tailed t-tests 
(Microsoft Excel).  Electrocardiographic indices, echocardiographic measurements and 
effective refractory period values obtained during or after the pacing protocol were compared 
to baseline measurements with paired two-tailed t-tests (Microsoft Excel).  P<0.05 was 
considered statistically significant.  
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Statistics Cx43-deficient mice: 
Data are expressed as mean ± SEM. Electrocardiographic indices and echocardiographic 
measurements obtained after the pacing protocol were compared to baseline measurements 
with paired two-tailed t-tests (Microsoft Excel). Electrocardiography, echocardiography, 
programmed electrical stimulation and cellular electrophysiology results in the paced and 
unpaced Cx43+/− mice and their wildtype littermates were compared between groups with 
ANOVA followed by Fisher’s protected least significant difference (PLSD) post-test using 
StatView 5.0 (SAS Institute, Inc., Cary, NC). A post-hoc analysis was performed to compare 
IK1 in wildtype versus Cx43+/− myocytes. IK1 in unpaced versus paced subgroups was first 
compared using ANOVA, followed by pooling and comparison of all data from wildtype 
versus Cx43+/− myocytes at each voltage using ANOVA. P < 0.05 was considered statistically 
significant.  
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Results: 
Determining the duration necessary to induce GJR; “Cx43 Lateralization” 
study: 
 
As mentioned in chapter 3, I performed experiments at 1hr, 4hr and the 6hr time point 
representing approximately 1,2½ and 4 half-lives for Cx43.At each of these time points I 
determined whether short term pacing induced functional effects in terms of 
electrocardiography while 1hr and 6hr time points were measured in vivo for arrhythmia 
inducibility using programmed electrical stimulation (i.e. whether pacing resulted in a 
“pathological arrhythmia prone” phenotype).  
Qualitative	  Microscopy	  
Immunostaining with 3 blinded observers (Dr Gutstein, Ms Liu and I) was undertaken at each 
time point 1hr, 4hr and 6hr and examined microscopically for evidence of gross differences 
in Cx43 immunosignal and distribution. Furthermore, we looked at low power at the whole 
heart as well as at higher power within regions of the RV, LV, Base, Apex and Epicardium, 
Mid and Endocardial layers for profound differences in Cx43 immunostaining signal 
intensity and distribution. It became evident to all that using this approach we were unable to 
distinguish sham-paced compared to neither paced mice at any of the three stated time points 
nor identify differences in a particular region.  
To further test whether pacing induced dyssynchrony was having any effect at all on gap 
junction remodelling or lateralisation a set of blinded slides was prepared for analysis by an 
external examiner. The external blinded observer (Dr Kaba) was to review a set of slides to 
see if he were able to determine any gap junction changes between the groups utilising a 
subjective semi-quantitative scoring tool developed in Prof Peter’s lab. 
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I also embarked on a set of immunostaining experiments using a semiquantitative method 
designed and refined by me to attempt quantifying the immunosignal of gap junctions along 
lines described in the Yamada/Saffitz lab. 
Finally, to further assess structural changes tissue samples were prepared for ultrastructural 
techniques and electron microscopy. 
Electron	  Microscopy	  experiment.	  
	  
Pravina Patel kindly performed the staining for gap junctions and electron microscopy on 
tissue prepared by me in the USA and sent to the UK.I provided a paced heart after 6hr 
pacing to assess if any gap junction lateralisation was observed. Pravina’s experiment is 
illustrated in the figure below (see Figure 32).The electron microscopy findings supported the 
notion that only very subtle remodelling was occurring with evidence of lateralisation seen on 
EM. 
 
[174]	  
	  
 
Figure 32. EM staining demonstrating subtle presence of lateralised gap junctions (x 9300 
magnification and x 68 000 magnification for inset panel).  
Experiment kindly performed by Pravina Patel (unpublished figure). 
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Lateralisation	  Scoring	  Experiment:	  
Samples were examined by a 4th blinded observer (Dr Kaba) to further assess the effects of 
short-term pacing on targeting of Cx43 protein along the cardiac myocyte membrane. He 
used a subjective scoring system developed by Kaba and colleagues. The degree of Cx43 
immunosignal at the lateral myocyte borders in sections from paced and sham-paced hearts 
was compared. Paced and sham paced hearts were assigned scores ranging from 0 (no 
lateralization) to 3 (extensive lateralization).We found that sham sections demonstrated 
extensive subjective lateralization of Cx43 signal (2.75 ± 0.25) and that the extent of 
lateralization did not appear significantly different in the paced hearts (2.40 ± 0.40,p=ns)
 
Figure 33 Semi-quantitative scoring of lateralised Cx43 immunosignal. 
After 6hour sham pacing (n=4) and 6 hour pacing (n=5) there were no significant 
differences(p=ns) unpublished figure (179). 
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Semiquantitative protocol experiments. 
Distribution of Cx43 Immunosignal area after 6hr pacing. 
I developed a protocol for semi-quantitatively measuring the degree of fluorescence on a 
regional basis and applied this to blinded images taken from immunostained samples. The 
methodology of this approach was stated earlier in the chapter. I proceeded to examine 
prepared tissue for evidence of Cx43 lateralisation or differences in immunosignal on a 
regional basis by measuring the Cx43 signal as a ratio to tissue area and also the size and 
number of gap junction plaques in the groups that were paced or sham paced. This was 
initially commenced with pilot data at low magnification 10x tissue field but no differences 
were observed and I proceeded to a 40x high power regional analysis of wildtype mice at 1hr 
and 6hr pacing duration. No differences were observed after 1 hour pacing. 
Cx43 signal area/total tissue area % after 6hr pacing 
LV immunosignal 
I performed all the quantification experiments for the LV. Initially I utilised a 10x wide field 
for the analysis but could detect no differences and so I chose a higher field of view at 40x as 
I considered the possibility that the differences may be more subtle and region specific e.g. 
Base vs. Apex; Epicardium vs. Midmyocardium vs. Endocardium; Septum vs. LV free wall. 
Cx43 immunosignal was distributed heterogeneously only in gap junction plaques in the LV 
free wall with a gradient noted from epicardium to endocardium. Sham-paced hearts 
demonstrated a greater Cx43 signal area as a percentage of total tissue area in the LV free 
wall endocardium compared to the epicardium (9.12 ±1.2% and 6.82 ± 0.4% respectively; 
p<0.05). This transmural gradient of Cx43 has also been observed by the Yamada group. The 
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effect of six hours of pacing was to reduce the Cx43 immunosignal area at the LV free wall 
endocardium (6.76 ± 0.6%) compared to sham-paced controls(p<0.05) yet no change 
occurred in the epicardium (6.41 ± 0.3%). These changes in the Cx43 signal area appeared 
significantly reduced only at basal LV segments in paced hearts compared to sham-paced 
hearts (6.38% ± 0.5% in paced vs 9.36 ± 1.28% in sham-paced hearts, p<0.01).The apex and 
mid ventricle endocardial and epicardial regions were not significantly reduced with respect 
to Cx43 signal area (6.76 ± 0.89% in paced vs 7.97 ± 0.96% in sham at the apex and 7.15% 
±0.69% in paced vs 9.10 ± 1.59% in sham at the mid-ventricle).  
RV	  quantification	  of	  immunosignal	  
Also, no differences in Cx43 signal area were observed in right ventricular sections between 
paced and sham-paced mice (3.40 ± 0.25% and 3.91 ± 0.45% respectively). A specific 
analysis was made of the RV apex where the pacing electrode was sited with Cx43 signal 
area in paced (4.16  ± 0.53%) and sham-paced (3.51 ± 0.46%) hearts showing no significant 
difference. 
Gap Junction Plaque Size and Number of Gap Junction Plaques 
No significant differences were noted between the groups in terms of plaque size. There was 
no significant difference in the number of gap junction plaques per 40x field in sham-paced 
and paced endocardial and epicardial regions. 
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Figure 34 Immunofluorescene Images of Cx43 and Cadherin Staining in the Epicardial 
and Endocardial Regions of Sham-Paced and Paced Hearts.  
Cx43 immuno-signal area is higher in the endocardium than the epicardium in sham-paced 
hearts (Panels A and B). In the paced hearts, Cx43 immuno-signal area is decreased 
specifically at the endocardium, thereby eliminating the gradient of endocardial to epicardial 
Cx43 immuno-signal area seen in the sham paced hearts (Panels C and D). Cadherin staining 
pattern and area is unchanged in the paced hearts (Panels E-H). Co-localization of Cx43 and 
cadherin immuno-signal, as demonstrated by the merged images, is statistically unchanged in 
the paced hearts compared to sham-paced controls (Panels I-L). Quantification of Cx43 
immuno-signal area shows an increasing epicardial-to-endocardial gradient in the sham but 
not in the paced mice, due to decreased signal area specifically in the endocardial region of 
the paced mice (Panel M). Average Cx43 gap junction (GJ) plaque size appears to increase 
from epicardium to endocardium in sham but not paced mice, although these differences were 
not statistically significant (Panel N). There were no significant differences in the number of 
Cx43 GJ plaques per high power field in epicardial vs. endocardial segments of sham and 
paced mice (Panel O). Cx43 immunostaining pattern appeared similar at the RV apex of 
sham (Panel P) and paced hearts (Panel Q). RV epicardial surface is denoted by asterisks. 
Epi, epicardial region; Endo, endocardial region. Reproduced with permission from 
Kontogeorgis et al (179) 
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Impact of short-term pacing on the relationship of Cx43 to its binding partner 
cardiac adherens junctions(AJ) 
	  
Adherens junctions like gap junctions are concentrated at the intercalated discs of adult 
cardiac myocytes. Cadherin is a critical component of the adherens junction and co-localises 
with Cx43.There was no epicardial-to-endocardial gradient of cadherin immunosignal in 
control hearts and after 6 hours of pacing. This suggests that the reduction in Cx43 
immunosignal occurs in the absence of changes in the distribution of the adherens junctions. 
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Quantifying expression of Cx43 mRNA in the LV free wall after 6hr pacing 
Since Cx43 immunosignal was reduced at the LV endocardium after 6hours of pacing we 
determined to test the transcription levels of Cx43 mRNA. qRT-PCR of paced samples 
demonstrated a 2.5 ± 0.1 fold down-regulation in expression of Cx43 mRNA at the 
endocardial region of the paced hearts compared to controls (p=0.001;n=3 sham and 3 
paced). 
 
 
 
Figure 35  Quantitative Real-Time PCR(qRT-PCR) of LV free wall endocardium and 
epicardium. 
This demonstrates reduced Cx43 mRNA levels in paced hearts. Both the endocardium and 
the epicardium of the LV free wall demonstrated significantly reduced Cx43 mRNA levels 
after the short-term pacing protocol(179). With permission from Kontogeorgis et al.  
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Cx43 Protein levels in the LV endocardial region after short-term pacing. 
There was no significant change in Cx43 protein expression in the paced LV endocardial 
region compared to sham-paced controls (n=11 sham and 11 paced). Quantitative 
densitometry confirmed no significant difference in  mean Cx43/GAPDH 0.92 vs 0.84 
arbitrary units (a.u.) .Furthermore densitometry comparing slower migrating Cx43 bands as a 
ratio of  lower most bands to assess differences in phosphorylation state were also not 
significantly different. 
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Figure 36. Cx43 Protein levels after 6hours of pacing. 
Cx43 protein levels remain unchanged compared to sham-paced controls normalized to 
GAPDH (endocardial lysates). Note that there are 3 bands within Cx43 and represent various 
states of phosphorylation from top to bottom P2,P1,P0 respectively(179). With permission 
from Kontogeorgis et al (179). 
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Figure 37. Cx43 densitometry relative to GAPDH loading expressed as arbitrary 
units(A.U.). 
There is no significant difference in Cx43 immunoblotting after 6hours of pacing and sham-
pacing(179). With permission from Kontogeorgis et al(179). 
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Figure 38. Cx45, Cx40 and Cadherin protein levels after 6 hours of pacing. 
 Cx45, Cx40 and Cadherin protein levels are unchanged after 6 hours of pacing without 
significant difference in the mean band densities normalized to GAPDH (endocardial 
lysates).(179)  With permission from Kontogeorgis et al (179). 
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Cadherin,Cx40 and Cx45 protein expression. 
Cadherin, Cx40 and Cx45 levels were statistically unchanged after pacing in the endocardium 
of the LV free wall. 
Fractionation	  study	  
Heart samples demonstrated significantly reduced Cx43 abundance in the membrane-
enriched fraction isolated from paced hearts compared with controls (40.4 ± 8.7% decrease in 
the paced hearts; p<0.05; n=11 sham and 12 paced hearts). In contrast, Cx43 levels in the 
supernatant (non-membrane fraction) increased by 104.0 ± 35.5% (p<0.05). These findings 
suggest intracellular redistribution of Cx43 protein. 
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Figure 39 Cx43 levels in membrane and cytosolic pools after 6hr pacing and sham-
pacing. 
Cx43 levels in membrane (sarcolemmal) fraction n=4 after 6hr paced and sham-paced 
showing a significant reduction. There is a significant increase post pacing as compared to 
cytosolic (non-sarcolemmal) pool of Cx43  (p<0.05). Cx43 mean band densities 0.73 in 
paced and 1A.U. in unpaced Cx43membrane bound fraction(179). With permission from 
Kontogeorgis et al. 
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Immunoprecipitation study- Cx43 gap junction degradation. 
 
To test whether degradation of gap junctions appear to be disrupted Dr Gutstein and Ms 
Gupta kindly performed an immunoprecipitation study of Cx43 from lysates generated (5 
sham and 5 paced hearts) and these were immunoblotted with ubiquitin. Immunoblotting for 
ubiquitin revealed a substantial increase in expression of ubiquitinated forms in the paced 
hearts.  
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Figure 40. Cx43 distribution and ubiquitination with pacing and Ubiquitin Quantification at 
baseline and after 6hr pacing. 
Immunoblot demonstrating increased accumulation of ubiquitinated Cx43 in paced hearts. In 
this image, monoubiquitinated Cx43 is seen just above the 40kD size marker and 
polyubiquitinated forms of Cx43 appear as a slower migrating smear(179). With permission 
from Kontogeorgis et al. 
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Figure 41 Significant increase in mean ubiquitinated Cx43 after 6hr pacing normalised 
to GAPDH (p=0.01). 
Ubiquitin mean densitometry expressed as a ratio to GAPDH loading in arbitrary units and 
 error bars indicating standard deviation. 
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Electroanatomical correlation in Cx43+/- mice. 
Cellular	  electrophysiologic	  properties	  post	  myocyte	  isolation	  using	  
whole	  cell	  patch	  clamp.	  
 
To investigate how pacing in the setting of reduced Cx43 expression (Cx43+/−) influences 
electrophysiologic properties, I designed and undertook a set of experiments that would 
investigate the repolarisation properties of these hearts at a cellular level. Dr Li executed 
experiments using whole cell patch clamp techniques to record action potentials in ventricular 
myocytes obtained from unpaced and paced wildtype and Cx43+/− mice respectively (Figure 
41  and Table 13 ). Findings are presented over the next section and I present the following 
parameters: 
1. Resting membrane potential, action potential maximal amplitude and morphology and 
Action Potential Duration at 50 and 90ms (see figure 41 and Table 13) 
2. I assisted Marc Ponzio and executed the immunostaining of Cx43+/− hearts; sections were 
costained with cadherin for qualitative microscopy (see fig 42) to assess the pattern of 
distribution of Cx43. Furthermore western blots were undertaken of samples from Cx43+/− 
paced and unpaced hearts to compare levels of Cx43 (fig 43). Findings confirmed that the 
transgenic hearts express 66% reduced levels of Cx43 on quantitative immunoblotting (see 
fig 43 panel A). 
3. I assisted Mr Feig who kindly tested the effects of pacing on levels of mRNA in Cx43+/− 
hearts in order to assess any potential transcriptional effects. 
4. I worked with Dr Morley’s lab and optically mapped the Cx43+/− hearts after 6hr pacing to 
determine the sinus rhythm breakthrough activation pattern. 
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Figure 42. Action Potentials in Unpaced and Paced Wildtype and Cx43+/− 
Cardiac Myocytes.  
A) Representative action potentials from unpaced and paced wildtype and Cx43+/− cardiac 
myocytes. Action potentials were recorded from adult ventricular myocytes in current-clamp 
mode, with cells stimulated by 3ms, 3 – 5 mV pulses at a frequency of 1 Hz. B) Summary 
data of action potential duration at 50 percent (APD50) and at 90 percent (APD90) of 
repolarization. Unpaced Cx43+/− cells had shorter APD50 and APD90 values compared with 
the unpaced wildtype cells. APD increased significantly in the Cx43+/− cells with pacing, 
whereas there was no significant change with pacing in the wildtype cells(161). Reproduced 
from Kontogeorgis et al.  
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Action	  Potential	  Duration	  in	  Unpaced	  Cx43+/−	  Myocytes	  and	  WT	  
Myocytes	  
Myocytes isolated from unpaced Cx43+/− hearts had significantly shorter action potentials 
than unpaced wildtype cells. In wildtype myocytes, pacing had no effect on APD. Myocytes 
isolated from unpaced wildtype hearts demonstrated APD measurements that were no 
different from paced wildtype myocytes (APD50 = 9.7 ± 1.0 ms in unpaced wildtype vs. 9.9 
± 0.8 ms in paced wildtype; APD90 = 54.1 ± 4.8 ms in unpaced wildtype vs. 55.3 ± 3.0 ms in 
paced wildtype; p = NS for both comparisons) (figure 41 and table 13). 
Action	  Potential	  Duration	  in	  Paced	  Cx43+/−Myocytes	  and	  WT	  Myocytes:	  
Cx43+/− myocytes demonstrated significant prolongation of APD after pacing compared to 
unpaced Cx43+/− myocytes (APD50 = 5.8 ± 0.9 ms in unpaced Cx43+/− vs. 8.5 ± 0.6 ms in 
paced Cx43+/−, p < 0.05; APD90 = 35.0 ± 3.2 ms in unpaced Cx43+/− vs. 52.7 ± 4.1 ms in 
paced Cx43+/−; p <0.01). While pacing resulted in no significant change in APD in wildtype 
cardiac myocytes, the imposition of pacing on Cx43-deficient cells resulted in a significant 
lengthening of APD compared to its unpaced baseline (figure 41 and table 13). 
Action	  Potential	  Amplitude	  and	  Resting	  Membrane	  Potential:	  
Action potential amplitude and resting membrane potential were no different among the 
unpaced and paced wildtype and Cx43+/− subgroups (figure 41 and table 13)..  
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Table 13. Comparison of Action Potential Parameters in Wildtype and 
Cx43+/− Unpaced and Paced Mice 
 
 
 WT unpaced  WT paced  Cx43+/− Cx43+/−paced  
 (n=6)  (n=11)  unpaced (n=7)  (n=10)  
Amplitude, mV  101.8 ± 3.8  97.2 ± 1.7  97.6 ± 4.0  97.8 ± 2.0  
RMP, mV  -72.0 ± 0.5  -72.5 ± 1.0  -71.5 ± 1.0  -72.0 ± 1.0  
APD20, ms  2.7 ± 0.3  2.6 ± 0.2  2.0 ± 0.2  2.3 ± 0.2  
APD50, ms  9.7 ± 1.0  9.9 ± 0.8  5.8 ± 0.9*  8.5 ± 0.6  
APD90, ms  54.1 ± 4.8  55.3 ± 3.0  35.0 ± 3.2†  52.3 ± 4.1  
 
Data are presented as group means ± SEM. Comparisons between groups were performed 
with ANOVA. *, p < 0.05 compared to all other groups; †, p < 0.01compared to all other 
groups. RMP, resting membrane potential; APD, action potential duration (161). With 
permission from Kontogeorgis et al (161).
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Assessment	  of	  Cx43	  protein	  expression	  at	  basal	  levels	  and	  after	  6hr	  
pacing:	  
Immunosignal	  assessment: Cx43 and cadherin in unpaced Cx43+/− hearts compared 
to 6hr paced hearts was not significantly altered (figure 42).	  
	  
Figure 43. Cx43 (green) and Cadherin (red) immunostaining in Cx43+/− mice. 
Courtesy of Dr Gutstein; Cx43 and Cadherin immunosignal in paced and unpaced mice 
showed no significant differences.   
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Immunoblotting:	  
Cx43+/− hearts had reduced Cx43 protein levels compared to matched samples from littermate 
WT (34.3 ± 4.4%; p <0.01). Pacing for 6hr did not significantly affect overall Cx43 protein 
levels in Cx43+/− mice. 
 
 
Figure 44. Cx43 expression in Cx43+/− hearts:  
Western blot showing reduced Cx43+/−  (A)compared to wildtype (66% reduction on 
quantitative densitometry normalised to GAPDH , data not shown). The effect of pacing on 
Cx43 protein levels (B) in Cx43+/- mice was not significantly altered (161). Reproduced from 
Kontogeorgis et al. 
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Relative	  Cx43	  mRNA	  abundance	  in	  Cx43+/−	  mice	  after	  6hr	  pacing:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
No significant differences were found in Cx43 mRNA abundance in Cx43+/- hearts relative to 
their baseline levels after 6hour pacing (figure 44). 
 
Figure 45. Relative Cx43 mRNA abundance 
Relative Cx43 mRNA abundance in Cx43+/− hearts after 6hour pacing were not significantly 
changed(161). Reproduced from Kontogeorgis et al 
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Epicardial sinus activation breakthrough after 6hr pacing. 
Using optical mapping we tested for altered epicardial activation or breakthrough between the 
right and left ventricle (normally earliest activation occurs on the right followed by the left) 
and found no significant evidence to suggest Bundle branch block as a mechanism for 
mechanical dyssynchrony. 
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Figure 46 Epicardial activation breakthrough patterns in Cx43+/− unpaced and Cx43+/− 
paced hearts. 
 Epicardial breakthrough patterns and time difference between LV and RV breakthrough 
were not significantly altered.  
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Investigating repolarization properties as potential determinant 
of altered action potential duration in cardiac myocytes: 
 
Since action potential duration in cardiac cells is largely determined by voltage-dependent 
potassium channels (160), a set of experiments were undertaken to determine whether 
changes in repolarization in unpaced and paced Cx43+/− myocytes might result from altered 
potassium current properties of: 
1. Inward rectifier K+ current (IK1) 
2. Total Outward K+ current (IKpeak) comprised of : 
i) Steady state K+ current (Iss)-this is the 4-AP insensitive component of the outward current 
ii) The 4-AP sensitive component of the outward K+ current, (Ito). 
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Assessing	  the	  Inward	  Rectifier	  Potassium	  Current	  (IK1)	  in	  RV	  Cx43+/−	  
Myocytes:	  
 
IK1 was measured in the whole-cell configuration, in which calculated cell capacitances are 
144.6 ± 7.6 pF in wild type RV myocytes (n=28) and 145.9 ± 5.5 pF in Cx43+/− RV myocytes 
(n=29; p = NS). 
The background inward rectifier potassium current, IK1, which is responsible for maintaining 
the resting membrane potential and influences the late phase of repolarization was 
investigated first(180). Initially, no significant differences were observed in a 4-way 
comparison of IK1 in unpaced wildtype (peak current = -14.3 ± 1.4 pA/pF), paced wildtype (-
13.7 ± 1.3 pA/pF), unpaced Cx43+/− (-17.7 ± 1.2 pA/pF) and paced Cx43+/− myocytes (-16.3 
± 1.3 pA/pF; Figure 46 A-E). Because IK1 was not statistically different in unpaced versus 
paced wildtype myocytes across all of the tested voltages, the data from these two groups was 
pooled at each voltage to increase statistical power. IK1 values in unpaced and paced Cx43+/− 
myocytes were also pooled at each voltage, since they were not significantly different (except 
at -30 mV, p = 0.028).  A post-hoc analysis of the pooled values from wildtype versus 
Cx43+/− myocytes revealed significantly increased IK1 in the Cx43+/− myocytes compared to 
wild types (Figure 46 F).  Thus, increased IK1 in Cx43+/− myocytes may contribute to APD 
shortening. However, there was no significant effect of pacing on IK1 in either wildtype or 
Cx43+/− myocytes.  
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 Figure 47. Effect of Pacing on the Inward Rectifier Potassium Current, IK1, in 
Wildtype and Cx43+/− Right Ventricular Cardiac Myocytes.  
A and B) Representative recordings of IK1 from wildtype (panel A) and Cx43+/− (panel B) 
unpaced and paced right ventricular myocytes at a potential of –140mV. C) Voltage-clamp 
protocol consisted of steps of 10mV increments between -140mV and -20mV (1s duration, 
0.01Hz) from a holding potential of –60mV. D and E) IK1 amplitude, measured at the end of 
[203]	  
	  
a 1s pulse, was plotted as a function of applied voltage for wildtype unpaced (n=5) and paced 
(n=5) right ventricular myocytes (panel D) and Cx43+/− unpaced (n=5) and paced (n=6) 
myocytes (panel E). Results indicate that there are no significant differences between any of 
the four subgroups. F) Post-hoc analysis of pooled IK1 values comparing results from all 
wildtype versus Cx43+/− cells at each voltage showed significantly increased IK1 in the 
Cx43+/− myocytes compared to wild types at voltages of ≤ -70mV. *, p < 0.05. (From 
Kontogeorgis et al (161). 
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Table 14. Comparison of Ito Inactivation, Steady-State Inactivation and Recovery from 
Inactivation in Wildtype and Cx43+/− Unpaced and Paced Mice 
 
WT unpaced  WT paced  
Cx43+/−unpaced  Cx43+/−paced 
  
 Ito Inactivation Kinetics   
τf, ms  47.4 ± 6.7  49.2 ± 5.5  45.9 ± 3.8  43.6 ± 1.3  
τs, ms  1138 ± 188  1161 ± 182  1104 ± 126  1190 ± 144  
a0, nA  0.4 ± 0.06  0.4 ± 0.05  0.4 ± 0.04  0.4 ± 0.04  
a1, nA  1226 ± 304  1176 ± 305  1295 ± 275  1450 ± 309  
a2, nA  1.7 ± 0.4  1.6 ± 0.3  1.5 ± 0.4  1.6 ± 0.4  
 Steady-State Inactivation  
Vh, mV  -26.3 ± 2.0  -27.9 ± 2.4  -30.5 ± 3.5  -26.8 ± 2.3  
K, mV  11.3 ± 1.2  11.0 ± 1.3  9.5 ± 1.0  8.3 ± 1.2  
 Recovery from Inactivation  
τrecovery, ms  31.5 ± 4.6  30.3 ± 4.9  44.3 ± 5.5  36.6 ± 3.7  
 
Data are presented as group means ± SEM (n = 8 per group). f, time constant of the fast 
component of inactivation; s, time constant of the slow component of inactivation; a1 and a2, 
amplitudes of the inactivating current components; a0, residual amplitude of the steady-state, 
non-inactivating component of the total outward K+ current after subtraction of the 4-AP 
insensitive component; Vh, half maximal inactivation potential; K, slope factor for steady-
state inactivation curves at the half-maximal inactivation potential; recovery, time constant of 
recovery from inactivation. Comparisons between groups were performed with ANOVA. P = 
NS for all comparisons. With permission from Kontogeorgis et al (161). 
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Changes	  in	  Steady-­‐State	  Potassium	  Current	  (Iss)	  in	  Unpaced	  and	  Paced	  
RV	  WT	  and	  Cx43+/−	  Myocytes	  	  
 
The two components of the total voltage-dependent outward potassium current are also critical in 
determining APD (Figure 47A); they are distinguished by sensitivity to 4-aminopyridine (4-AP). 
Outward potassium current in cardiac myocytes is comprised of a 4-AP insensitive component (Iss; 
Figure 47B) and a 4-AP sensitive component (Ito; Figure 47C) (177;181;182). Figure 47 recordings 
from an adult murine RV myocyte.  
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Figure 48. Outward Potassium Current in Adult Murine Right Ventricular Cardiac 
Myocytes.  
A) Total outward potassium current, as shown, is termed IKpeak. B) A 4-AP insensitive 
steady-state current, Iss, was obtained after 2mM 4-AP was applied. C) The transient outward 
potassium current, Ito, was obtained offline by subtracting Iss from IKpeak. D) Voltage-
clamp protocol consisted of steps of 10mV increments between –50mV and +50mV (1s 
duration, 0.01Hz) from a holding potential of –60mV (161).Reproduced from Kontogeorgis 
et al. 
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Changes	  in	  4-­‐AP-­‐sensitive	  current	  (Ito)	  in	  unpaced	  and	  paced	  WT	  and	  
Cx43+/−	  Myocytes:	  
There was no difference in amplitude among the unpaced wildtype, paced wildtype, unpaced 
Cx43+/− or paced Cx43+/− mice in the 4-AP-sensitive current, Ito (Figure 48). 
 
Inactivation	  kinetics	  of	  Ito	  and	  recovery	  indices:	  	  
 
There were no differences in the inactivation kinetics of Ito and indices of recovery of Ito 
from inactivation in any of the groups (Figure 49 and Table 14). 
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Figure 49. Effect of Pacing on the Transient Outward Current, Ito, in Wildtype and 
Cx43+/− Right Ventricular Cardiac Myocytes.  
A and B) Representative Ito traces from wildtype (panel A) and Cx43+/− (panel B) unpaced 
and paced right ventricular myocytes at +52mV. C and D) Ito peak amplitude was measured 
and plotted as a function of applied voltage for WT unpaced and paced (n = 6 and 5, 
respectively; panel C) and Cx43+/− unpaced and paced myocytes (n = 6 and 7, respectively; 
panel D). There were no significant differences between any of the subgroups(161). 
Reproduced from Kontogeorgis et al. 
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Figure 50 . Effect of Pacing on Kinetics of Ito Inactivation Properties and Recovery of 
Ito from Inactivation in WT and Cx43+/− Myocytes.  
A) Representative Ito recording made during a 2-pulse voltage-clamp protocol to assess 
voltage dependence of steady-state inactivation. B) The 2-pulse protocol consisted of a 1 s 
prepulse delivered from a holding potential of –60mV in 5 mV increments from –80mV to 
+5mV, followed by a 500ms test pulse to +40mV. C and D) Steady-state inactivation curves 
obtained from peak current obtained during second pulse in wildtype unpaced and paced (n = 
6 each; panel C) and Cx43+/− unpaced and paced myocytes (n = 6 and 5, respectively; panel 
D). Data were normalized to peak current amplitude at a prepulse of –80mV, plotted as a 
function of prepulse potentials and fitted with the best nonlinear least-squares fit of a 
Boltzmann function. E) Representative tracings of recovery of Ito from inactivation. F) 
Recovery of Ito from inactivation was measured by using 2 depolarizing pulses to +40mV, 
from a holding potential of -60mV, separated by intervals of increasing duration from 5ms to 
185ms in 10ms increments. G and H) Recovery of Ito current was obtained from WT 
unpaced and paced (n = 8 and 7, respectively; panel G) and Cx43+/− unpaced and paced cells 
(n = 8 each; panel H). Data were normalized to maximum current value, plotted as a function 
of recovery time and fitted with a first-order exponential function. No significant differences 
among the subgroups were identified in inactivation properties or recovery kinetics of Ito. 
Reproduced from Kontogeorgis et al(161).  
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Steady-­‐State	  Potassium	  Current	  (Iss)	  in	  Unpaced	  and	  Paced	  RV	  WT	  and	  
Cx43+/−	  Myocytes	  
 
Mice with conditional loss of Cx43 expression in the heart demonstrate significant elevations 
in the 4-AP insensitive current, Iss, in right ventricular myocytes(13) . In this study, Iss was 
significantly increased in unpaced Cx43+/− myocytes (peak current = 4.2 ± 0.5 pA/pF) 
compared to unpaced wildtype myocytes (2.4 ± 0.2 pA/pF; p < 0.01). Pacing did not affect a 
significant change in Iss current density in wildtype myocytes (2.7 ± 0.1 pA/pF after pacing; 
Figure 50 A and C). Pacing was associated with a significant reduction of Iss current density 
in the Cx43+/− myocytes (2.9 ± 0.2 pA/pF; p < 0.01 compared to unpaced Cx43+/− myocytes; 
Figure50 B and D).At these levels they were not statistically different from those of the 
wildtype myocytes. Changes in the Iss density most likely represent a major mechanism 
underlying corresponding alterations in APD in unpaced and paced Cx43+/− myocytes.  
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Figure 51. Effect of Pacing on Steady-State Outward Potassium Current, Iss.  
A and B) Representative recordings of Iss from wildtype unpaced and paced (n = 6 each; 
panel A) and Cx43+/− unpaced and paced myocytes (n = 5 and 6, respectively; panel B) at 
+50mV. C and D) Iss amplitude was measured at the end of the depolarization pulse, and 
plotted as a function of applied voltage for wildtype (panel C) and Cx43+/− cells (panel D). 
The results indicated that Iss was not altered by pacing in the wildtype cells. However, Iss 
was elevated in the Cx43+/− unpaced cells in comparison to all other groups, and was 
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diminished significantly by pacing in the Cx43+/− myocytes. *, p < 0.05; †, p < 
0.01.Reproduced from Kontogeorgis et al (161). 
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Electroanatomical correlation in Cx40+/+, Cx40+/- and Cx40-/- mice, 
age dependence and regional analysis. 
	  
Dr Morley and Leaf requested practical help with immunostaining and quantification of gap 
junctions along similar lines to that described earlier in the pacing model. To explore further 
electroanatomical correlation between gap junction remodelling and altered 
electrophysiologic functional effects a transgenic Cx40 knockout mouse was studied. 
Utilising quantitative immunohistochemistry and immunoblotting, characterisation of 
anatomical data for a cohort of Cx40+/+, Cx40+/- and Cx40-/- mice was performed. 
These were correlated with functional data obtained from optical mapping experiments in 
collaboration with Dr Leaf. 
 
Assessing	  Cx40	  and	  Cx43	  Expression	  
The	  blinded	  Mean	  Cx43	  Fluorescent	  Index	  study	  	  
	  
Expression of Connexin 43 (Cx43) immunosignal in Wild type mice and Cx40-/- mice was 
evaluated and compared (n=4+4) to assess for compensatory changes. A small age-dependent 
sub-group analysis was performed; 2 mice were less than 8 weeks old and 2 older than 8 
weeks in each sub-group. 
Quantification of the mean fluorescent signal of Cx43 involved standardised image 
processing in Adobe Photoshop 7.0.1(San Jose, California, USA).Utilising Image J (NIH 
available online) , raw data measurements included total pixel count area and total tissue area. 
The mean fluorescent Cx43 signal was calculated and comparison made of the Right and Left 
Atrium in each heart. 
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The	  blinded	  Mean	  (Cx43/Cx40)	  colocalisation	  Index	  study-­‐regional	  
analysis-­‐RAA	  vs.	  LAA	  and	  effects	  of	  ageing.	  	  
  
The age-dependent colocalised Cx43 and Cx40 signal in wild type Cx40+/+ mice was 
compared . Fluorescent measurements were assessed in mice aged less than 8 weeks and 
those older than 8 weeks (n=6+6). Prior to fluorescent staining standard H&E staining was 
undertaken to identify suitable blinded regions representing the right atrial appendage (RAA ) 
, right atrium (RA), left atrial appendage (LAA) and left atrium (LA).Quantification of the 
mean colocalisation index of Cx43 and Cx 40 required multiple 8-bit images for a colocalised 
measurement of each region RA, RAA, LA, LAA (Figure 52).   
Statistical	  analysis.	  
Data are presented as means ± SEM for the RA, LA, RAA, LAA as well as old and young 
mice for each heart respectively. Comparison between these groups was performed with a 2-
tailed t test using Microsoft Excel software. P, < 0.05 was considered statistically significant. 
Changes in colocalisation data between young and old mice per region were compared using 
one-way ANOVA in Prism and Statview. 
Results	  
Analysis	  of	  Cx40	  protein	  levels	  to	  assess	  atrial	  differences	  
Cx40 immunostaining to assess protein levels was performed to determine whether gradients 
in Cx40 expression were present in the mouse atria (Figure 51). Comparing samples of 
Cx40+/+ mice revealed no overt regional right–left differences. 
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Figure 52 Regional comparison of Cx 40 immunostaining in wild type mice. 
No significant difference in Cx40 immunosignal in RAA and LAA tissue of wildtype mice. 
Reproduced with permission from Leaf et al(183)  
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The	  mean	  Cx43	  fluorescent	  index	  	  
Cx43 immunostaining in both Cx40+/+ and Cx40-/- mice was performed to exclude the 
possibility of compensatory changes in Cx43 (Figure 52). Cx43 expression did not appear 
altered in the Cx40-/- compared with the Cx40+/+ mice nor were right–left differences detected 
in mice of either genotype suggesting that there was no apparent upregulation of Cx43.In 
addition, there was no significant quantitative difference comparing younger to older mice for 
Cx43 immunosignal heterogeneity +/ upregulation. 
The	  mean	  colocalisation	  index  
Mean colocalisation of  young and old Cx40+/+ hearts comparing the RA to RAA as well as 
LA to LAA were not significant (figure 53). The ANOVA analysis was not significant (figure 
54).  
 
Figure 53 Cx43 immunostaining in Cx40+/+ and Cx40-/- mice. 
Regional as well as age comparison of colocalised Cx40 and Cx43 immunosignal without 
significant differences. With permission from Leaf et al (183). 
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Figure 54. Cx43/Cx40 Colocalisation index, regional comparison in young and old 
hearts. 
Comparison of regional Cx43/Cx40 colocalisation showed no significant difference in young 
and old hearts. 
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Figure 55. Comparison of Cx43/Cx40 colocalisation between young and old hearts. 
No significant difference of Cx43/Cx40 colocalisation when comparing young vs old hearts 
on a regional basis. 
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Discussion:	  
 
Pacing in wild type Cx43+/+ mice seems to have a significant effect on mRNA transcription 
and or stability at the LV free wall epicardium and endocardium suggesting that early 
regulatory changes are being implemented to reduce overall gap junction levels.  
These in turn likely reduce the amount of Cx43 available at the cardiac membrane and alter 
the degree of electrical coupling. Models of arrhythmia strongly associate with reduced levels 
of Cx43 as seen in animal models of infarction (canine and rat models) as well as the 
conditional Cx43 knockout mouse model which succumbs to lethal arrhythmias.  
However, in this study the overall magnitude of Cx43 reduction may be insufficient to 
precipitate arrhythmia on inducibility testing in the wildtype mouse. It is possible that 
additional insults such as infarction or pre existing heart failure might alter this risk of 
arrhythmia.  
Altering the duration of the pacing protocol to a longer period of time, i.e. 6hours did not 
result in extensive gap junction remodelling as might have been predicted. This also did not 
result in a significant change in ECG, ECHO or PES measures. 
Cx43 is degraded along the ubiquitin proteasome pathway via a highly regulated process that 
includes but is not limited to epidermal growth factor (EGF) which hyperphosphorylates gap 
junction protein. However, I did not find a difference in the ratio of Cx43 upper bands/lower 
bands in the paced endocardium to suggest a difference with pacing suggesting that a non-
EGF pathway may be targeting the gap junctions towards degradation. 
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 Altered degradation may represent  a regulatory step in altering the distribution and levels of 
Cx43 expression at the cardiac membrane in order to modulate the degree of electrical 
coupling in response to pacing but without significant functional effect. 
Prolonging the pacing duration to even longer time point e.g. 12 or 24 hours may have 
revealed such an effect. I did not undertake such an experimental direction due to practical 
time constraints and additional concerns regarding fluid balance within the preparation. 
Regional heterogeneities exist within the normal heart and Cx43 expression at a regional 
level may have important effects on cardiac electrophysiology. Pacing reduced the level of 
Cx43 signal area/total tissue area at the LV endocardium. It is possible that a normal heart 
may tolerate such subtle changes better than hearts where pre-existing disease or additional 
insults may be far more deleterious from an electrophysiology perspective. 
To test this further I embarked on a trial to pace mice with heterozygous loss of Cx43 
(Cx43+/−) at baseline and compared them to wildtype mice and found an association with 
prolonged ventricular refractoriness that sustained itself despite a 2hr rest period. To 
investigate the prolonged refractoriness further a set of experiments to study action potentials 
and potassium currents were performed. 
Cx43 deficient murine hearts have shorter action potential duration without differences in 
resting membrane potential or action potential amplitude when compared to wildtype mice. 
These are likely due to increased Iss and IK1 density. Pacing lengthens the duration of the 
action potential with a corresponding reduction in Iss but not IK1 Cx43+/− myocytes. 
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Chapter 7 
Conclusions 
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Introduction 
The work in this thesis set out to explore the effects of pacing induced cardiac dyssynchrony 
on gap junction remodelling in a mouse model. The effects of cardiac dyssynchrony (and the 
resulting aberrant ventricular activation) were studied by adapting a novel model previously 
used for programmed stimulation for subdiaphragmatic pacing. The functional effects of 
dyssynchrony were characterised in this model utilising electrocardiography, 
echocardiography and programmed electrical stimulation (for VERP and arrhythmia 
inducibility) in vivo in mice expressing wild type levels of Cx43, Cx43+/+.To model clinical 
and animal arrhythmia disease models, where gap junction remodelling and reduced levels 
are observed, a group of Cx43+/− mice expressing 66% reduced Cx43 levels were also paced 
transdiaphragmatically to determine the effects of dyssynchrony. 
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Summary	  of	  Key	  Findings	  in	  this	  Thesis.	  
	  
The key findings are listed below and address the aims and objectives set at the outset of this 
thesis in Chapter 1.To aid the reader they are included in this section. 
Development	  of	  the	  pacing	  model:	  
 
The following findings fulfilled objectives 1,2 and 3 which were outlined in Chapter 1 and 
are repeated briefly here for reference: 
1.To develop and refine an in vivo subdiaphragmatic murine pacing induced dyssynchrony 
model that allows short term pacing, with 100% stable capture, is well tolerated and 
reproducible without thoracic, abdominal, vascular or cardiac injury, without need for 
intubation and in the absence of ischaemia or hypothermia. 
2. To demonstrate feasibility of the pacing protocol, undertake a set of experiments designed 
to test the duration of pacing tolerated in wildtype mice: 
Over the short term i.e. 15, 30, 45 and 60 mins. 
Over the longer term i.e. 4hr and 6hr. 
3. To demonstrate survival of animals after 1hr pacing experiments in wildtype mice 
   immediate survival experiment- 4.5hr survival study (3 half-lives) 
   Long-term survival experiment-2 week survival study. 
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Findings 
1.I have shown that murine pacing induced dyssynchrony, is feasible using the 
subdiaphragmatic approach, and can be safely undertaken for 1- 6hours. 
2. It successfully induces electrical and mechanical dyssynchrony as evidenced by altered 
ECG morphology during pacing as well as late activation of the posterior LV wall on 
echocardiography.  
3. The model has no overt disease process i.e. tachycardia induced heart failure 
ischaemia/infarction or direct traumatic injury. 
4. It appears well tolerated as mice are able to survive their procedures for up to two weeks.  
5. The macroscopic appearance of the heart and the stable thresholds, further support the 
absence of an overt disease process. 
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In	  Wild	  type	  Cx43+/+	  mice:	  	  
 
The following findings relate specifically to wildtype Cx43+/+ mice, the objectives outlined in 
Chapter 1 and they are reminded here: 
 Objective 4.To establish whether there is any effect of subdiaphragmatic pacing on cardiac 
function, assess the following measurable parameters in wildtype Cx43+/+ mice  
4.1 Characterise ECG parameters, at baseline, and after pacing at 15, 30, 45 
mins, 1hr, 4hr and 6hr. 
4.2 Characterise ECHO parameters, at baseline, during pacing and after 1hr 
and 6hr pacing.  
4.3 Characterise arrhythmia inducibility testing using PES and determine the 
VERP, at baseline and after 1hr and 6hr pacing. 
4.4 Characterise the pacing threshold at baseline and after 1hr, 4hr and 6hr 
pacing. 
Objective 7.Characterise cellular electrophysiology (using patch clamp) in Cx43+/+ wildtype 
mice at baseline and after pacing and look at the following measurable parameters: 
 7.1 Resting membrane potential,  
7.2 Action potential duration at 50ms and 90ms. 
 7.3 Activation and repolarisation kinetics  
7.4 At baseline and post 6hr pacing in the Cx43+/+ mice. 
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Objective 8.To determine the effects of subdiaphragmatic pacing on cardiac 
architecture/structure. 
8.1 Macroscopic study of whole heart and cellular architecture:  
After 1 hour of pacing (using HPS staining to determine macroscopically whether 
there are features of cellular injury due to the electrode or pacing). 
8.2 Establish a semiquantitative method (using immunohistochemistry) for assessing 
Cx43 cellular and tissue immunofluorescence in wildtype Cx43+/+ mice  
8.2.1 Assess measurables at baseline and after 1hr, 4hr and 6hr pacing.  
8.2.2 Mean Cx43 Immunofluorescence Index 
8.2.3 Assess Cx43 Distribution using Cx43 immunosignal/tissue area as well 
as Cx43 lateralisation study  
8.2.4 Cx43 plaque numbers 
8.2.5 Size of Cx43 plaques. 
Objective 9. Assess these parameters outlined in 8.2 in whole heart and on a regional basis to 
determine if there is local or spatial Cx43 heterogeneity post sham-pacing and pacing in 
Cx43+/+ and Cx43+/− mice. 
9.1 LV vs. RV 
9.2 LV Base vs. Mid vs. Apex 
9.3 LV septum vs. LV free wall 
9.4 Epicardium vs. Mid-myocardium vs. Endocardium. 
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Objective 11.Characterise changes in Cx43 protein expression levels (using immunoblotting) 
after sham-pacing and after pacing in wildtype Cx43+/+ mice: 
11.1 At baseline and after 6hr pacing and sham-pacing 
11.2. Determine Cx43 expression using immunoblotting  
11.2.1. at baseline and after 6hr pacing. 
11.2.2 on a regional basis  
LV epicardium and endocardium. 
LV free wall and LV septum 
LV Base and Apex 
Objective 12.Assess rates of Translation at baseline and after 6hr pacing in whole heart 
lysates from Cx43+/+ mice and assess Cx43 mRNA on a regional basis (using qRT-PCR) in 
12.1.  LV free wall epicardium 
12.2.  LV free wall endocardium 
Objective 13 Assess Cx43 distribution at baseline and after 6hr pacing using Cell 
fractionation techniques to assess Cx43 trafficking between membrane associated and 
cytosolic pools. 
Objective 14 Assess degradation of Cx43 in Cx43+/+ mice after 6hour sham-pacing and 6hr 
pacing  using immunoblotting for ubiquitin (with Cx43 coimmunoprecipitation). 
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Objective 15.Examine the relationship of Cx43 with other connexin isoforms (Cx40, Cx45) 
and its binding partners e.g. cadherin (using immunofluorescence colocalisation methods) 
after 6hr sham-pacing and 6hr pacing  
  15.1 In wildtype mice 
  15.2 In Cx43+/- mice 
 
Cx43+/+ Findings: 
1. Dyssynchrony alters ECG and ECHO during pacing in WT mice but there are no persistent 
changes after 1hr or 6hr pacing; programmed electrical stimulation demonstrates no change 
in VERP or inducibility into arrhythmia after 1hr or 6hr pacing. The pacing threshold remains 
stable after 1hr, 4hr and 6hr pacing. This addresses objectives 4 of this thesis. 
2. Altered ventricular activation using pacing results in redistribution of Cx43 immunosignal 
at the LV endocardium with loss of the baseline transmural Cx43 gradient across the LV free 
wall. Regional and whole heart analysis demonstrated no differences in immunostaining 
when comparing the following regions in objective 9. 
9.1 LV vs. RV 
9.2 LV Base vs. Mid vs. Apex 
9.3 LV septum vs. LV free wall. 
The changes were consistent with observed Cx plaque size, numbers and distribution but no 
evidence of overt lateralisation was seen on immunostaining; though electron microscopy 
suggested that very subtle remodelling may be taking place . 
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3. Dysynchrony does not result in differences in Cx43 protein expression at the whole heart 
level after 6hr pacing and sham-pacing and when comparing regional segments. This 
addresses objective 11. 
4. Pacing induced dyssynchrony results in reduced membrane bound Cx43 gap junctions and 
higher cytosolic component of Cx43 gap junctions on fractionation study. This supports 
objective 13. 
5. Dyssynchrony does not alter the distribution of gap junction associated proteins such as 
cadherin, an important and critical component of the adherens junction. 
6. Dyssynchrony results in significant reductions in Cx43 mRNA transcription and or 
stability at the epicardium and endocardium of the LV free wall. 
7. Dyssynchrony appears to disrupt the process of degradation of Cx43 along the ubiquitin 
proteasome pathway without a discernible difference in the phosphorylation state of Cx43 
suggesting this may be via an EGF independent pathway. 
8. Dyssynchrony does not alter APD in wild type isolated cells after 6hr pacing or sham-
pacing. There are no significant differences in the resting membrane potential or 
repolarisation properties in Cx43+/+ isolated cells after 6hr pacing and sham-pacing thus 
addressing the aims of objective 7. 
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In	  Cx43+/−	  mice: 
	  
The following findings relate specifically to Cx43+/− mice and to the objectives outlined in 
Chapter 1 and are briefly repeated: 
Objective 5.Repeat all of the measured parameters and determine functional effects in 
transgenic Cx43+/− mice: 
5.1 Characterise ECG, parameters at baseline and after 6hr pacing. 
5.2 Characterise ECHO parameters at baseline and after 6hr pacing 
5.3 Characterise arrhythmia inducibility and VERP at baseline and after 6hr 
pacing. 
5.4 Characterise the pacing threshold at baseline and after 6hr pacing 
5.5 Characterise functional effects, if any, and whether sustained after a period 
of recovery (2hr). 
Objective 6.To determine the epicardial breakthrough activation pattern and conduction 
velocity post pacing using optical mapping in Cx43+/+ and Cx43+/- mice  
Objective 7.This has already been outlined above for wildtype Cx43+/+ mice in terms of 
characterising cellular electrophysiology (using patch clamp) in Cx43+/− mice at baseline and 
after pacing and looking at specific measurable parameters (see objective 7 above). 
Objective 8. This has already been outlined earlier for wildtype Cx43+/+ mice and here we 
look at Cx43+/-  mice in terms of  determining the effects of subdiaphragmatic pacing on 
cardiac architecture/structure (see objective 8 above). 
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Objective 9. Refer to earlier on pg 232 where this is outlined in detail for Cx43+/+ and Cx43+/- 
mice.. 
Objective 11.This has already been outlined earlier (refer to objective 11 above). 
Objective 12.Also outlined in objective 12 earlier (see objective 12). 
Objective 15.This has been outlined earlier (refer to objective 15). 
 
Cx43+/− Findings: 
1. There were no significant changes in ECG and ECHO data, however, dyssynchrony 
induces prolonged and sustained (after a 2hr rest period) refractoriness (VERP) and 
mechanical dyssynchrony (SPWMD)  after 6hours of pacing in Cx43+/− hearts. 
2. Dyssynchrony does not alter the epicardial sinus activation breakthrough pattern between 
the right and left ventricle. 
3. Dyssynchrony in Cx43+/− mice does not alter Cx43 protein levels on immunoblotting nor  
Cx43 immunostaining patterns and colocalisation with its binding partner cadherin.  
4. Dyssynchrony does not induce any difference in relative mRNA abundance between paced 
and unpaced Cx43+/− hearts. 
5.Cx43+/− myocytes have shortened APD compared to paced WT isolated cells  due to an 
increased Iss and IK1 density at baseline. 
6. Dyssynchrony in Cx43+/− mice induces APD prolongation with reduction in Iss but not IK1 
after pacing. 	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Mice	  expressing	  Cx40+/+,	  Cx40+/-­‐	  and	  Cx40	  -­‐/-­‐:	  
The role of Cx40 in cardiac arrhythmogenesis is not fully understood.  
The principal structural findings from the immunosignal and colocalization study are outlined 
here and address objective 14 laid out in Chapter 1. 
1.) No difference is observed in Cx43 expression in Cx40-/- mice and Cx40+/+ mice. 
2.) No significant difference is observed in Cx40 expression between LA and RA in Cx40+/+ 
mice.  
3.) Cx43 and Cx40 colocalise in wild type Cx40+/+ mice with no age dependent differences 
4.) Cx43 and Cx40 colocalise in wild type Cx40+/+ mice with no RA/LA/RAA/LAA regional 
differences. 
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Clinical	  relevance	  of	  cardiac	  dyssynchrony	  and	  utility	  of	  murine	  model	  
of	  pacing	  induced	  dyssynchrony:	  
 
This study furthers what we know in terms of small animal model pacing induced dyssynchrony and 
induction of gap junction remodelling with differences in the response to pacing seen in wildtype 
mice as compared to Cx43+/− mice. 
In Chapter 1 I outlined the factors that modulate gap junctions both in terms of their distribution, 
trafficking and degradation and it is likely that there are layers of regulation and changes taking place 
in response to pacing with Cx43 playing a permissive role to electrical  heterogeneity and changes in 
action potential duration.   
The association of Cx43 with other proteins at the intercalated disc affects the trafficking of 
Connexins and there appears to be feedback to alter these proteins too. The role of altered 
phosphorylation state and also enzyme interactions responsible for unhooking connexin from its 
binding partners has been postulated as a molecular mechanism of remodelling. However, in my study 
there appeared to be no change in the colocalisation of Cx43 with its other isoforms and importantly 
the cadherin protein at the intercalated disc(51;117). 
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ECG,ECHO	  and	  PES	  ;	  effects	  of	  pacing	  induced	  dyssynchrony	  in	  Cx43+/+	  
mice:	  
 Interestingly, the measured data from ECG parameters and ECHO were not altered after 1hr, 
4hr or 6hr asynchronous pacing in wild type mice suggesting that wild type mice did not 
develop any significant electrical remodelling. Nonetheless, subtle morphological changes at 
1hr and 6hr suggested that prolonged pacing may have resulted in a more significant effect of 
long term cardiac memory as has been described in the canine pacing model (21 days of 
pacing were utilised). A further limitation of the study is that I was not able to measure the 
contribution of any functional mitral regurgitation that may have developed as a consequence 
of the pacing induced dyssynchrony. In addition, no haemodynamic measurements were 
made to invasively correlate pacing effect on cardiac pump function during pacing but Dr 
Gutstein and I agreed that the invasive requirement would have compromised the stability of 
the animal for a 6hr period. The non invasive nature of echo made it our preferred choice. 
Despite the gap junction remodelling that occurs in this model with redistribution of gap 
junctions to the intracellular pool I did not observe any sustained mechanical dyssynchrony 
on ECHO or ECG change with cessation of pacing. It is possible that the magnitude of 
change with asynchronous pacing in wild type mice is insufficient to result in significant 
change especially since the experiment lasted no longer than six hours in this project. This 
may also account for the non inducibility to arrhythmia with programmed electrical 
stimulation. However, in the setting of reduced levels of Cx43 as in some disease states, the 
effects of dyssynchrony may be far more pronounced and may work together with disease 
processes such as ischaemia and scarring to promote arrhythmia.  
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Structural remodelling 
The significant reductions in Cx43 transcription and/or mRNA stability suggest that in wild 
type mice there is an effect on transcription that may represent a negative feedback loop 
mediated through Cx43 during dyssynchrony to downregulate the gap junctions at the surface 
and limit their expression in the longer term. This suggests that sustained pacing induced 
dyssynchrony may modulate gap junction intercellular communication by regulating 
transcription. This underscores the possibility that a longer period of pacing may have 
resulted in more dramatic effects to gap junction remodelling. That gap junctions should also 
be targeted to the ubiquitin proteasome pathway with accumulation of ubiquitinated Cx43 
forms as a consequence of asynchronous pacing suggests that other regulatory steps in the 
degradation pathway of biotrafficking are also thrown into play in order to reduce the 
available gap junctions at the cell surface and presumably alter cellular coupling. Whether the 
observed effects in murine wild type hearts translate to human clinical studies is uncertain but 
this study adds to the current level of understanding dyssynchrony and its effects on gap 
junction remodelling and raises hypotheses that can potentially be pursued in human studies 
of pacing induced dyssynchrony. 
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Limitations 
A limitation of this study is that the role of Ca2+ has not been characterised in pacing 
induced dyssynchrony. Alterations in the canine model of pacing induced dyssynchrony 
described by Spragg included a 30% reduction in sarcoplasmic Ca2+ (2). Furthermore the 
ischaemic (post MI) rabbit heart has been shown to demonstrate a reduction in Ca2+ 
transients with marked inhomogeneities(184;185). Work by Kohlhaas et al has highlighted 
the importance of CaMKII in sensitising the ryanodine receptor to Ca2+ by 
hyperphosphorylation in rabbit hearts, supporting work previously done in mice(186). The 
macromolecular complex of the Ryanodine Receptor and its associated proteins has been 
characterised by Marks et al and there is a clear relationship with phosphorylation proteins 
including PKA(187-190). It is unclear from the study in wild type mice whether there are 
changes in the Ca2+ subcellular pools or changes in the phosphoproteins activity. However, 
there appeared to be no difference in the level of Cx43 phosphorylation between the sham 
paced and paced groups suggesting that gap junctions were unaffected in terms of their 
phsoporylation state. Of course, we did not assess any potential differences in Ca2+ gating of 
gap junctions in this model as a possible mechanism for reducing coupling. 
This concept in gap junction biology has become accepted though considerable debate 
remains regarding the electro-anatomical correlation. When connexons are visualised in 
tissue there exists an assumption as to their functionality (i.e. whether they are in the “open” 
or “closed” configuration of a pore-like channel) and this is a key limitation in the field(65). 
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Furthermore,there are other cell based techniques to study coupling or gap junction function 
using dye transfer techniques or gap junction specific patch clamp but these were not available or 
used to test the model in this thesis (27;58;191). 
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ECG,ECHO	  and	  PES;	  Dyssynchrony	  in	  mice	  expressing	  66%	  reduced	  
levels	  of	  Cx43.	  
Down-regulation of Cx43 is a common finding in a multitude of cardiac diseases and 
potentially contributes to the arrhythmogenic substrate. To study the effects of dyssynchrony 
I used a cohort of mice expressing lower levels of Cx43 at baseline. 
Structural remodelling 
Dyssynchrony in Cx43+/− mice did not alter Cx43 protein levels on immunoblotting and there 
is neither discernible redistribution of Cx43 on immunostaining nor disruption of 
colocalisation with its binding partner cadherin. This confirms that despite reduced levels of 
Cx43 the cadherin component of the intercalated disc structure is not remodelled and 
colocalises with the available Cx43. In the context of reduced levels of Cx43 it appears that 
there is no discernible redistribution of the available gap junctions on immunostaining and 
immunoblotting. However, a potential limitation of this study is that I did not perform any 
fractionation experiments to look for subtle redistribution as occurred in the wild type mice. 
However, the qRT-PCR data support the notion that Cx43 may not be altered in these animals 
In terms of regulation at the protein level or transcription level since dyssynchrony did not 
induce any difference in relative mRNA abundance between paced and unpaced Cx43+/− 
hearts. Though speculative, it may be that in this context there is a hierarchy of regulation; 
once gap junction levels have been reduced there is targeting of the ion channels to reduce the 
coupling properties of the myocardium with dyssynchrony.  
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ECG,ECHO and PES 
Since there was evidence of sustained mechanical dyssynchrony without ECG evidence of a 
bundle branch block pattern I asked Dr Morley’s lab to investigate the pattern of epicardial 
breakthrough activation in sinus rhythm. Optical mapping experiments have been useful in 
characterising the local conduction patterns in mouse models including the Cx40-/- mouse 
which was shown by the Jalife group to demonstrate conduction slowing in the right bundle 
(178;192). Subsequent characterisation by Dr Morley looking of the Cx43+/− mouse did not 
shown any evidence of local conduction slowing (178). What isn’t known is how pacing 
might modulate the local conduction properties in the latter group and since there was 
evidence of APD prolongation, sustained refractoriness and mechanical dyssynchrony a re-
evaluation of this group of mice was undertaken. Dyssynchrony however does not alter the 
epicardial sinus activation breakthrough pattern between the right and left ventricle.  
 It was particularly interesting that these animals should have prolonged refractoriness and 
sustained dyssynchrony even after a 2hour rest period. They demonstrated shortened APD at 
baseline which prolonged with asynchronous pacing. Shortened APD90 has been observed in 
NRVM cultured strands isolated from Cx43+/− hearts (193;194). The cardiac specific 
conditional knockout Cx43 mouse also shows a reduced APD with corresponding increased 
outward K currents (13). At the time of this project this was the first study to demonstrate that 
pacing Cx43+/− deficient mice alters indices of repolarisation and refractoriness and this 
resembles cardiac memory. Cardiac memory has been described in larger mammals such as 
canines and in humans but has not previously been reported in mice. However, as mentioned 
earlier, the mouse is not an ideal species for studying cardiac memory due to species 
differences in repolarising currents. However, Cx43 appears to play a role in pacing induced 
dyssynchrony altering repolarisation currents as these were only seen in the Cx43+/− hearts. 
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Recent work from Yoram Rudy’s group on humans subjected to right ventricular pacing has 
also shed light on the mechanism of cardiac memory and observed increased dispersion of 
repolarisation gradients nearest to the pacing site(195).  
In the context of dyssynchrony, the interaction between gap junctions and ion channels 
appears to be dynamic with Cx43 playing a permissive role in the remodelling of repolarising 
currents which in the context of disease can potentially create a substrate for re-entrant 
arrhythmias. This concept of gap junction and ion channel interactions is supported by the 
finding of altered repolarisation as a mechanism for arrhythmia in the Cx43 knockout mouse 
as well as a recent publication in 2012 from the Delmar group demonstrating Cx43 regulating 
Nav1.5(13). 
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Future	  directions:	  
Animal	  Studies	  
In animal models of infarction, pacing induced gap junction remodelling could be utilised 
subdiaphragmatically as a Gap junction modulator, prior to ligation of the coronary artery to 
assess the prevalence of acute, reperfusion and chronic MI arrhythmia burden. 
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Concluding	  remark:	  
The data in this thesis suggests that short-term cardiac pacing at rates just fast enough to 
ensure capture alters myocardial activation and induces electrical and mechanical 
dyssynchrony of the left ventricle in the murine heart. Limited exposure to dyssynchronous 
activation in wildtype Cx43 hearts, results in remodelling of the cardiac gap junctions in the 
absence of sustained measurable effects on contractility or arrhythmic inducibility.  
Myocardial tissue with reduced baseline expression of Cx43 responds quite differently to 
pacing than does myocardium with wild-type levels of Cx43.This may be especially relevant 
in the clinical setting of cardiac disease where abundance of Cx43 is shown to be focally 
reduced in zones of ischaemia and hibernation. The imposition of pacing in such a clinical 
scenario could lead to the remodelling of repolarisation currents in regions of reduced Cx43, 
thus greatly enhancing dispersion of refractoriness around hibernating or ischaemic zones, 
potentially creating a substrate for arrhythmia reentry.  
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Dear Dr Kontogeorgis, 
  
Thanks for using BIOPAC. Please accept this email as authiorization to 
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(MP100 System) in your dissertation. 
  
For the web links, please use these instead: 
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http://www.biopac.com/research.asp?SubCatID=59&Main=Electrodes - 
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Best regards, 
 Jocelyn Mariah Kremer 
 
42 Aero Camino, Goleta, CA 93117 
Tel 805.685.0066 x128 | Fax 805.685.0067 | www.biopac.com 
 
From: Andy Kontogeorgis   Sent: Tuesday, July 29, 2014 10:34 AM To: 
info@biopac.com Subject: Permission request to use figure on website for 
PhD Dissertation with Imperial College London. 
  
Dear Biopac, 
  
I utilised your equipment for my research whilst in Dr Gutstein's 
Lab at NYU and wanted to use a photograph/figure in my 
dissertation taken from your website of the needle electrodes-see 
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  gratefully 
Dr	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the use of the individual or entity to which it is addressed and may 
contain information which is privileged, confidential, and exempt 
from disclosure under applicable law. If you are not the intended 
recipient, or an employee or agent of the intended recipient, you 
are hereby notified that any dissemination, distribution, or copying 
of this communication is strictly prohibited. If you have received 
this communication in error please notify us immediately by 
replying to 
postmaster@biopac.com. *********************************
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Good afternoon and thank you for contacting us. You are more than welcome to 
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Regards, 
 
Marie Carretta,  
Co-Owner/President/CEO 
VetEquip, Inc. 
marie@vetequip.com  
800-466-6463 
925-463-1828 
 
 
-----Original Message----- 
From: Andy Kontogeorgis [mailto:andykontogeorgis1@gmail.com]  
Sent: Tuesday, July 29, 2014 10:27 AM 
To: Marie Carretta 
Subject: Permission request to use a figure from Vetequip website. 
 
Dear Vetequip, 
 
I utilised your vaporiser equipment for my PhD research and wanted to include a 
photo in my dissertation taken from your website. 
I am writing to request permission in this respect. 
 
The figure in question is at the following link and I will of course make reference 
and acknowldegment to the company and this link. 
http://www.vetequip.com/images/big-901806.jpg 
 
Sincerely and gratefully 
Dr Andy Kontogeorgis 
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Dear	  Andy, 
I	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  you	  are	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  That	  figure	  is	  mine.	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  be	  fine	  if	  you	  
just	  put	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  “courtesy	  of	  Dr	  Rasheda	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Thanks 
Rasheda 
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Dr	  Rasheda	  Chowdhury	  MA	  (Cantab)	  MSc	  (Oxon)	  PhD 
	   
Research	  Associate 
	   
Myocardial	  Function 
National	  Heart	  and	  Lung	  Institute,	  Imperial	  College, 
4th	  floor,	  Imperial	  Centre	  for	  Translational	  and	  Experimental	  Medicine 
Hammersmith	  Campus 
Du	  Cane	  Road 
London	  W12	  0NN 
	   
Tel:	  0207	  594	  3614 
	   
From: Kontogeorgis Andy [mailto:A.Kontogeorgis@rbht.nhs.uk]  Sent: 29 
July 2014 16:03 To: Chowdhury, Rasheda A Subject: Re Figure 
Permissions. 
  
Hi Rasheda, 
  
Hope that you are well. 
I just wanted to check with you regarding a figure I used in my 
thesis that I had from a previous version of the transfer report 
which you had given me(it was either yours or Para's). 
Where did it originate from and where should I direct my 
permission request? 
This is the figure I am referring to(attached). 
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 DISCLAIMER: The information contained in this email may be 
subject to public disclosure under the NHS Code of Openness or 
the Freedom of Information Act 2000. Unless the information is 
legally exempt from disclosure, the confidentiality of this email, 
and your reply cannot be guaranteed. The information and material 
in this email is intended for the use of the intended addressee or the 
person responsible for delivering it to the intended addressee. It 
may contain privileged or confidential information and/or 
copyright material. If you receive this email by mistake please 
advise the sender immediately by using the reply facility in your 
email software or notify Royal Brompton & Harefield NHS 
Foundation Trust Help Desk on +44(0) 20 7351 8696 
Communication is not sent through a secure server; Royal 
Brompton & Harefield NHS Foundation Trust cannot accept 
responsibility for the accuracy of outgoing electronic mail. Any 
views or opinions expressed are solely those of the author and do 
not represent the view of Royal Brompton & Harefield NHS 
Foundation Trust unless specifically stated.   --   
 
 
 
 
From: Andy Kontogeorgis andykontogeorgis1@gmail.com
Subject: Permission to use EM figure in my dissertation.
Date: 12 August 2014 21:49
To: pravina.patel@imperial.ac.uk
Dear Pravina,
Hope that you are well.It has been a long time and I'm sorry to be troubling you now.
I wanted to ask if you would be happy for me to include an EM figure in my dissertation that you had emailed me/sent me while I was
away in New York?
It is greatly appreciated.
Sincerely and warmest wishes
Andy Kontogeorgis
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Creative Commons
Creative Commons License Deed
Attribution 2.0 Generic (CC BY 2.0)
This is a human-readable summary of (and not a substitute for) the license.
Disclaimer
You are free to:
Under the following terms:
Notices:
A new version of this license is available. You should use it for new works, and you may want to relicense
existing works under it. No works are automatically put under the new license, however.
 
The applicable mediation rules will be designated in the copyright notice published with the work, or if none
then in the request for mediation. Unless otherwise designated in a copyright notice attached to the work,
the UNCITRAL Arbitration Rules apply to any arbitration.
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the
license terms.
Attribution — You must give appropriate credit, provide a link to the
license, and indicate if changes were made. You may do so in any
reasonable manner, but not in any way that suggests the licensor endorses
you or your use.
No additional restrictions — You may not apply legal terms or
technological measures that legally restrict others from doing anything the
license permits.
You do not have to comply with the license for elements of the material in
the public domain or where your use is permitted by an applicable
exception or limitation.
No warranties are given. The license may not give you all of the
permissions necessary for your intended use. For example, other rights
such as publicity, privacy, or moral rights may limit how you use the
material.
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Creative Commons
Attribution 2.0
CREATIVE COMMONS CORPORATION IS NOT A LAW FIRM AND DOES NOT PROVIDE LEGAL
SERVICES. DISTRIBUTION OF THIS LICENSE DOES NOT CREATE AN ATTORNEY-CLIENT
RELATIONSHIP. CREATIVE COMMONS PROVIDES THIS INFORMATION ON AN "AS-IS" BASIS.
CREATIVE COMMONS MAKES NO WARRANTIES REGARDING THE INFORMATION PROVIDED,
AND DISCLAIMS LIABILITY FOR DAMAGES RESULTING FROM ITS USE.
License
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS CREATIVE
COMMONS PUBLIC LICENSE ("CCPL" OR "LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT
AND/OR OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS AUTHORIZED UNDER
THIS LICENSE OR COPYRIGHT LAW IS PROHIBITED.
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT AND AGREE TO BE
BOUND BY THE TERMS OF THIS LICENSE. THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED
HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND CONDITIONS.
1. Definitions
a. "Collective Work" means a work, such as a periodical issue, anthology or
encyclopedia, in which the Work in its entirety in unmodified form, along with a
number of other contributions, constituting separate and independent works in
themselves, are assembled into a collective whole. A work that constitutes a
Collective Work will not be considered a Derivative Work (as defined below) for the
purposes of this License.
b. "Derivative Work" means a work based upon the Work or upon the Work and
other pre-existing works, such as a translation, musical arrangement,
dramatization, fictionalization, motion picture version, sound recording, art
reproduction, abridgment, condensation, or any other form in which the Work may
be recast, transformed, or adapted, except that a work that constitutes a Collective
Work will not be considered a Derivative Work for the purpose of this License. For
the avoidance of doubt, where the Work is a musical composition or sound
recording, the synchronization of the Work in timed-relation with a moving image
("synching") will be considered a Derivative Work for the purpose of this License.
c. "Licensor" means the individual or entity that offers the Work under the terms of
this License.
d. "Original Author" means the individual or entity who created the Work.
e. "Work" means the copyrightable work of authorship offered under the terms of
this License.
f. "You" means an individual or entity exercising rights under this License who has
not previously violated the terms of this License with respect to the Work, or who
has received express permission from the Licensor to exercise rights under this
License despite a previous violation.
2. Fair Use Rights. Nothing in this license is intended to reduce, limit, or restrict any rights
arising from fair use, first sale or other limitations on the exclusive rights of the copyright owner
under copyright law or other applicable laws.
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3. License Grant. Subject to the terms and conditions of this License, Licensor hereby grants
You a worldwide, royalty-free, non-exclusive, perpetual (for the duration of the applicable
copyright) license to exercise the rights in the Work as stated below:
a. to reproduce the Work, to incorporate the Work into one or more Collective Works,
and to reproduce the Work as incorporated in the Collective Works;
b. to create and reproduce Derivative Works;
c. to distribute copies or phonorecords of, display publicly, perform publicly, and
perform publicly by means of a digital audio transmission the Work including as
incorporated in Collective Works;
d. to distribute copies or phonorecords of, display publicly, perform publicly, and
perform publicly by means of a digital audio transmission Derivative Works.
e. For the avoidance of doubt, where the work is a musical composition:
i. Performance Royalties Under Blanket Licenses. Licensor waives
the exclusive right to collect, whether individually or via a
performance rights society (e.g. ASCAP, BMI, SESAC), royalties for
the public performance or public digital performance (e.g. webcast)
of the Work.
ii. Mechanical Rights and Statutory Royalties. Licensor waives the
exclusive right to collect, whether individually or via a music rights
agency or designated agent (e.g. Harry Fox Agency), royalties for
any phonorecord You create from the Work ("cover version") and
distribute, subject to the compulsory license created by 17 USC
Section 115 of the US Copyright Act (or the equivalent in other
jurisdictions).
f. Webcasting Rights and Statutory Royalties. For the avoidance of doubt, where
the Work is a sound recording, Licensor waives the exclusive right to collect,
whether individually or via a performance-rights society (e.g. SoundExchange),
royalties for the public digital performance (e.g. webcast) of the Work, subject to
the compulsory license created by 17 USC Section 114 of the US Copyright Act (or
the equivalent in other jurisdictions).
The above rights may be exercised in all media and formats whether now known or hereafter
devised. The above rights include the right to make such modifications as are technically
necessary to exercise the rights in other media and formats. All rights not expressly granted by
Licensor are hereby reserved.
4. Restrictions.The license granted in Section 3 above is expressly made subject to and limited
by the following restrictions:
a. You may distribute, publicly display, publicly perform, or publicly digitally perform
the Work only under the terms of this License, and You must include a copy of, or
the Uniform Resource Identifier for, this License with every copy or phonorecord of
the Work You distribute, publicly display, publicly perform, or publicly digitally
perform. You may not offer or impose any terms on the Work that alter or restrict
the terms of this License or the recipients' exercise of the rights granted
hereunder. You may not sublicense the Work. You must keep intact all notices that
refer to this License and to the disclaimer of warranties. You may not distribute,
publicly display, publicly perform, or publicly digitally perform the Work with any
technological measures that control access or use of the Work in a manner
inconsistent with the terms of this License Agreement. The above applies to the
Work as incorporated in a Collective Work, but this does not require the Collective
Work apart from the Work itself to be made subject to the terms of this License. If
You create a Collective Work, upon notice from any Licensor You must, to the
extent practicable, remove from the Collective Work any reference to such Licensor
or the Original Author, as requested. If You create a Derivative Work, upon notice
from any Licensor You must, to the extent practicable, remove from the Derivative
Work any reference to such Licensor or the Original Author, as requested.
b. If you distribute, publicly display, publicly perform, or publicly digitally perform the
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Work or any Derivative Works or Collective Works, You must keep intact all
copyright notices for the Work and give the Original Author credit reasonable to the
medium or means You are utilizing by conveying the name (or pseudonym if
applicable) of the Original Author if supplied; the title of the Work if supplied; to
the extent reasonably practicable, the Uniform Resource Identifier, if any, that
Licensor specifies to be associated with the Work, unless such URI does not refer
to the copyright notice or licensing information for the Work; and in the case of a
Derivative Work, a credit identifying the use of the Work in the Derivative Work
(e.g., "French translation of the Work by Original Author," or "Screenplay based on
original Work by Original Author"). Such credit may be implemented in any
reasonable manner; provided, however, that in the case of a Derivative Work or
Collective Work, at a minimum such credit will appear where any other comparable
authorship credit appears and in a manner at least as prominent as such other
comparable authorship credit.
5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING, LICENSOR OFFERS
THE WORK AS-IS AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND
CONCERNING THE WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING,
WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTIBILITY, FITNESS FOR A PARTICULAR
PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY,
OR THE PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT DISCOVERABLE. SOME
JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO SUCH
EXCLUSION MAY NOT APPLY TO YOU.
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO
EVENT WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY FOR ANY SPECIAL,
INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF THIS
LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.
7. Termination
a. This License and the rights granted hereunder will terminate automatically upon
any breach by You of the terms of this License. Individuals or entities who have
received Derivative Works or Collective Works from You under this License,
however, will not have their licenses terminated provided such individuals or
entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8
will survive any termination of this License.
b. Subject to the above terms and conditions, the license granted here is perpetual
(for the duration of the applicable copyright in the Work). Notwithstanding the
above, Licensor reserves the right to release the Work under different license
terms or to stop distributing the Work at any time; provided, however that any
such election will not serve to withdraw this License (or any other license that has
been, or is required to be, granted under the terms of this License), and this
License will continue in full force and effect unless terminated as stated above.
8. Miscellaneous
a. Each time You distribute or publicly digitally perform the Work or a Collective Work,
the Licensor offers to the recipient a license to the Work on the same terms and
conditions as the license granted to You under this License.
b. Each time You distribute or publicly digitally perform a Derivative Work, Licensor
offers to the recipient a license to the original Work on the same terms and
conditions as the license granted to You under this License.
c. If any provision of this License is invalid or unenforceable under applicable law, it
shall not affect the validity or enforceability of the remainder of the terms of this
License, and without further action by the parties to this agreement, such provision
shall be reformed to the minimum extent necessary to make such provision valid
and enforceable.
d. No term or provision of this License shall be deemed waived and no breach
consented to unless such waiver or consent shall be in writing and signed by the
[290]	  
	  
 
party to be charged with such waiver or consent.
e. This License constitutes the entire agreement between the parties with respect to
the Work licensed here. There are no understandings, agreements or
representations with respect to the Work not specified here. Licensor shall not be
bound by any additional provisions that may appear in any communication from
You. This License may not be modified without the mutual written agreement of
the Licensor and You.
Creative Commons is not a party to this License, and makes no warranty whatsoever in
connection with the Work. Creative Commons will not be liable to You or any party on any
legal theory for any damages whatsoever, including without limitation any general, special,
incidental or consequential damages arising in connection to this license. Notwithstanding the
foregoing two (2) sentences, if Creative Commons has expressly identified itself as the
Licensor hereunder, it shall have all rights and obligations of Licensor.
Except for the limited purpose of indicating to the public that the Work is licensed under the
CCPL, neither party will use the trademark "Creative Commons" or any related trademark or
logo of Creative Commons without the prior written consent of Creative Commons. Any
permitted use will be in compliance with Creative Commons' then-current trademark usage
guidelines, as may be published on its website or otherwise made available upon request from
time to time.
Creative Commons may be contacted at http://creativecommons.org/.
« Back to Commons Deed
